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ABSTRACT
FROM DATA TO DECISION: AN IMPLEMENTATION MODEL FOR THE USE OF
EVIDENCE-BASED MEDICINE, DATA ANALYTICS, AND EDUCATION IN
TRANSFUSION MEDICINE PRACTICE
by
Nazanin Tabesh
The University of Wisconsin-Milwaukee, 2015
Under the Supervision of Professor Timothy B. Patrick

Healthcare in the United States is underperforming despite record increases in spending. The
causes are as myriad and complex as the suggested solutions. It is increasingly important to
carefully assess the appropriateness and cost-effectiveness of treatments especially the most
resource-consuming clinical interventions. Healthcare reimbursement models are evolving from
fee-for-service to outcome-based payment. The Patient Protection and Affordable Care Act has
added new incentives to address some of the cost, quality, and access issues related to healthcare,
making the use of healthcare data and evidence-based decision-making essential strategies.
However, despite the great promise of these strategies, the transition to data-driven, evidencebased medical practice is complex and faces many challenges.

This study aims to bridge the gaps that exist between data, knowledge, and practice in a
healthcare setting through the use of a comprehensive framework to address the administrative,
cultural, clinical, and technical issues that make the implementation and sustainability of an
evidence-based program and utilization of healthcare data so challenging. The study focuses on

ii

promoting evidence-based medical practice by leveraging a performance management system,
targeted education, and data analytics to improve outcomes and control costs.

The framework was implemented and validated in transfusion medicine practice. Transfusion is
one of the top ten coded hospital procedures in the United States. Unfortunately, the costs of
transfusion are underestimated and the benefits to patients are overestimated. The particular aim
of this study was to reduce practice inconsistencies in red blood cell transfusion among
hospitalists in a large urban hospital using evidence-based guidelines, a performance
management system, recurrent reporting of practice-specific information, focused education, and
data analytics in a continuous feedback mechanism to drive appropriate decision-making prior to
the decision to transfuse and prior to issuing the blood component.

The research in this dissertation provides the foundation for implementation of an integrated
framework that proved to be effective in encouraging evidence-based best practices among
hospitalists to improve quality and lower costs of care. What follows is a discussion of the
essential components of the framework, the results that were achieved and observations relative
to next steps a learning healthcare organization would consider.
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Chapter 1:

1.1

Problem Statement

Introduction

Healthcare in the United States (U.S.) is underperforming despite record increases in spending.
The causes are as myriad and complex as the suggested solutions. It is increasingly important to
carefully assess the appropriateness and cost-effectiveness of treatments including the most
resource-consuming clinical interventions 1,2. One of the most promising solutions lies in a shift
from authority-based medicine to evidence-based medicine (EBM). While there have been signs
of a shift in this direction 3,4, very few healthcare organizations can point to tangible examples of
improved outcomes and cost reduction that are directly the result of more informed decision
making. The Patient Protection and Affordable Care Act, commonly referred to as the
Affordable Care Act (ACA) has added new incentives to address some of the cost, quality, and
access issues related to healthcare, making evidence-based decision-making an increasingly
important strategy.

Despite its great promise, the transition to evidence-based medical practice faces many
challenges. It is commonly known that healthcare organizations are ―data rich and information
poor‖ 5. This study demonstrates the effectiveness of a framework that bridges the gaps that exist
between data, knowledge, and practice through the use of evidence-based guidelines, data
analytics, enhanced contextualized data-driven practice information, education focused on the
latest evidence, and feedback mechanism to assess the changes in practice. The American
Hospital Association (AHA) has made a series of recommendations at this transformational
1

juncture in healthcare delivery. The AHA four priority strategies are incorporated into this
study‘s process framework and include: alignment of hospitals, physicians and other healthcare
providers across the care continuum; utilization of evidence-based practices to improve quality
and patient safety; improvement of efficiency through productivity and financial management,
and development of integrated information systems in a cohesive manner to operationalize the
multiple components.

Even though the basic principles behind evidence-based medicine (EBM) have been known for
many years, the concept and the approach to integrating evidence-based decision making into
day-to-day practice has only begun to evolve in the past twenty years 6. Different approaches to
the development and implementation of evidence-based practice have been proposed and used,
including: professional education and development, audit and feedback, evidence-based
guidelines, total quality management, economic incentives, and organizational changes. A
number of well-designed studies

7-11

have examined attempts to modify clinical practices using

mostly one or infrequently more than one of the above approaches 7. However, an understanding
of just which approaches are most effective in which settings remains unclear.

Blood transfusion has been the focus of practice improvement efforts because it is among the top
ten coded hospital procedures 12,13with significant cost and patient outcome implications. Patient
Blood Management (PBM) is defined as ―an evidence-based, multidisciplinary approach to
optimize the care of patients who might need transfusion‖

14

. Research findings in the areas of

clinical evaluation of patients, transfusion outcomes, and decision-making processes have shown
compelling evidence for the need for improvement of transfusion medicine practice. Blood is a
2

precious and a limited resource that carries inherent risks for patients when transfused

15

.

Extensive donor screening and infectious testing have made blood products much safer by
drastically decreasing the rate of transfusion-transmitted infectious diseases. However, recent
discoveries point to increased non-infectious transfusion hazards that have emerged as the
leading complication of transfusion-associated morbidities

16,17

and even mortalities

18-20

.

Transfusion of allogeneic blood has long been suspected of consuming ―more healthcare
resources than previously reported‖21. The underestimated cost and overestimated effectiveness
of this long-standing and common clinical practice1 have contributed to higher associated
expenditures which strain healthcare organization budgets.

Lack of evidence for the need for practice improvement is not the issue. ―Transfusion medicine
is currently adapting the principles and research methodologies that support EBM‖ 22. High level
research has been undertaken at the same rate as in all other medical specialties in terms of
numbers of randomized controlled trials and meta-analyses22. However, even today broad
variation exists in transfusion medicine practice within and across hospitals and healthcare
organizations. There is a demonstrated need to bring PBM evidence into the day-to-day practice
of physicians and other healthcare providers. There are compelling motives and numerous
incentives to introduce EBM practices into transfusion medicine as part of a PBM program.

In this study, a comprehensive framework was developed and used to implement a data-driven,
evidence-based patient blood management program at a large (385 bed), accredited, general
medical hospital served by BloodCenter of Wisconsin in Milwaukee. The study demonstrates an
approach that bridged the gaps that exist between data, knowledge, and practice through the use
3

of evidence-based guidelines, enhanced contextualized data-driven reports and focused education
on the latest evidence. An analytics framework provided a feedback mechanism to evaluate
changes directly impacted by the program, identified new areas for improvement, and helped
avoid unintended consequences and outcomes. Focus on the tight integration of these elements
successfully altered healthcare providers‘ inappropriate practices, increased adherence to the
medical practices based on best scientific evidence (EBM), led to appropriate decision-making
and interventions (EBP), and resulted in cost savings. The method, applicable in areas of
healthcare beyond transfusion medicine, improved patient outcomes and reduced healthcare
expenditures.

1.2

Current Healthcare Landscape

1.2.1. United States Healthcare System
In 2011, total healthcare spending accounted for 10.1 percent of the world‘s gross domestic
product (GDP)

23,24

. At the same time, the United States spent 17.7 percent of its GDP on

healthcare. This share roughly doubled from nine percent in 1980s 25. Health data released by the
Organization for Economic Cooperation and Development (OECD) indicate that the United
States compared to any other OECD country spends more on healthcare per capita

24

. If

healthcare expenditures continue to rise at historical rates, the Council of Economic Advisers
projects the share to reach 34 percent of GDP by 2040

26

. Despite the increase in healthcare

spending, comparative analysis has shown that the United States underperforms in most
dimensions of a high performance healthcare system (i.e. quality, access, efficiency, equity, and
healthy lives) relative to other countries, such as Australia, Canada, Germany, the Netherlands,
New Zealand, and the United Kingdom 27.
4

1.2.2. United States Healthcare Complexities
The healthcare system in the U.S. is comprised of a vast array of complex interrelationships
among patients, providers, payers, and insurers

28

, in addition to the pharmaceutical and

biomedical technology industries. These interdependencies have created a multifaceted and
complex care delivery model, which has been sustained for many decades by a set of mutually
reinforcing elements. Some of the elements include: ―organization by specialty with independent
private-practice physicians; measurement of ―quality‖ defined as process compliance; cost
accounting driven not by costs but by charges; fee-for-service payments by specialty with
rampant cross-subsidies; delivery systems with duplicative service lines and little integration;
fragmentation of patient populations such that most providers do not have critical masses of
patients with a given medical condition; siloed IT systems around medical specialties; and
others‖29. The interlocking structure of the current healthcare system contributes to process
inefficiencies, structural barriers, and system failures, which are significant impediments to
quality care and prevent the delivery of effective, efficient, evidence-based health care

29,30

.

These factors highlight the complexity and explain resistance to change.

1.2.3. Affordable Care Act
The Affordable Care Act (ACA) was signed into law on March 23, 2010. It consisted of ten
separate legislative Titles with several major aims. Passing ACA introduced a significant
regulatory overhaul to the current healthcare system through mandates, subsidies, and health
insurance exchanges

31

. The provisions of ACA were designed to control increasing healthcare
5

costs, expand coverage, and improve patient access, healthcare delivery, patient outcomes, and
population health

32

. The enactment of ACA drastically shifted the operational landscape of

healthcare organizations, insurers, payers, patients, and care providers, by moving away from a
supply driven healthcare system organized around providers to a patient-centered system,
focusing on patients‘ needs

29,33

. The intent of the law was to lower overall healthcare costs by

better aligning patient care with holistic approaches to treatment, with a significant focus on
preventative medicine 33 and population health. One of the major aims of ACA was to ―improve
health-care value, quality, and efficiency while reducing wasteful spending and making the
health-care system more accountable to a diverse patient population‖ 34. Value may be defined as
―health outcomes achieved that matter to patients relative to the cost of achieving those
outcomes‖29. Value for healthcare organizations senior executives, providers, and stakeholders
translates into improving one or more outcomes without increasing cost (in some cases even
lowering cost) without compromising outcomes

29

. Improving value is critical in the new

healthcare environment. Failure to improve value can decrease profitability and competitiveness
of healthcare organizations and hospitals in the marketplace. To be better positioned for the road
ahead, a fundamental departure from past practices is essential.

1.2.4. Additional Healthcare Challenges
Change is inevitable for healthcare systems and hospitals in order to drive transformation,
operationalize care delivery, and move from volume to value as required by ACA. Healthcare
organizations and hospitals are facing mounting pressure as they deal with: increasing cost of
patient care, uncertainty surrounding healthcare reform, governmental mandates, cost
6

containment requirements, industry consolidation, challenges in enhancing patient outcome
quality and safety, population health management, change in physician reimbursement models,
physician hospital relations, caring for uninsured, improving patient satisfaction, conforming to
new information technology, and creating accountable care organizations35-37. Healthcare
systems and care providers must operate under new sets of outcome based demands and avail
themselves of the latest research evidence and technological advancements. A paradigm shift is
required of healthcare systems and care providers if they are to deliver quality patient care in the
most effective and efficient manner, with outcome quality tracked, rewards granted based on
evidence-based best-practice and quality metrics met as measured through an aggregation of hard
data 38.

At the industry level, the current culture of healthcare environment is characterized by
―competition, misaligned incentives, and inherent distrust among stakeholders‖, which is
exacerbated by tensions among ―consumers who ask for high service and low out-of-pocket
costs, payers who select risk and limit cost, and purchasers demand more value at the lowest
cost‖

30

. In addition, vast investments in biomedical research and technology, pharmaceutical,

genetics and genomics research and discoveries have led to new and improved clinical
approaches. Technological and scientific breakthroughs have led to a marked proliferation of
new diagnostic and treatment technologies, which has led to a sharp increase in healthcare costs
30

.

Healthcare organizations in the United States have not fully leveraged clinical data to improve
health outcomes. Siloed and diverse information technology systems within and across
7

healthcare organizations make cost and outcome measurement difficult and limit the value of
these technologies. Three major impediments to the full use of health data include: limited
integration capabilities in the design of various health information systems for health information
technology (HIT) and other technologies (i.e. imaging systems, lab, pharmacy, transfusion
service information systems and etc.); limited access to data, which is exacerbated by inadequate
adoption of electronic health records (EHRs); and lack of data standards. These barriers and
more have resulted in misuse or overuse of various systems and have hampered their ability to
improve quality of care and delivery of services. The ―crush of information, plethora of new
technologies, increased regulatory oversight, an aging population, and heightened consumer
awareness and expectations have all contributed to the disorganization, fragmentation, and
discontinuity of patient care‖30.

1.2.5. American Hospital Association Recommendations
To help healthcare systems and hospitals‘ senior leadership navigate the fluid environment, the
American Hospital Association (AHA) Committee on Performance Improvement has identified
priority strategies and core organizational competencies to be considered by healthcare systems
and hospitals in order to remain successful during this transformational period

39

following AHA strategies, the first four are considered major priorities:


Aligning hospitals, physicians and other providers across the care continuum



Utilizing evidence-based practices to improve quality and patient safety



Improving efficiency through productivity and financial management



Developing integrated information systems
8

. Among the



Joining and growing integrated provider networks and care systems



Educating and engaging employees and physicians to create leaders



Strengthening finances to facilitate reinvestment and innovation



Partnering with payers



Advancing through scenario-based strategic, financial and operational planning



Seeking population health improvement through pursuit of the ―triple aim 39

The AHA recommendations highlight the need for today‘s healthcare systems and care providers
to operate under a new set of outcome based demands. The paradigm shift requires healthcare
systems and care providers to deliver quality patient care in the most effective and efficient
manner, with quality of outcomes is tracked and rewarded based on evidence-based best practice
measures, and meeting various quality metrics that can be measured through aggregation and
analysis of hard data 38.

1.2.6. Affordable Care Act Implementation Challenges
The manner in which many healthcare systems have been implementing the different
components of the new healthcare law has resulted in a succession of narrow piecemeal solutions
some of which are designed to preserve existing roles

29

. Some attempts to improve consumer

access to care further fragment care delivery and add to the problem. Convenient care clinics
improve access to primary care, but they are not designed to provide holistic and continuous care
for healthy patients, or acute and preventative care for patients with complex chronic, or acute
conditions29. Global capitation can strongly incentivize providers to reduce spending, without
necessarily improving value or outcome for patients. Care coordination on top of a fragmented
9

healthcare system can produce very limited savings29. Information technology solutions are a
critical component of an effective patient-centered healthcare system. However, misuse, and
overuse of disparate, incompatible, and heterogeneous health information systems have
intensified and further fostered siloed and fragmented care delivery models despite attempts to
establish care-coordination and continuity of patient care.

Practicing evidence-based medicine, for the purpose of improving quality and patient safety is
appropriate but it is not without implementation challenges. Even though studies have shown that
development and implementation of evidence-based clinical practice guidelines appear to be one
of the most promising and effective tools for improving quality of care, many guideline are not
used soon after dissemination

40

. Evidence-based clinical practice guidelines become outdated

quickly due to rapid advances in medical knowledge, clinical research, and technology. Quality
measures and metrics are high-level and limited. Many measures track and report only providers‘
compliance with certain guidelines, and dismiss outcomes achieved related to adherence with the
guidelines. Measuring compliance with guidelines does not translate into practicing evidencebased medicine, especially if improved patient outcomes are unquantifiable. Disappointing
results from various attempted cost reduction strategies has fostered skepticism about whether
value improvement in healthcare is possible with some concluding that the only solution to
escalating cost of healthcare is rationing of services and shifting the cost to patients or taxpayers
29

.
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1.3.

Reshaping the Healthcare Ecosystem

The healthcare ecosystem is being reshaped by two powerful and opposing economic forces: (1)
to improve quality of care, and (2) to reduce cost. There is pressure to do more with less. In
order to achieve more with less, any healthcare organization with a vision of the future must face
a fundamental question, how to best to use limited resources while better managing patient care?
The answer to this question lies within healthcare organizations‘ data. Clinical, administrative,
and other healthcare related data holds the key to transforming the healthcare system, by
providing greater insight to patients, providers, and policy makers on the appropriate
interventions, quality, and cost of care

41

. As a result, the healthcare system model is changing

into ―information driven‖, ―evidence-based‖, and ―outcome-driven‖ model 42. Using technology
effectively and managing the overwhelming quantity of data to derive new information are at the
forefront of the change.

1.3.1. Information Driven Healthcare
Healthcare data offer the opportunity to accelerate progress on the six characteristics of quality
care, in which a healthcare system must deliver. These characteristics include:
1. Safe: Care should be as safe for patients in healthcare facilities as in their homes;
2. Effective: Science and evidence behind healthcare should be applied and serve as the
standard in the delivery of care;
3. Efficient: Care and service should be cost effective and waste should be removed
from the system;
4. Timely: Patients should experience no waits or delays in receiving care and services;
11

5. Patient Centered: The system of care should revolve around the patient, respect
patient preferences, and put the patient in control;
6. Equitable: Unequal treatment should be a fact of the past; disparities in care should be
eradicated 43-45.
Addressing the above dimensions of quality care, necessitate an understanding of the scope of
the potential and missed opportunity. This requires a sound knowledge of existing healthcare
data (i.e. disparate data sources, types, accessibility, and use)

41

. The combination of

administrative and clinical data is a powerful and vital resource. Significant quantities of data
permeate healthcare organizations and have the potential to transform healthcare delivery and
performance

46,47

. However, data alone is neither information nor knowledge. Data requires

collection and processing (manipulation of items of data) to produce information
combination of

47,48

. The

a robust information technology infrastructure, technology expertise and

informatics expertise are required to perform the data profiling, aggregation, analytics,
visualization, interpretation, and presentation in order to produce meaningful information and
provide the knowledge that is required to contribute to informed decision-making in healthcare
services and policies 47. However to date, many healthcare organizations have not fully embraced
the expertise, technologies, and key business management processes or techniques (such as
knowledge management, data mining, business intelligence, analytics, intuitive reporting
systems, and etc.) required to maximize this invaluable resource 46.
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1.3.2. Data Abundance and Information Scarcity in Healthcare
Other industries (i.e. banking, retail, supermarkets, manufacturing, etc.) have been far more
successful in harnessing the value from large-scale integration and analysis of their industry and
organizational data 5. Healthcare is just getting its feet wet 49. Although ―healthcare is inherently
an information based endeavor‖50, it is commonly known that healthcare organizations are data
rich and information poor

51

. Only the fraction of available healthcare data is being used for

analysis and reporting. Information rests at the core of healthcare. Meaningful, well managed,
easily accessible, and timely information is fundamental to the future of medicine, cost
containment, improvement of patient quality care and outcome

50

. One solution is the effective

use of health information technology (HIT), which can be defined as the ―array of devices,
procedures and processes for collecting, referencing and/or managing health information
electronically

50

‖. HIT encompasses broad categories of technologies including: electronic and

personal health records, e-prescribing, computerized physicians order entry, clinical decision
support, telemedicine, advanced medical imaging, smart pumps, bar coding devices and etc. HIT
offers improvement by augmenting decision-making for healthcare professionals and assisting
healthcare staff in patient care. Healthcare professionals, particularly physicians, are struggling
with information overload. It is beyond human capability to continuously learn, remember, and
apply the mounting evidence and the knowledge that is being generated on a daily basis. HIT
aims to compensate for human limitations, enhance decision-making, improve delivery of care,
and offer value for patients. The Health Information Technology for Economic and Clinical
Health (HITECH) Act provided thirty billion dollars to promote ―meaningful use‖ of EHRs
through the Medicare and Medicaid electronic health record incentive programs

52-54

. The

incentive program ―provides financial support for hospitals in the form of payments for the
13

meaningful use of health information technology through Medicare. Payments are made for
adopting, implementing, or upgrading an existing EHR through the Medicaid program‖54.
However, HIT is not without challenges. The implementation of HIT faces great challenges
including: organizational, sociological, political, and technological. Fear of change, misaligned
financial incentives, and performance limitations of the technologies themselves are among the
challenges 50,54-58.

1.3.3. Healthcare Digitization
Digitization of healthcare data and information management has mirrored the transition to
computerization in other industries. The initial digitization phase of an industry is designing and
using systems that specifically support transaction-based workflow and data collection

59

. The

first wave of information technology in the 1950s was on the business and administrative side of
healthcare using technology for the automation of repetitive tasks such as accounting and
payroll, Healthcare payers and other industry stakeholders began to use information technology
to process vast amounts of statistical data.

Twenty years later, the second wave started with a focus on digitization patient‘s medical record,
which began with the use of electronic medical record (EMR) systems in place of paper charts 60.
EMRs contained the medical and treatment history of patients in a single practice. The EMR
advantages over paper record were considerable and included the ability to track patients over
time, to easily identify patients due for preventative screening, and to monitor patients on certain
parameters (i.e. vaccination, blood sugar, etc.)

61

14

. However, major drawbacks were associated

with EMR systems. Some disadvantages which emerged included: inability to maintain
longitudinal medical records of patients being cared by multiple care provides62; limited ability
to support coordination between clinicians and settings due to their design and lack of
standardization of key data elements required for information exchange; difficulty in the
management of information overflow; inability to adequately capture the medical decision
making process and future care plans for care coordination; not designed for non-billable care
coordination activities but rather for fee-for-service billable events (i.e. office visits, procedures,
etc.) 63,64.

Relatively recent changes in healthcare models (e.g. Pay-For-Performance, Patient Centered
Medical Home, and Accountable Care Organization) highlight the need to embrace technologies
that facilitate easier retrieval and tracking of patient data with a focus on the longitudinal health
of patients and contribute to the urgency for conversion from paper records and EMR to EHR
systems. EHR systems are defined as ―a longitudinal electronic record of patient health
information generated by one or more encounters in any care delivery setting. Included in this
information are patient demographics, progress notes, problems, medication, vital signs, past
medical history, immunization, laboratory data, and radiology reports‖ 64. EHR is designed to go
beyond the standard clinical data collection in a provider‘s office and is inclusive of a broader
view of a patient‘s care. EHR has all the EMR capabilities in addition to the accessibility to
computerized records and the ability to share information with other healthcare providers (i.e.
laboratory, specialists, etc.).

EHR contains information from all clinicians involved in the

patient‘s care. EHR data ―can be created, managed, and consulted by authorized clinicians and
staff across more than one healthcare organization‖
15

61

. EHR systems have many potential

capabilities, but three particular functionalities hold great promise in improving the quality of
care and reducing cost. These include: clinical decision support (CDS) systems, computerized
physician order entry (CPOE) systems, and health information exchange (HIE)

65

.

EHR

capabilities, in addition to the above particular functionalities, became the required criteria for
―meaningful use‖ set forth by the Health Information Technology for Economic and Clinical
Health Act (HITECH) of 2009

53,65

. HITECH sought a means to address the alignment of

economic incentives between payers and providers, to promote digitization, to strengthen
healthcare delivery with seamless transfer of patient information, to provide transparency, and to
improve the consumer experience. The enactment of HITECH led to widespread EHR adoption
for sharing data and health information among members of workflow teams 59. While digitization
of patient and healthcare data is a necessary first step toward a data-driven care delivery, EHR
alone is not enough. A platform that enables an enterprise-wide, consistent view of information
that is aggregated from multitude of diverse and disparate data sources 66 is required.

The third wave of digitization in healthcare focuses on the analysis of different aspects of data,
information, and workflow that are reflected in the patterns of aggregated data

59

in order to

provide value. This phase of information technology focuses on the utilization of data to improve
care. Without a way of organizing the clinical, financial, administrative, other healthcare related
data into a single source of truth, a healthcare system cannot extract value from their data. In
order to gain actionable clinical, financial, and operational insights, data from EHR and other
internal and external source systems must be captured, aggregated, analyzed, and presented in a
meaningful manner60. This phase is characterized by the implementation and adoption of data
repositories for aggregation of clinical data and building electronic data warehouses. To address
16

healthcare inefficiency and information deficiency, leading healthcare organizations have begun
implementation of data repositories to aggregate clinical data and are building data warehouses
to support the analytical needs of various initiatives, mandates, and programs, such as evidencebased practices, performance monitoring, quality improvement initiatives, outcome-based
reimbursement models, and etc.

Analytics is defined as ―systematic use of data and related business insights developed through
applied analytical disciplines (e.g. statistical, contextual, quantitative, predictive, cognitive, other
[including emerging] models) to drive fact-based decision making for planning, management,
measurement and learning. Analytics may be descriptive, predictive or prescriptive 67‖. It enables
healthcare organizations or hospitals to analyze a set of structured, semi-structured, and
unstructured patients and healthcare data in search of valuable business information and insight.
However, healthcare organizations are struggling to successfully manage the myriad
stakeholders, regulations, and privacy concerns required to build fully integrated information
technology systems 60.

1.3.4. Big Data and Healthcare
The transition to the use of analytics unleashes the potential of ―big data‖. Big data in a
healthcare setting would include data from the following sources: EHR; patient registries; CPOE
systems, CDS systems, ambulatory and emergency care records; physicians‘ written notes;
prescriptions; medical imaging results; laboratory values; pharmacy records; insurance
information; administrative data; machine generated/sensor data. Raw data or data with no
17

context has no value on its own. Without context, it is nothing but a meaningless cluster of
numbers, letters, or words 68. Transforming raw data into insightful information requires a team
of experts with core skills of computer science, analytics and statistics, as well as domain
knowledge, blended with strong communication skills 69. Datasets must be identified, extracted,
transformed, and linked together in order to be organized into a specific format, and be analyzed
using techniques that provide answers to a specific set of questions. In healthcare, these basic
steps alone pose a significant challenge. Often it is very difficult to identify and pin-point
relevant and contextual data that can deliver value. One source characterized the process as
finding ―insight among the chaos‖

68

. Other impediments to data management include: data

volume, velocity, variety, variability, veracity 70. Healthcare complexity and lack or limited data
governance across healthcare organizations contribute to the problem. Yet another challenge is
inadequate accessibility to raw data for utilization in analytics because of vendor restrictions,
proprietary databases, lack of data integration or lack of appropriate data stores.

1.3.5. Healthcare Analytics Capabilities
There are challenges associated with use of analytics, including insufficient resources,
inadequate technological infrastructure and a lack or limited understanding of the application of
analytics to business, quality issues, and performance goals across organizations and
stakeholders. Even though the availability of data in data repositories, data warehouses, or data
marts has been a great starting point, data often remains unanalyzed and unreported among
stakeholders for actionable outcome. Technologies must be evaluated for interoperability and
compatibility, and for measures that are necessary in data standardization for future data utilities
18

71

. Investments may be required to develop linkages across the source systems and data

warehouses to leverage access to both administrative and clinical data.

71

. Human capital is

another facet of analytics that must be taken into account. There has been a limited supply of
analytics talent. Analytics tools, technology, and infrastructure are necessary but the right people
who understand the need, desired goals and objectives are critical for success. They deploy their
knowledge, skills, and the appropriate tools to provide relevant and current information for
information users, decision makers and other stakeholders at all levels in the organization. The
lack of appreciation of the importance of an analytics team can be a problem. Many healthcare
analytics teams become inundated by requests for a variety of reports, dashboards, and other
analytics applications. The team becomes too involved in information development requests
from users, rather than focusing on enhancing the analytics infrastructure and developing new
tools of tactical and strategic significance 72. Furthermore, healthcare analytics is often impeded
by regulatory concerns, resource constraints, and more importantly organizational cultures that
are slow to trust and accept the role and importance of analytics 73.

1.3.6. Evidence-Based Healthcare
The philosophical origin of Evidence-Based Medicine (EBM) dates back to mid nineteenth
century 74. It is defined as ―conscientious, explicit, and judicious use of current best evidence in
making decisions about the care of the individual patient‖ 74. It is the translation and integration
of clinical expertise, with the best available external clinical evidence from systematic research,
and patients values into the decision making process, for the purpose of medical intervention
74,75

. Evidence-based practice is perceived by a majority as an important element in enhancing
19

patient quality of care by reducing unnecessary and inappropriate variations in medical practice
76-78

. Practice of EBM aims to keep medicine current with the latest findings

79

. This involves

frequent updates to clinical knowledge base ( i.e., references that provide answers to clinical
questions), dissemination of knowledge, and adherence to the latest acquired evidence

77

. Such

an approach faces significant and often justifiable barriers with regard to applicability,
feasibility, implementation, and suitability of evidence-based practice 80-82.

1.3.7. Authority-Based to Evidence-Based Medicine Shift
EBM enhances a healthcare organization‘s ability to meet both its clinical and business needs.
Challenges in the current healthcare environment, including the need to ―cope with information
overload, cost-control, and the public‘s impatience for the best in diagnostics and treatment‖

83

make EBM a necessity. EBM employs clinical and financial logic to determine whether or not an
action taken was beneficial

83,84

. In the United States, the persistent increase in the cost of

healthcare affects the cost of healthcare insurance. The cost of health insurance is rising faster
than wages at a rate that is not sustainable

85

. Cost-benefit analysis indicates that the quality of

healthcare, measured in outcomes, safety, and service, has remained lower than expected 85. The
value of healthcare delivered in the United States is lower than most developed nations in the
world, when compared to relatively rich European countries such as France, Sweden, the United
Kingdom, etc. Among individual states within the United States there is great variability in the
value of healthcare delivered

86

. On average only ten percent of the states provide high-value

care, which has resulted in growing cost of care and poor outcome relative to developed
countries on most dimensions of care

27

. Ongoing cost-benefit analysis indicates increased
20

dissatisfaction with volume driven healthcare and authoritative-based medicine, which highlights
the need for quality and cost control measures, and efforts to make the best use of finite
resources.

1.3.8. Challenges to Evidence-Based Medicine Implementation
There has been a shift from authority-based medicine to evidence-based medicine over the past
decade. The shift has introduced fundamental changes in the business of healthcare, in clinical
practice, in health research, and in medical education

3,4

. Transition to the practice of EBM

requires evaluation and acceptance of the possibility for improvement, and necessitates a process
of life-long and self-directed learning. The shift to the practice of EBM has been highly praised
but implementation of EBM has been very challenging and at times harmful

4,87-89

. The

foundation of EBM rests on two core principles: an empirical approach to optimal clinical
decisions regardless of pathophysiology (i.e. Does the bottom line show a gain or loss?), and its
quantitative expression (How big is that gain or loss?)

90

. These two core principles require

some mastery of epidemiology and statistics, in addition to comprehensive domain knowledge.
These requirements have been repelled and resisted by many physicians and even many medical
students who view them as too mathematical and remote from clinical practice

90

. Even though

EBM has evolved to provide the skills needed to manage the potential information overload, it
faces significant challenges. EBM challenges can be divided in four broad categories: volume of
evidence, availability of relevant evidence, time and ability to interpret evidence appropriately,
and translation of knowledge into clinical practice 4.
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1.3.9. Volume of Basic Science and Clinical Research Evidence
The volume of basic-science and clinical research evidence is growing at a high rate. ―Medicine
must keep current with the research literature, and keeping current requires continuously
updating the clinical knowledge-base‖, which is defined as references that provide answers to
clinical questions that can lead to healthcare decisions for patients

79

. A major barrier is the

amount of clinical literature published in a variety of sources. The sheer volume of new articles
published every day is growing exponentially, which makes it almost impossible for individual
physician to remain up-to-date in their area of specialty, not even considering the latest evidence
in related areas within their specialty. In 1992, around twenty English language clinical journals,
with a focus on adult internal medicine published over 6,000 articles with abstracts. To keep up
with the latest publications, an internal medicine physician would have had to read at least
seventeen articles per day related to internal medicine alone to try to remain up-to-date

91

. A

Medical Subject Heading (MeSH) study in 1994, estimated that over 30,000 biomedical journals
and over 17,000 new medical text books were being published annually. In 2004, Alper and
colleagues quantified the volume of published medical literature potentially relevant to primary
care to be 7,287 articles in a month and estimated it would require 627.5 hours per month for
trained physicians in medical epidemiology to evaluate these articles for updating a clinical
knowledge-base

79

. A 2005 study

92

on growth and decentralization of the medical literature

examined data for all journal articles published from 1978 through 2001 which were available in
2003 on MEDLINE which is maintained by the National Library of Medicine (NLM). The study
reported publication of 8.1 million articles during the time period. The results indicate that
―between 1978 to 1985 and 1994 to 2001, the annual number of MEDLINE articles increased by
46 percent, from an average of 272,344 to 442,756 per year, and the total number of pages
22

increased from 1.88 million pages per year during 1978 to 1985 to 2.79 million pages per year
between 1994 to 2001‖

92

. The study reported the growth to be particularly concentrated in

clinical research with an increased proportion of studies with human subjects. Medical Subject
Heading changes indicated a shift from basic science headings toward clinical care and public
health related topics i.e. public health, quality of healthcare, epidemiology, etc. 92.

1.3.10. Availability of Relevant Evidence
To access the best available evidence it is essential to know: how and where to search and
retrieve the best research studies; which databases are rich and reliable; and how to conduct a
systematic and purposeful search strategy. Limited knowledge of the best available evidence
may be one of the reasons behind inappropriate, wasteful, or controversial medical interventions.
Guidelines are important in the practice of evidence-based medicine. EBM guidelines are
defined as ―systematically developed statements to assist the practitioner in making patient
decisions for appropriate health care interventions for specific clinical circumstances

11

.

Evidence-based guidelines can be synthesized from numerous sources with the overall goal to
aggregate the best available evidence and use the conclusions to assist in clinical decision
making

93-95

. There are challenges involved in the implementation of EBM in day-to-day

practice. The volume of clinical research has been growing considerably, but optimal evidence is
often not available for many physicians 4. Systematic literature reviews have demonstrated that
large numbers of studies are grossly inadequate, and are thus potentially misleading 83. A study
by Haynes

91

―estimated over 95% of articles in medical journals do not meet the minimal

standard of critical appraisal.‖ Critical appraisal is a ―systematic process used to identify the
23

strengths and weaknesses of a research article in order to assess the usefulness and validity of
research findings‖ 96. The most important components of a critical appraisal are an evaluation of
the appropriateness of the study design for the research question and a careful assessment of the
key methodological features of this design. Other factors that must be considered include:
suitability of the statistical methods used; interpretation of statistical methods; potential conflicts
of interest; relevance of the research to area of practice

96

and study biases. To assess clinically

meaningful patient outcomes, physicians require well-designed, large-sale clinical studies that
are reflective of approaches or interventions in their particular domain.

1.3.11. Interpretation of Evidence
―The limited or lack of time and training on the part of well-intentioned physicians to critically
and independently evaluate evidence threatens the very basis of EBM 4‖. Successful application
of evidence-based practice depends on domain knowledge and the acquisition, appraisal, and
applicability of clinical evidence
expertise in these key skills

97

. Physician and faculty clinicians often lack or have limited

4,83,97

thus are unable to demonstrate the processes for other

physicians, residents, and medical students

97,98

in order to promote the practice of EBM. Many

physicians gain limited knowledge and training as medical students in statistics classes or
residency journal club, a common venue to learn basis of EBM) 97. ―These forums can leave the
impression that EBM requires hours of study to answer a single patient care question, a difficult
time commitment for clinically active physicians, who therefore lose appraisal skills over time‖
97

. Required skills are fundamental in distinguishing between poorly designed or high quality

research studies, and interpreting information when studies of equally high quality are
conflicting in their findings 4. In addition to a lack of the required skills, there is resistance within
24

a subset of clinicians who prefer to exclusively consult colleagues for less familiar diagnoses
rather than do research frequently encountered patient problems. Additional obstacles include,
aversion of physicians and medical students to learning and understanding statistics and
epidemiology

90

. There is a growing volume of evidence regarding the overall difficulty of

translating the acquired EBM knowledge into behavioral change 99.

1.3.12. Translation of Knowledge into Clinical Practice
―Assuming the volume of published studies, availability of information, time, and ability to
independently and critically evaluate evidence, translation of evidence to practice may still be
challenging‖ 4. The preponderance of research evidence is in the form of clinical trials and
observational studies which pose advantages and limitations for translation of the studies‘
outcomes 4. The designs of clinical trials are intently focused on specific patient populations who
are subjected to strict monitoring parameters, which create a somewhat artificial environment.
Consequently, translation of the outcome becomes difficult and may not be reflective of the
majority of patients who would normally be seen in a clinical setting and be evaluated with the
same stringent parameters 4. Observational studies answer many human health research questions
and provide great contributions to medical knowledge. However, observational studies
potentially have inherent selection bias based on age, socioeconomic status, information bias,
measurement errors, confounders, etc. and have a limited level of clinical details, which makes
the interpretation and translation of outcome difficult to answer relevant clinical questions
4,100,101

. Given these challenges, it is naïve to assume that evidence is the only impediment to

evidence-based clinical decision making. There are a multitude of other factors such as patient
preferences, social circumstances, presence of disease, disease-drug and drug-drug interactions,
25

clinical conditions, etc. that influence clinical decision making 4. Besides the quality of the
evidence itself, there are other barriers to surmount in order to provide the most consistent and
best possible care to patients 102.

1.3.13. Continuous Quality Improvement Barriers to Evidence-Based Practice
Outside of clinical and patient specific issues there are many other factors that play a critical role
in the translation of knowledge into informed clinical practice. The factors can be broadly
categorized at the individual and the institutional levels

4,102

. There are four major interrelated

dimensions: strategic, cultural, technical, and structural with an effect both on individual and
institutional levels

102,103

. ―The strategic dimension includes the activities and processes that are

most important to the organization and provide greatest opportunities for improvement, such as
vision, budget, priorities, and long-term strategy. The cultural dimension represents the
organization‘s beliefs, values, norms, and behavior. The technical dimension encompasses
training and information infrastructure. The structural dimension refers to the ways that
knowledge is acquired and dispersed throughout the organization‖

102,103

. An individual may

practice EBM as a means to provide better care for patients or as a result of interest in a
particular intervention or condition102. The institution may be inclined to practice EBM as means
to maintain ―magnet accreditation, attract more payers, or to be eligible for incentives‖

102

. The

challenge arises when ―individuals or institutions do not know about, nor see the value in
practicing EBM‖ 102.
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1.3.14. Outcome Driven Healthcare
As part of the transformation of the healthcare system, the context in which physicians and other
healthcare providers deliver care has also shifted

104

. The reshaping of the healthcare landscape

has led to the trend toward physician employment by healthcare institutions and consolidation of
healthcare systems

104-106

. Fee-for-service reimbursement models encouraged fragmented

healthcare delivery systems. Changes and reform in payment policies have encouraged a shift to
a system that encourages integration and care coordination that holds physicians and other
healthcare providers accountable for patient outcomes and costs

104

. It is unclear whether the

changes in incentives and payments will result in improved quality of care, enhanced health
outcomes, and lower cost for patients and healthcare organizations because of the potential
disconnects in organizational and individual physician incentives

104

. Many payment reforms

such as shared savings and various risk-based models are targeted at healthcare organizations.
However, within these healthcare organizations, countless decisions are being made daily by
physicians, nurses, and other healthcare provides who will predominantly determine
organizational performance

104

. Although bundled payment, shared savings, and other reform

initiatives may have an effect on reducing the proportion of payments linked to volume at the
organizational level, ―healthcare providers are still being paid to do more‖

104

. ―The providers

are often largely being compensated by their organizations based on productivity‖ 104. To achieve
alignment, healthcare organizations, ACOs, and other healthcare delivery systems must redesign
financial incentives to link payments to patient outcomes. The size and timing of the reward play
a critical role in how individuals respond 107. Shortening the lag time between delivered care and
rewards improves saliency 108. Strategies include decoupling outcome driven financial incentives
from other usual compensation

109

, and evaluating,
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timing , frequency, size, and other

characteristics of incentives, including how to link them to a specific set of performance
measures 104. Non-financial incentives that appeal to intrinsic motivation also have an influence
on behavior change110,111, including the desire to do a challenging task in order to positively
impact the lives of others

112

, peer comparison (i.e. quality report cards)

individual healthcare providers‘ goals in writing

114

113

, and putting

. As the number of hospital and healthcare-

organization-―owned‖ physicians and practices increases, (significant increase was observed
from16 percent in 2007 to 29 percent in 2012) 115, the need to align organizational and individual
provider incentives will likely increase in the future 104. Current evidence on the use of financial
and non-financial incentives to drive ―quality improvement in healthcare has been mixed at best‖
116

.

1.3.15. Healthcare Organizations Improving the Value of Care Delivered
In order to improve the effectiveness and value of care delivered, healthcare organizations must
build their capacities for ―ongoing study and monitoring of the relative effectiveness of clinical
interventions and care processes through expanded trials and studies, systematic reviews,
innovative research strategies, and clinical registries (They must also improve) system‘s ability
to apply what is learned from such study through the translation and provision of information
and decision support‖117. For a healthcare organization to thrive, it must a successfully
implement a learning healthcare system. This is defined as a system that is designed to generate
and apply the best evidence for the collaborative healthcare choices of each patient and provider,
to derive a process of discovery as a natural outgrowth of patient care, and to ensure innovation,
quality, safety, and value in healthcare

118

. It must incorporate the best available scientific

evidence as it seeks to improve the quality of patient care and outcomes, to quantify and report
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on performance, and to design and implement a feedback mechanism to enable learning from
various experiences and interventions. To achieve this high level of performance a higher level
of organizational capacity is essential. This requires a robust information technology
infrastructure and a new breed of skills such as informatics and performance management
expertise, in order to achieve clinical integration
present in most healthcare settings

119

119

. Such a high level capacity currently is not

. Given the complexity of modern medicine, information

technology plays a central role in the redesigning of the healthcare system if a substantial
improvement in quality is to be achieved over the coming decade

120

. Information is critical to a

learning healthcare system; health informatics focuses on what, how, and why of managing
information

121

. The ultimate goals of health informatics approaches are to streamline the

processes of patient care, provide clinicians with accurate information in a timely manner,
educate providers, healthcare consumers and stakeholders, improve the quality of care, and
provide the means to identify cost saving measures 122,123

Healthcare organizations need to leverage their information technology infrastructure and
informatics capability to: provide the best available evidence

124

; use organizational culture to

effectively foster the intrinsic motivation of physicians to ensure providers ―buy-in‖104; develop
effective educational methods (i.e. systematic practice-based interventions as opposed to
continuing medical education); effectively incorporate evidence-based knowledge into day-today operations125; and align financial and non-financial incentives to promote environments that
encourages effective professional behavior104. This will best encourage and alter the behavior
and practice of their frontline healthcare providers in a way that enhances their performance and
outcomes. While any single intervention may have relatively minor impact, over time the
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combination of various incremental steps can lead to significant strides in improving quality of
care and reducing cost for both patients and healthcare organizations 104.

1.4.

Application of Evidence-Based Medicine in Transfusion Medicine

1.4.1. Rationale and Need
To date, healthcare organizations in the United States have under-estimated and overlooked the
cost of red blood cells (RBC) transfusion as part ―doing business‖ 21,126. As a result, the true cost
of transfusions, both to patients and to healthcare organizations, has been widely unappreciated
21,127-129

. In a 2010 study, accurate measures were employed that revealed the cost of a

transfusion ranging from $522 to $1,183 per unit depending on geographic location (these
figures do not take morbidity into account) 21. Beyond the cost of transfusion, each unit of RBC
has inherent risks, which are potentially associated with increased cost of care. In particular,
liberal transfusion practices that occur at higher hemoglobin levels can increase the cost of care
more than those given at lower hemoglobin levels 126.

In transfusion medicine, as in other areas of medical practice, there is a gap between the latest
knowledge and current physician practice. Transfusions of blood products, which include whole
blood, RBC, platelets, plasma, and cryoprecipitate, are a critical component of clinical care. In
the United States, RBC transfusion is one of the most frequent procedures performed in
hospitals, with one in ten inpatients receiving one or more units of blood

130

. In 2011, five

million patients received RBC transfusions; 13.7 million RBC units were transfused

131

. In the

latest statistical reports (2010 and 2011) by Healthcare Cost and Utilization Project (H.CUP),
blood transfusion is among the top ten prominent coded procedures in United States hospitals as
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evidenced in discharge records. In the same report, the cost of transfusion accounted for ten to
fifteen billion dollars annually

12,13,132

. In a recent blood transfusion cost analysis study, the

actual cost of RBC transfusion was determined to be 3.2 to 4.8 fold higher than previously
estimated

21

. The under- representation in the cost of blood transfusion is

a result of an

incomplete accounting of the required resources and the associated activity-based costs

21

. The

factors not fully taken into account include, but are not limited to, patient testing, pre-transfusion
preparation, transfusion administration, follow-up, and long-term tracking of patients

133-135

. The

actual cost of a blood product unit and transfusion related activities accounts for a significant
portion of hospital spending. ranging from 1.6 – 6.0 million per hospital surveyed

136

. Product

acquisition costs contribute only 21 to 32 percent to transfusion related expenditure. Blood unit
costs vary geographically with regional variation. Mandatory, transfusion-specific, informed
consent in the United States accounts for 1.2 to 2.5 percent of total transfusion-related
expenditures

21

. Materials plus fixed and variable labor costs contribute approximately 18

percent and indirect overhead (including equipment, utilities, nonprofessional personnel, and
property) is estimated to contribute 46 percent to the total cost of cost of blood product
transfusion 21,137. As a result, total expenditure and utilization varies by 2.3 fold across healthcare
organizations. The spending variation cannot be explained entirely by hospital size, number of
beds, or surgical volume 21. Hospitals‘ total cost of blood annually has been largely driven by the
transfusion rate, which includes factors such as case-mix index; proportion of surgical patients
transfused, number of RBC units per patient transfused, and practice differences
factors have contributed to variation in transfusion rates among hospitals
rate has not been associated with worse outcomes
potential to reducing costs dramatically 21.
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138

138

21,138

. These

. Lower transfusion

. Reducing either of these factors has the

1.4.2. Current Practices
As commonly as transfusions occur in the United States, one may assume that physicians
practice transfusion medicine based on strict standard guidelines. However, the efficacy of blood
product transfusion is poorly understood among practicing physicians

139-143

. A broad variation

exists not only with regard to what type of blood components to transfuse and how much, but
also with regard to whether to transfuse at all

144-149

. ―For 100 years, we‘ve assumed blood

transfusion is good for people, but most of these clinical practices grew before we had the
research to support it 150‖. ―The current transfusion triggers were established over sixty years ago
at the time when transfusion medicine was still in its infancy‖

150

. Over the past fifteen years,

scientific studies have highlighted the overuse of blood transfusion based on outdated transfusion
triggers and guidelines of practice

151-155

. A recent systematic review of 494 studies on the

appropriateness of allogeneic RBC transfusion has illustrated that up to 59 percent of
transfusions are unnecessary 142, providing either no benefit, or heightened risk of complications
for patients, and increased cost of care

142,156

. Additionally, published studies have associated

blood transfusions with negative outcomes including longer length of stay, increased rate of
infection, postoperative complications, myocardial infarction, pulmonary edema, and mortality
131,157

. Transfusion reaction is defined as any adverse event or complication that occurs in

relation to the transfusion of a blood component

152,158

. Historically, infections were considered

the main risk, but because of the abundant donor testing and thorough donor screening, the risk
of acquired infectious diseases through transfusion has declined drastically 159,160. The infectious
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complications and the current infectious risks of blood transfusion are represented in Table 1 161178

.

Table 1 - Infectious complications and risks of blood transfusion, 2007 to 2012.

With the decrease in rate of transfusion-transmitted infectious diseases, non-infectious serious
hazards of transfusions have emerged as the leading complication of transfusion 16. Research has
shown, a patient is 1000 fold more likely to experience non-infectious complications than an
infectious complication of transfusion

179

. Some of the more common non-infectious serious

hazards of transfusions include transfusion reactions such as hemolytic, febrile, septic, allergic,
urticarial, and anaphylactic. Transfusion of the incorrect product to the incorrect recipient is
another potential hazard. Other problems include transfusion-related acute lung injury (TRALI),
transfusion associated circulatory overload, post-transfusion purpura, transfusion-associated graft
versus host disease, microchimerism, transfusion-related immunomodulation, alloimmunization,
metabolic derangements, massive coagulopathic transfusion complications, red cell storage
lesion complications, over or under transfusing complications, and iron overload 16. Table 2 lists
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the non-infectious complications and the current non-infectious risks of blood transfusion with
associated clinical signs and symptoms 161-178. An analysis by the Food and Drug Administration
(FDA) showed hemolytic transfusion reaction alone has accounted for more than twice of
transfusion-associated fatalities compared to all infectious hazards combined

180

. Meta-analysis

from risk-adjusted observational studies has shown RBC transfusions are associated with a 69
percent increase in mortality and 88 percent increase in morbidity 181. The major concern now is
the non-infectious hazards of blood transfusion.

Table 2 - Non-infectious complications and risks of blood transfusion, 2007 to 2012.

1.4.3. Need for Change in Transfusion Medicine Practice
It has been more than a decade since the publication of the landmark study ―Transfusion
Requirements in Critical Care (TRICC) trial‖

148

and many others studies

supporting the restriction of RBC transfusions for patients
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185

140,142,149,155,182-184

. Since then, there have been some

reports indicating improvements in transfusion practices, mostly with regard to reduced
hemoglobin thresholds at which patients are transfused

186-188

). Nonetheless, the overall use of

allogeneic RBC transfusions in clinical practice remains relatively high and still varies widely
185,189-191

among many centers and practitioners

. One underlying issue is that many physicians

were trained before transfusion research and evidence were available regarding transfusions. For
example ―the leading risk factor for perioperative transfusion is preoperative anemia‖.
Preoperative anemia can be feasibly corrected with advanced testing and preoperative
interventions such as vitamin B12, folic acid, erythropoietin

154,192,193

. Historically, some

physicians have been taught liberal transfusion practice and to follow the maxim ―if you are
going to transfuse, why not give two‖
examined RBC

15,194,195

148,149,155,162,182,183,196,197

. Now, however, numerous research studies have

and platelet use

27,198-202

. This has led the American

Association of Blood Banks (AABB), the Joint Commission, the World Health Organization,
and other groups, to publish guidelines to help guide evidence-based practice in transfusion
medicine

15,162,203,204

. Nonetheless, many clinicians are slow to change

15

, and some are even

skeptical without seeing hard evidence, such as individualized data driven reports, information
on latest research evidence in practice, reports on their individual practice and the practice of
their peers.

1.4.4. Scrutiny of Transfusion Efficacy
Over the past two decades, the efficacy of transfusion, particularly RBC, has been challenged.
Recent clinical studies have indicated that transfusion of critically ill patients with traditional
hemoglobin level triggers i.e. to maintain hemoglobin levels in the range of 10.0-12.0 g/dL, may
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not improve patient outcomes

153,205-208

. Restrictive RBC transfusion practices, in which RBC

transfusions are given at lower than ―traditional‖ hemoglobin levels i.e. to maintain hemoglobin
levels in the range of 7.0-9.0 g/dL, have been proven safe in multiple randomized controlled
trials 139,140,158,209. Given that RBC transfusion is one of the top five overused procedures 210 with
its increased risks and costs, there is a growing recognition of the need to implement strategies to
reduce transfusions. The concept of Patient Blood Management (PBM) has evolved as a strategy
to promote a proactive rather than reactive approach.

Even though, over the past twenty years, ―high-level research in transfusion medicine has been
undertaken at the same rate as in all other medical specialties in terms of numbers of randomized
controlled trials and meta-analyses‖

211

,

there is a considerable variability that exists in

transfusion practices within different groups of patients 142,149,212-217, including critically ill 205,218220

and acutely ill 182,221-223 hospitalized patients, obstetric patients224,225, and patients undergoing

various surgical procedures (i.e. cardiac

146,226-228

, hip and knee

229-232

, neck and spine

188,233-235

surgeries. Variation in transfusion practices has been observed nationally among physicians
practicing in the same geographic region or even in the same healthcare institution performing
the same procedures on patients but producing different rates of transfusion and, consequently,
varying outcomes. The decision on whether or not a patient receives a blood transfusion depends
on each physician‘s training on the clinical indication of anemia, the tolerance level of anemia,
the patient‘s physiological condition and the level of need for correction of the anemia

217,236

. In

addition, since it is known that untreated anemia can have adverse effects, physicians are often
prompted to transfuse even if the benefits of transfusion are not entirely certain

237

. Another

significant contributing factor is inadequate formal training of clinicians on the clinical
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indications for blood transfusion therapies during their time at medical school

238-240

. Audits and

review of clinical transfusion practices have consistently demonstrated deficiencies in knowledge
and practice of blood product transfusion, which impact patient safety and outcomes. Studies 241243

on the effect of formal educational programs on transfusion safety have identified deficiencies

in the practice of transfusion medicine, including inappropriate transfusion prescribing, improper
administration of blood products, improper documentation, and inadequate identification of
potential transfusion recipients.

1.4.5. Patient Blood Management
Patient Blood Management (PBM) is defined as ―timely application of evidence-based medical
and surgical concepts designed to maintain hemoglobin concentration, optimize hemostasis, and
minimize blood loss in an effort to improve patient outcome‖

204

. Further it is defined as ―an

evidence-based, multidisciplinary approach to optimize the care of patients who might need
transfusion.‖ It encompasses all aspects of ―patient evaluation and clinical management
surrounding the transfusion decision-making process, including the application of appropriate
indications, as well as minimization of blood loss and optimization of patient red cell mass‖ 244.
The concept of PBM promotes a proactive rather than reactive approach to the practice of
transfusion medicine addressing anemia, coagulation conditions, and blood conservation, with a
focus on the practice of restrictive approaches in order to ―reduce or eliminate transfusions when
applied as a multimodality approach‖127. The goal of PBM is to reduce unnecessary or
inappropriate resource utilization and improve patient outcomes
evidence-based approach to medicine.
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245,246

. PBM is rooted in an

1.4.6. U.S. Department of Health and Human Services Recommendations
The United States Department of Health and Human Services (HHS) Advisory Committee on
Blood and Tissue Safety and Availability has recognized the significant risks associated with
transfusions, the wide variability and deficiencies in transfusion practices, the changing patterns
of demand for blood, and the documented success of PBM programs. Therefore, the Advisory
Committee on Blood and Tissue Safety and Availability has made the following
recommendations:


Identify mechanisms to obtain data on PBM, utilization of transfusion and clinical
outcomes.



Support, develop, and circulate national standards for blood use recognizing the value of
patient management, blood conservation, and conservative blood use.



Establish transfusion expertise integral to transfusion practices in hospitals and other
patient care settings.



Establish metrics for good practices of blood use and PBM.



Advise the Office of the National Coordinator for Health Information Technology on the
need to integrate PBM and blood utilization into electronic health records.



Promote education of medical students and practitioners on optimizing PBM and the use
of transfusion, and elevate awareness of the essential role of PBM in the quality and costefficiency of clinical care.



Promote patient education about the risks, benefits and alternatives of transfusion to
promote informed transfusion decision-making.



Support demonstration projects on PBM.
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Support research on non-invasive clinical measures to define indications for transfusion,
e.g., ischemia, hemostasis, platelet function, and patients‘ functional status247.

1.4.7. Recommendations of Health Organizations
The World Health Organization (WHO) followed the HHS recommendations with the adoption
of declaration 63.12 ―addressing the global importance of incorporating PBM into clinical
practice as a patient safety measure

247

‖. In conjunction with these activities, the American

Medical Association (AMA) and the Joint Commission have introduced Patient Blood
Management Performance Measures to help evaluate the appropriateness of transfusions as a
continuous quality indicator 210. Establishing an evidence-based approach to blood utilization has
the potential to encourage appropriate transfusion practice and simultaneously reduce blood
utilization, while improving patient outcomes and substantially lowering healthcare organization
expenditures

142,164,246,248-251

. Such an approach conserves a precious resource and permits the

same blood products to be re-directed to other patients who are in true need of the supply within
or outside the hospital 251,252.

1.4.9. Implementation of a Patient Blood Management Program
To date, practice of transfusion medicine has followed the approach of traditional medicine,
where the decision-making relied more on physicians‘ background knowledge, clinical
experiences, consultation with senior physicians and textbooks 93. Even though some of the basic
principles behind evidence-based medicine have been known for many years, the concept and
approach to integrating evidenced-based decision making into clinical practice on a day-to-day
basis have only evolved over the past twenty or more years 6. The emergence of compelling
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evidence of the benefit and the need to change has begun to change the landscape of transfusion
medicine. The shift is to base decision making on evidence-based practice, and to promote a
convergence of both individual clinical expertise and the best available evidence 6,93,253.

1.4.8. The Need to Promote EBP in Transfusion Medicine through PBM
A 2011 editorial on blood transfusion practices stated, ―Possibly the major obstacle to making
transfusion practice more consistent and in line with published guidelines and evidence-based
medicine is the overall lack of knowledge regarding transfusion medicine shared by clinicians
across specialties as evidenced by published data. This evidence would seem to indicate that
medical education in transfusion medicine continues to lag behind. Thus, no matter what the
conclusions of future studies on transfusion efficacy turn out to be, there will be little impact on
blood utilization overall if we continue to fail to educate the end users

217

‖. Transfusion triggers

cannot be precisely defined and there are questions as to whether a non-bleeding patient will
benefit from blood transfusion, particularly a patient whose hemoglobin concentration is in the
middle range of published guidelines, i.e. between 7.0 and 10.0 g/dL [257]. This has led to
inconsistent transfusion practices and often inappropriate transfusions. There is a particular need
to bridge the gap between evidence and transfusion medicine practice.

1.4.10. Patient Blood Management Implementation Requirements
Organizational Structure and Engagement
There is mounting physiological, medical, ethical and financial evidence that a change in
physician transfusion practices is essential to ensure patients‘ improved quality of care and
40

outcomes. Implementation requires a top-down approach.
clinicians, which makes the effort difficult to embrace

PBM challenges the training of
254

. Endorsement from top senior

executives is essential to prioritize, determine urgency, and allocate resources (i.e. human,
financial, and information technology services) in order for the program to successfully roll-out
across different hospitals

255

. The level of support and engagement provided by hospital

executives can greatly impact the success of the program both positively or negatively. In order
to engage physicians and other clinical providers, it is essential for executives to be educated on
the evidence supporting PBM, so they can speak knowledgably to the initiative. Implementation
of PBM involves and requires diverse groups of stakeholders including: administrative (C-suite
executives, senior vice presidents, vice presidents, department heads, and quality teams), clinical
(multispecialty [i.e. surgery, anesthesiology, intensive care, etc.], multidisciplinary [medical,
nursing, perfusion, etc.], laboratory [pathology, blood bank, and transfusion service]), and
information technology and informatics. Healthcare organizations or hospitals have to overcome
significant practical and political challenges to effectively implement PBM programs at their
facilities.

At its core, PBM aims to re-educate healthcare providers on the latest evidence-based research in
order to promote the change to best-practices. Re-education of physicians with ingrained
transfusion practices is difficult. PBM principles apply to many different medical disciplines and
affect many patients‘ clinical care and treatment plans which makes implementation of a robust
and scalable PBM program healthcare system-wide or hospital-wide very challenging. The
program requires a Transfusion Medicine Medical Director who is knowledgeable of the
intricacies of transfusion medicine and a PBM Committee whose members are tasked with
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driving implementation of the program in their area of discipline. The Committee should consist
of respected stakeholders and physician champions from different medical disciplines to
illustrate the legitimacy of the initiative within a hospital

255,256

. The committee must be

convinced of the value of the program, believe in the principles of PBM and trained in their
roles, responsibilities and the vision for the program. It is essential for senior executives to work
closely with the PBM Committee as well as with quality and IT personnel to assess the hospital
areas in greatest need of improvement from a PBM approach and to ensure that the planned
initiatives are relevant for surgical and non-surgical physicians within each discipline 256.

Prior to implementation, assessment and base line analysis must be conducted to evaluate current
practice and to identify areas of focus that should be communicated to all stakeholders. Current
state and continuous analysis of transfusion medicine practice requires: a deep knowledge of
transfusion medicine; familiarity with the context and type of data and information that is
required for assessment; knowledge of the various health information systems in play; and a
mechanism for bringing fragmented data and information together for coherent reporting and
evaluation. The significant challenge associated with this analysis will be discussed in depth.
PBM requires transfusion medicine expertise to routinely evaluate and examine the latest
transfusion medicine evidence and guidelines for different disciplines, in order to synthesize and
communicate educational materials to relevant medical disciplines. Reports must be developed
based on hard data and evidence to provide physicians and other clinical professionals with
information about their practice relative to current evidence-based best-practice guidelines.
Evaluation and analysis of transfusion medicine practice and communication of the progress in
outcomes are the key factors in the success and sustainability of PBM program.
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Data, Analytics, and Reporting
Identification, extraction, aggregation, and analysis of contextual data are critical in providing
the meaningful information needed to raise awareness and empower informed decision making.
Transfusion related data is captured in different formats and in several diverse and disparate
source systems both on the administrative and the clinical side. This impedes the aggregation of
the minimum data sets required to feed the measures and indicators, thus hinders reporting and
analysis. In transfusion medicine, in order to provide a comprehensive view on performance of a
healthcare organization and individual physician practice, data from both clinical (clinical
service lines, laboratory, pharmacy, transfusion service, etc.) and administrative (billing, finance,
information services, credentialing, etc.) departments are required. Healthcare organizations have
always generated a multitude of data including: administrative information, clinical indicators,
procedural indicators, provider and staff measurements and interpretations and equipment
readings. However, most of the generated data is stored in hard copy form, outdated legacy
platforms, or siloed information systems. Even though the aim of digitization of healthcare is to
transition from fragmented healthcare delivery systems to integrated healthcare models,
challenges remain. Even as EHRs are becoming the norm as a way to provide fast and easy ways
to share data and make information accessible to more members of patients‘ care delivery teams,
many components of healthcare organizations and hospitals still operate on diverse and disparate
departmental information systems with inefficient and ineffective data and information gathering
and reporting systems

257

. While each department and branch of operations has unique needs,

siloed technical and information ecosystems compromise cross departmental data aggregation,
reporting, and analysis and foster fragmented clinical and administrative decision-making.
Transfusion practice reporting and performance tracking is often not available. If it is available,
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it may not contain the detailed level of information necessary to highlight trends in an individual
physician‘s practice. Manual data collection and analysis is not feasible or sustainable. It requires
alignment of staff and resources in order to accomplish an arduous process on an ongoing basis.
The process is time consuming, challenging, inefficient, and costly 258.

Presentation of Actionable Information
The meaningful presentation of actionable information must be provided on a routine basis to
guide transfusion practice and encourage sustainable behavior change. The information should
provide a baseline of current practice against which to measure progress in future improvement
initiatives. Many healthcare organizations lack the reporting mechanisms. The lack of necessary
information negatively impacts the work of the PBM Committee, the Transfusion Medical
Director, and the physicians because they are unable to adequately monitor the manner in which
transfusion medicine is being practiced. To date, monitoring physicians‘ transfusion practice has
been primarily achieved through individual chart reviews by a transfusion committee to ensure
appropriateness of transfusions as determined by the hospital‘s medical staff

238,259

. However,

the common practice of individual chart review frequently fails to recognize the forty to sixty
percent 142,260 of inappropriate and non-beneficial transfusions that occur in almost every hospital
259

. There are many reasons that individual chart review is not as effective as it is intended to be

259

, including:


the underlying complexities surrounding transfusion medicine;



lack of or limited subject matter expertise;



limited knowledge of the intricacies of transfusion practice;



lack of awareness of the latest evidence and best practices;
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outdated and inappropriate transfusion criteria and guidelines for evaluation of
transfusions, e.g. using a single lab value as a reference point for determination of
appropriateness, in contrast to a comprehensive evaluation of the patient‘s condition;



limited or lack of a ―big-picture‖ view of hospital and provider transfusion practice;



uncompensated physicians‘ review time;



organizational culture and disciplines;



reviewer bias, particularly when physicians review the work of other physicians with
whom they may have work, economic, political, social, and referral relationships. 259.

1.5.

Current Approaches

Data gathering from diverse and disparate systems within a healthcare organization is a major
impediment to implementation of an evidence-based PBM programs. Some forward-looking
healthcare organizations have been relying on manual processes to capture transfusion data and
report information

258

. This approach is highly redundant and time-consuming and introduces

great potential for human error. It is important to note that manual analysis and review are taking
place in healthcare settings with diverse health information ecosystems, where interoperability
and data integration is very limited or non-existent. In such environments, data is stored in
multiple disparate systems, with limited or lacking interface capabilities with other systems. As a
result, one must work with fragmented data which can create an incomplete view of a clinical
event. This method of monitoring can create conflicting perspectives on the type of data
necessary to capture and report258. Such an approach may also introduce tension between
colleagues, which can negatively impact the benefits of monitoring efforts and affect both quality
and compliance measures. Traditional manual processes are resource intensive and most likely
45

require multiple full-time equivalents to handle the laborious task. Therefore, this approach is not
feasible and sustainable on an ongoing basis258. To date there is no framework for efficiently
accessing relevant data and information in a coherent, contextual manner, in order to learn about
and evaluate transfusion practices and monitor providers‘ transfusion behavior in an
organization.

Bringing together data from diverse and disparate systems remains a major

impediment to the practice of evidence based transfusion medicine practice.

1.6.

Conclusion: Application of an Evidence-Based Data Analytics Framework

Healthcare is undergoing a paradigm shift from authority-based to evidence-based medical
practice in response to current clinical, financial and regulatory challenges. Significant hurdles
face organizations as they struggle to implement successful, scalable evidence-based programs
4,93,261-263

. A great deal of attention is being paid to evidence-based practice in the area of

transfusion medicine with the implementation of Patient Blood Management programs. Despite
the fact that blood transfusion is among the top ten most prominent coded procedures according
to U.S. hospital discharge records

12,13

, the efficacy of blood product transfusion is poorly

understood among practicing physicians18,152,181,222,228,264,265 making transfusion medicine an area
ripe for improvement through evidence-based approaches.

This study demonstrates the effectiveness of an evidence-based approach to transfusion medicine
practice that can be applied to many areas of medical practice. It takes into account the clinical,
administrative, cultural and technical issues that make the implementation of an evidence-based
program so challenging. The study focuses on reducing the inappropriate practices in transfusion
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medicine, particularly in the transfusion of allogenic RBC in healthcare institutions.

A

framework was developed that promotes the use of evidence-based guidelines by:


Obtaining broad organizational engagement;



Obtaining physician engagement and attain accountability;



Incorporating latest evidence and best practices into medical practice;



Identifying, extracting, and aggregating contextual data from diverse and disparate source
systems;



Identifying measures and indicators to track transfusion behavior in accordance with the
latest evidence;



Developing a performance management system;



Transforming physician specific data into meaningful information;



Providing current targeted information to physicians and administrators;



Enhancing awareness and education;



Developing a feedback mechanism;

This study demonstrates the importance and the effectiveness of the tight integration of these
elements to promote evidence-based decision-making at the point of care. The approach bridges
the gaps that exist between the latest medical knowledge and current physician practice and has
the potential to improve the quality of patient care, improve outcomes and decrease the cost of
care.
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Chapter 2:
2.1.

Literature Review

Healthcare Industry and Transformation of Clinical Practice

2.1.1. Evidence-Based Practice as a Way to Improve Quality of Care
Healthcare organizations are being pushed in the direction of evidence-based practice as a way to
improve quality and patient safety. Research has constantly shown clinical decisions are rarely
based on the most current and best available evidence. Rosenberg states in a 1995 article that
―For decades people have been aware of the gaps between research evidence and clinical
practice, and the consequences in terms of expensive, ineffective, or even harmful decision
making‖

266-268

. The current magnum opus of evidence-based practice is the book published by

Sackett and colleagues in 2000 titled Evidence-Based Medicine: How to Practice and Teach
EBM

84

. The book defines EBM as ―the integration of best research evidence with clinical

expertise and patient unique values and circumstances.‖ It also provides definitions for: (i) best
research evidence as ―clinically relevant research, sometimes from basic sciences of medicine,
but especially from patient-centered clinical research into the accuracy and precision of
diagnostic tests, the power of prognostic markers, and the efficacy and safety of therapeutics,
rehabilitative, and preventative strategies‖; (ii) clinical expertise as ―the ability to use clinical
skills and past experiences to rapidly identify each patients‘ unique health state and diagnosis,
their individual risk benefits of potential interventions, and their personal values and
expectations‖; (iii) patient values as ―unique preferences, concerns, and expectations each patient
brings to clinical encounter and which must be integrated into clinical decision if they are to
serve the patients‖; and (iv) patient circumstances as ―their individual clinical state and the
clinical setting‖84. Once ―the four elements are integrated clinicians and patients form a
diagnostic and therapeutic alliance, which optimizes clinical outcomes and quality of life‖84.
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Sackett and colleagues explicitly note that evidence-based practice is not a static state of
knowledge but rather represents a constantly evolving state of information. Healthcare
practitioners have the obligation to continually stay abreast of clinical developments in research
and to incorporate such developments into daily care

84,269

. To practice EBM the following

steps must be followed 84:


Convert one‘s need for information into an answerable question.



Track down the best clinical evidence to answer that question.



Critically appraise the evidence in terms of its validity, clinical significance, and
usefulness.



Integrate this critical appraisal of research evidence with one‘s clinical expertise and the
patient‘s values and circumstances.



Evaluate one‘s effectiveness and efficacy in undertaking the four previous steps, and
strive for self-improvement.

Evidence-based practice offers healthcare providers both the opportunity and the challenge to
―avail themselves of the emerging knowledge-base and of the developing philosophy and
approach to service delivery known as evidence-based practice‖, which is ―scientifically tenable
and ethically incumbent‖

269

. Evidence-based practice presents significant complexities and

opportunities not only for those in academics in charge of developing and maintaining the stateof-the-science, and the state-of-the-art clinical training programs, but also to those providing
clinical supervision to physicians and other healthcare providers 269.
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2.1.2. Knowledge Translation
In 2000, the term knowledge translation was defined by the Canadian Institute of Health
Research 270 as ―the exchange, synthesis and ethically-sound application of knowledge— within
a complex system of interactions among researchers and users—to accelerate the capture of the
benefits of research for Canadians through improved health, more effective services and
products, and a strengthened health care system‖271. The World Health Organization (WHO)
defined knowledge translation as ― the synthesis, exchange, and application of knowledge by
relevant stakeholders to accelerate the benefits of global and local innovation in strengthening
health systems and improving people‘s health‖

272

. In other words, ―any activity or process that

facilitates the transfer of high-quality evidence from research into effective changes in health
policy, clinical practice, or products

273

‖. The Canadian Institute of Health Research

274

has

defined the steps for knowledge translation, to include: dissemination, communication,
technology transfer, ethical context, knowledge management, knowledge utilization, two-way
exchange between researches and those who apply knowledge, implementation research,
technology assessment, synthesis of results with the global context, and development of
consensus guidelines. The steps encompass elements previously implicated in the application of
knowledge270. Sudsawad characterizes knowledge transfer as:


Including all steps between the creation of new knowledge and its application,



Needing multidirectional communications,



An interactive process,



Requiring ongoing collaboration among relevant parties,



Including multiple activities,



A nonlinear process.
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Emphasizing the use of research-generated knowledge that may be used in conjunction
with other types of knowledge,



Involving diverse knowledge-user groups,



User and context specific,



Impact oriented,



An interdisciplinary process.



Knowledge translation has been increasingly valued in healthcare as it ―represents the
process of moving what is learned in research to actual application of such knowledge in
variety of practice setting and circumstances‖ 270.

2.1.3. Translation of Knowledge in Evidence-Based Practice
The growing interest in evidence-based practice which integrates research evidence into clinical
decision-making coincides with an increased emphasis on knowledge translation74,270. Evidencebased practice makes knowledge translation an increasingly imperative discipline

273

. It aims to

―conceptually combine elements of research, education, quality improvement, and electronic
systems development to create a seamless linkage between interventions that improve patient
care and their routine implementation in daily clinical practice

273

‖. Despite the strong

endorsement for evidence-based practice, the translation of research findings (knowledge) to
clinical practice is a well-recognized challenge in healthcare 270,275-279. Common hurdles include:
the sheer volume of research evidence; time required to gather findings; skills needed to interpret
research evidence; conflicting evidence, irrelevant evidence; limited access and cost of
continuing education; lack of supervisory support; lack of or limited access to scholarly articles;
physician attitudes towards evidence-based practice; inadequate organizational leadership;
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inadequate responsiveness to program participants; failure to include stakeholders from multiple
disciplines; lack of transparency to foster trust; and difficulty in evaluation of efficacy of final
program on patient health

96,99,262,279-282

.

As a result of the challenges associated with the

translation of knowledge into practice, gaps exist between research and clinical practice, which
present a real barrier to clinical implementation of innovative research findings

283

. The

consistent failure to translate evidence into practice, has contributed to three major shortcomings
in healthcare system

280

which include: preventing patients from benefiting from latest

discoveries and advances in treatments and interventions; exposing patients to unnecessary risks
of iatrogenic harms; and exposing healthcare systems to unnecessary expenditures at significant
cost

280

. Both the knowledge and the application of the knowledge are essential in all areas of

medical practice. It is imperative to bridge the gap that exists between research evidence and
practice.

2.1.4. Technology in Healthcare
Technology is the engine of change that has set the stage for an unprecedented transformation in
healthcare

284

. Digitization of data has been one of the key underlying factors in the rapid

transformation of healthcare as and in other industries. Digitization refers to the conversion of
an analog signal to a digital one 285, where analog data are measured as continuous variables and
digital data are measured as simple discrete variables 285,286. Digitization of patient care has been
driven by wireless sensors and devices, imaging, health information systems, and genomics

287

.

Each of the digital medical technologies is propelling healthcare forward at an unprecedented
pace, focusing on human biology, physiology, and anatomy to illuminate what Topol refers to as
the ―high definition man‖287. Use of technology in healthcare has been focused on digitization of
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various processes, which has led to the accumulation of large amount of diverse and siloed
electronic data related to admissions, billing, health records, finances, imaging scans, pharmacy,
lab, transfusion service, insurance claims, scheduling, and etc., in disparate health information
systems. Various reform efforts like the ACA‘s meaningful use requirement, accountable care
organizations, health information exchanges, public health exchanges, and other initiatives seek
to place patients at the center of care

288

with the use of various technologies. The aim of the

healthcare initiatives is to improve patient care and lower the cost through meaningful use of
patient data and information in order to enhance appropriate decision-making and interventions.
―Health information systems serve as an indispensable foundation for improved delivery of
routine health services in an evidence-based manner‖289. Development of information systems
has provided a way to reduce medical errors, improve patient outcomes, and increase
collaboration among care providers

290

. Although these approaches

have the potential to

dramatically improve the delivery and quality of healthcare, they are contingent upon data
exchanges and interoperability of the various information systems which to date have been a
great hurdle and ―largely an unreached goal 290‖.

2.1.5. Uniqueness of Healthcare Data and Complexity of Reporting
Healthcare data are unique both in complexity and diversity. Healthcare data have characteristics
that vary from any other industry. In a healthcare setting data reside in multiple source systems
(i.e. from EHRs, medical credentialing systems, claims processing systems to specific
department systems such as lab, transfusion service, pharmacy, radiology, etc.). Data also occur
in different formats (e.g. text, numeric, paper, digital, pictures, video, multimedia, etc.). It is the
norm for the data to exist in different systems and in different formats
53

291

. For example, in the

case of a patient with a broken arm, the medical records show an image of a broken arm.
However, the broken arm appears as ICD-9 code 813.8 in claims data. Additionally, contrary to
common belief, data have been anything but consistent. For years, clinical data have been
captured on paper in however way is most convenient for the healthcare provider with little
regard for how the data could eventually be aggregated and analyzed 291. EMR and EHR systems
have attempted to standardize the data capture process, but physicians and other healthcare
providers have been reluctant to adapt to a ―one-size-fits-all‖ approach. As a result, most of the
data have been captured in both a structured and an unstructured manner, which makes it
difficult to aggregate and analyze

291

. Another problem has been the variability and

inconsistencies of healthcare data. Variability exists in the length of the same data element (e.g.
patient last name 50, 25, 16 characters), and in the values for the same elements (e.g. Gender: M,
F, or U; or Male, Female, or Other). Inconsistencies exist in naming conventions (e.g. Date of
Admission, Admission Date, Admit Date, etc.), and in definitions of terms (e.g. patient access
modules defined date of admission as the date

inpatient or day surgery visit occurs; trauma

registry defined the date on which the trauma patient enters the operating room, and etc.)

292

.

Addressing the complexity surrounding the development of standard processes to improve
quality is one of the main goals of recent changes in healthcare system. However, aggregation of
administrative data (e.g. admissions, insurance, billing) with clinical data (e.g. EHR, pharmacy,
radiology, transfusion service, lab) to create a more complete picture of the patient‘s story is very
challenging. There is no finite number of identical parts to create identical outcomes. Rather
there is an amalgam of individual systems each with its own complexity designed to capture
different information about an individual. Managing data from disparate systems and turning
them into meaningful information requires a sophisticated set of tools, approaches, and a broad
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range of expertise 291. As research advances and knowledge is enriched, new best practices arise
with new definitions of terms, new criteria, and different approaches. Best practice is
continuously being redefined in an unpredictable manner contributing to the complexity of
aggregating contextual data. Furthermore, as medicine and healthcare technology evolve,
regulatory and reporting requirements change (i.e. CMS quality requirements such as
readmissions) adding to the burden of aggregating and reporting of data.

2.1.6. Diverse Health Information Systems
Integration and interoperability of different health information systems is a fundamental
requirement for achieving continuity of care and a comprehensive view of patients‘ health.
Currently, health information systems used in each department (i.e. admissions, billing,
laboratory, pharmacy, transfusion service, etc.) within hospitals and across healthcare
organizations have been developed independently with diverse sets of approaches in methods,
processes, and procedures for capturing data and presenting the information

293

. Additionally,

lack of specificity in healthcare standards and information sharing protocols, has resulted in a
―large number of heterogeneous and distributed proprietary models for recording and
representing patients‘ data and information‖290.

Diverse and disparate health information

systems pose great challenges for the exchange of patient data causing duplication of data, a
considerable amount of transcription (i.e. transfer of data from one system to another such as
transfer of patient diagnosis data from patient records to an order entry form) and maintenance of
referential integrity when data is replicated or duplicated 293. Other challenges include the cost of
uncontrolled redundancy, maintenance, and updating. Much of the difficulty pertains to the
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proprietary nature of each system and the syntactic and semantic differences across them. These
challenges are ―exacerbated by the lack of standardization between health information systems
and the costs associated with software upgrades and data restructuring‖

294

. As a result of the

disparity that exists among health information systems, gaining user acceptance is another major
challenge due to the learning curves associated with the use of each system resulting from
different user interfaces, overlapping features, separate user identification procedures, and many
more issues.

2.1.7. Data Integration Challenges
―A key attribute of a learning health care system is the ability to collect and analyze routinely
collected clinical data in order to quickly generate new clinical evidence, and to monitor the
quality of the care provided. To achieve this vision, clinical data must be easy to extract and
stored in computer readable formats‖ 295. Clinical data provide the health context directly related
to an individual patient. Clinical data include patient vital signs, laboratory tests, scans, medical
history, immunization record, family history, life-style information, physical exams, diagnoses,
progress notes, operative reports, ambulatory care reports, care plans, medication reports, and
etc. Integration of clinical data ―facilitates the coordination of patient care across conditions,
providers, settings, and time in order to achieve care that is safe, timely, effective, efficient,
equitable, and patient-focused‖

296

. Integrated data can greatly assist care providers in making

accurate assessments and interventions, administering proper treatments, and optimizing
operations among peers in the department and across organizations. However, achieving clinical
integration faces significant challenges due to heterogeneity of healthcare ecosystems in which:
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data tend to reside in multiple different sources; data collection occurs in different formats (i.e.
text, numeric, hand written paper, digital, pictures, videos, and etc.), and the same data exists in
different formats in multiple systems. Structured and unstructured data is another issue 297. EHR
systems attempt to standardize the data capture process. However, providers are disinclined to
adapt to a one-size-fits- all approach to documentation and unstructured data capture has been
put in place to allow autonomy and leniency in this process

290

. This approach introduces

inconsistency in data capture and makes data aggregation and analysis very cumbersome.
Complexity of medical data is another factor. Although construction of workflows and
standardized processes for data capture does improve quality, the number of variables that exist
in medicine makes the effort far more challenging, particularly when the variables are being
captured in disparate applications

291

and are subject to change as new evidence emerges. The

variability that exists in healthcare terminology and definition is also problematic

290

. Much of

the data are not available in easily extractable and structured formats. While textual and
unstructured data are convenient for both entering and reviewing of patient history and progress
by care providers, they present significant obstacles for graphic presentation, searching,
summarization, and statistical analysis 295.

―The principles of evidence-based health care posit that clinical and public health decisions
should be made using, among other elements, the best available clinical evidence‖75,295,298.
Evidence-based practice focuses on incorporation of the latest scientific and clinical evidence
into practice 75. It is gaining ground in the current healthcare environment as a means to improve
quality and productivity of healthcare services by reducing variation in care

75

. As great as

evidence-based practice is, it also contributes to the challenges of data integration. The
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continuous advancement in the understanding of the functions of the human body, adds new
variables, changes what is considered important, adds new variables, changes the how, what and
when of measurements, and alters how to determine goals and reach targets. As a result of our
advanced understanding we routinely add inconsistencies to ways we aggregate and manage
data. Changing and increasing regulatory and reporting requirements also affect data integration.
The Center for Medicare and Medicaid Services requires various types of reports such as clinical
quality measures, outcome based measures, readmission rate, and etc. to provide transparency in
quality and pricing information to public 291.

2.1.8. Issues of Interoperability
It is widely accepted that medicine requires complex and highly specialized information
technology systems

299

. This complexity has led to the development and use of a variety of

diverse health information systems that often address the needs of small units within a larger
organization.

The concept of seamless interoperability rests at the center of all this.

―Interoperability is a fundamental requirement for ensuring that widespread EMR adoption will
give us the social and economic benefits that we want‖300. There are three dimensions to
interoperability, which include:


Business Interoperability focuses on organizational context such as policies, agreed upon
organizational communication practices. Business Interoperability is independent of
existing technologies.



Technical Interoperability tolerates heterogeneity in hardware and software but allows
them to coexist in harmony, in addition to ―Plug-and-play‖ of new devices.
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Information Interoperability focuses on the ability to interchange data in a meaningful
manner through establishment of common semantics 301.

An interoperable healthcare technology system facilitates the ―right information at the right time
and place‖ and depends on ―systems being able to exchange information in a way that is safe,
secure, and reliable‖

302

. The concept of interoperability is multifaceted and means something

different for different individuals. HIMSS Dictionary of Health Information Technology Terms,
Acronyms, and Organizations lists seventeen different definitions from purely technical to
definitions that include all the various aspects of interoperability such as technical, social,
political, and organizational. A widely used definition has defined interoperability as the ―ability
of two or more systems or components to exchange information and to use the information that
has been exchanged‖303. There are three main components to this definition: (i) the exchange of
information (technical interpretability), (ii) the ability of recipient to use that information
(semantic interoperability), and (iii) the actual use of the information (process interoperability).
Each of the three types carries a same weight as the other two. Because of the interdependency
among them, all the dimensions must be present to deliver significant business benefits304.

Although significant funds have been allocated to address problems of interoperability, the
efforts have been largely unsuccessful

293

. Interoperability is beneficial, but certainly not easy to

achieve. This is because patient health records contain an extensive set of diverse data and
information types, ranging from family history, social habits, diagnostic tests, clinician
assessments, medical history, care interventions and treatment plans. As hospitals introduce new
workflows and technology capabilities to support increasing numbers of clinical quality
measures, they face numerous challenges around discrete data capture, data quality and
59

standardization, including accuracy, integrity, searchability, completeness, quality, redundancy
and consistency, and misaligned, or non-existent incentives 305,306.

Some of the high-level barriers that slow down attempts to achieve interoperability include:


Limited syntactic interoperability, different systems represent the same data in different
ways 307;



Limited ability to capture clinical notes, discharge summaries, administrative
information, etc. in an structured format 308;



Poor quality of data, which includes redundancy, duplication and incompleteness of data,
as well as multiple listings of the same data. Poor data quality hinders analyses and
creates lack of trust in users. In addition, correcting for poor quality data is both timeand resource-intensive undertake, which puts further pressure on already strained
healthcare intuitions 309;



Difficulty in employment of standards in health information technology. There is a
significant need for consensus in the use of standards in the healthcare industry. Types of
standards include:
o

Standards for data exchange and messaging (to allow transactions to flow
consistently between systems or organization using instructions for structure,
format, and data elements);

o

Clinical terminology standards (use of ontologies to provide specific codes for
clinical concepts);

o

Document standards (define for every documents what information must be
included and where they must be found);
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o Conceptual standards (allow data to be transported from one system to another
without losing meaning or context);
o Application standards (the manner in which business rules are implemented and
various software systems interact);
o Architecture standards (to define processes in data storage and distributions).
Although, there have been various initiatives and efforts to develop standards, there has been a
lack of effort and buy-in for deployment and effective use of those standards310. The issue of
standards on its own greatly hinders attempts for interoperability.
Other factors hamper interoperability efforts including:


Lack of cooperation between health information system vendors, as vendors may feel
siloed solutions are more beneficial to their bottom line

311

. Vendors have not been

incentivized to enable sharing of health information across vendor boundaries. As an
example, EHR vendors have been focused on promotion of information sharing only
through their monolithic systems as opposed to supporting interoperability standards 306.


Failure among providers and across organizations to share their data with each other, or
share the connection burden and costs 312.



Vendor resistance to initiatives, as the experts question the effectiveness of meaningful
use incentives in spurring efforts to achieve interoperability. This has led to speculation
that EHR and other solution vendors are purposefully stalling because it is not in their
best interest to achieve interoperability yet

311

. Such speculation bolsters the idea that

interoperability is not just a technical issue, but also a political, economic and even social
one.
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Other complexities of interoperability pertain to the dynamic nature of patient health records, the
rapid accumulation of patient data, and the limited or lack of availability of information in a
meaningful manner at the critical point of care for decision making.

The Affordable Care Act‘s meaningful use incentives are still in the ―carrot‖ phase, which
encourages and simultaneously forces health care organizations to potentially over-commit and
invest multi-million dollars on the implementation of a single EHR system to achieve the
mandated criteria, with the knowledge that interoperability remains a chief concern

313

. As a

result of the lack of interoperability, widespread adoption of EHR systems has exacerbated the
problems of information silos and the fragmentation of patient data and care delivery which exist
today. The ―stick‖ phase begins after 2015 and will affect healthcare organizations if they are
unable to generate and report complete patient quality measure outcomes, due to the
heterogeneity of the healthcare environment, disparate health information systems, and
fragmented patient data. This will potentially result in a significant financial impact

313

for

healthcare institutions. The push for healthcare organizations, hospitals, clinics, and physicians
to collaborate more closely to form an accountable care organizations may have unintentionally
created an atmosphere for slowing down cross-vendor interoperability efforts, as vendors use
these initiatives to further strengthen their sales pitch and push healthcare organization to buy-in
to monolithic systems

313

. Until healthcare reform initiatives properly incentivize vendors,

healthcare institutions, and providers, and until vendors and providers are willing to extend their
boundaries and share the responsibility of interoperability, health information exchange will
likely continue to progress slowly and will negatively impact continuity of care, quality of
patient care, and cost of healthcare

313

. These unintended consequences have potentially slowed
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down interoperability efforts. Without a complete and seamless interoperable environment, the
great promise of seamless patient health records will not be achieved.

2.1.9. Healthcare Silos
―Healthcare is not a system but a set of independent actions and activities that often have little or
no continuity. One reason for this lack of continuity is the silos that exist within the healthcare
environment‖314. The information silos are part of organizational culture and a way of thinking.
In a siloed organizational structure, departments generally do not share the same priorities, goals,
and even the same tools and information technology solutions

315

. Each department operates as

an individual unit or entity within a healthcare enterprise, with different priorities,
responsibilities and vision 316. For many years this model worked well, as there was limited need
to communicate with other departments, with healthcare providers within the hospital, or across
healthcare institutions

316

. As a result of siloed organizational structures, information gathering,

processing, communication, and management have also been operating in an insular manner

317

.

Although health information systems have been essential to health care delivery, they have been
incapable of reciprocal operations with other related information systems

317

. As a result of this

culture, ―the health care sector as a whole has historically trailed far behind most other industries
in investments in information and communications technologies‖

317,318

. Most healthcare related

information technologies and communication investments have been concentrated on the
administrative and business side of the healthcare, rather than on the clinical side. Until recently
because of this ―prolonged under-investment, little overall progress has been made toward
meeting the information needs of patients, providers, hospitals, clinics, and the broad regulatory,
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financial, and research environment in which they operate‖ 317. Healthcare systems are comprises
of a variety of databases that have been designed and built separately for different applications
with no common data model constructs. This makes communications across databases very
cumbersome. ―Communication between people using databases is not the same as
communication among people, which is adequately handled by natural language and
mathematics. Nor is it the same as communication between people and computers which is
adequately handled by computer programming language.

Communication across databases

requires a very different type of language, one that addresses data meaning using functional data
classification and a finite number of relations. Without the use of a data language,
comprehensive person to person communication via databases is extremely limited and true
system integration is virtually impossible‖319. Organizational structures, disparate health
information systems, data integration barriers, and lack of or limited health information systems
interoperability create silos at many different levels within and across healthcare institutions
resulting in fragmented care delivery systems.

2.1.10. Central Role of Analytics in Healthcare
Data analytics and continuous audits are not new concepts. Their appeal and vitality are on the
rise in the healthcare industry as it transitions from volume-based business to a value-based
business. ―With increasing demands from consumers for enhanced healthcare quality and
increased value, healthcare providers and payers are under pressure to deliver better outcomes‖
67

. Clinical and healthcare organizational data have a vast potential and broad range of uses, from

service line profitability, patient quality of care, and outcome analysis, to claims and revenue
64

cycle management and utilization. Building analytics competencies can help organizations
harness ―big data‖ providing critical insights in order to make assessments, meet organizational
goals and achieve competitive advantage

320

. Analytics will be central in demonstrating value

and achieving better outcomes by using new treatments and technologies, and refining outdated
practices. Analytics can improve effectiveness and efficiency in numerous ways by managing
small details as well as large processes, aiding in exploration and discovery, helping policy and
program design and planning, improving healthcare service delivery and operations, enhancing
sustainability, mitigating risk; and providing a means for measuring and evaluating critical
organizational data

67

. Healthcare organizations increasingly use analytics to consume, unlock

and apply new insights gained from their information.

According to a survey report by HIMSS321, healthcare organizations choose to report on the
following types of information:


Data that they are required to track by the government or other external organizations



Data that has the potential to significantly reduce costs and enhance their ability to reduce
the inventory of high-cost products;



Information that is required for recertification of professional staff.

Although healthcare institutions reside in a rich data environment, the healthcare industry lags
far behind in analytical capabilities because of the diversity and disparity among health
information systems and the challenges associated with interoperability and integration of the
various systems, lack and/or limited use of standards, and the use of different data types, data
models, and information. Performing analytics on data that is collected and aggregated using a
single health information system may not be as cumbersome. The difficulty comes with analytics
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that aim to examine heterogeneous data from multiple diverse source systems. This type of
analytics requires aggregation of patient data from multiple health information systems, data
such as admission and discharge records, patients‘ vitals, laboratory tests, patient medical
history, immunizations, family history, life style, physical exams, diagnoses, progress notes,
operative reports, ambulatory care, care plan, medication report, etc. in conjunction with
administrative data.

A 2010 report by Healthcare Information and Management Systems Society (HIMSS) has
identified a number of barriers and challenges that impact efforts to effectively perform analytics
on clinical and administrative data across multiple source systems and data warehouses

322

. The

following issues are in addition to interoperability and integration challenges indicated in
previous sections and they include322:


Static reporting of data and information, which is mostly done in a paper format. These
types of reports do not allow the recipient to manipulate data and the information.
Analysis of paper reports requires extensive data re-entry for manipulation purposes in
order to yield a satisfactory layout.



The assumption that electronically housed data is analysis ready. Data storage,
transformation, and governance are required prior to any analysis.



Limited or lack of access to data elements thatare required for analysis. These types of
data elements may be captured in an alternate format that is not streamlined into the
main data collection tool (e.g. lab values captured at a different site), which requires data
to be either entered manually or omitted from the overall analysis.
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Unstructured or free-form of data capture. These types of data require human curation
and conversion to a discrete or structured field, in order to be used for analysis.



Required expertise. Apple-to-apple results that include many different variables are
challenging and requires skills and expertise to understand what is being measured and
why. Additionally, it is also important to understand the clinical context of a particular
data point, and how the different clinical scenarios can impact that data point. There are
also issues with nomenclature, and ensuring that data is captured using the same
terminology (e.g. data normalization and semantic interoperability).



Limited and/or lack of skilled personal with combination of technical, statistical, and
clinical background to analyze the data that is required for evaluation. There are further
constraints not only because healthcare organizations lack the financial resources to hire
additional personnel, but also because it can be difficult to find individuals who possess
the right skills for the job. As a result, some organizations are turning to external
resources to meet these needs321. Many healthcare institutions rely on different
technological solutions to meet their analytics need with dependence on limited
information technology resources and solutions vendors to develop reports and tools in
order to effectively analyze clinical data. Others are turning to niche vendors that
specialize in the development of data warehouses or data mining to assist in different
types of analysis

321

. To date, the majority of the specialized reports are in a form of

managed static reports, which prevent the end user from manipulating the information for
better understanding or further analysis 67. Every question or a small change to the reports
requires involvement of technical personal and waiting for extended periods of time.
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2.1.11. Current Use and Challenges of Clinical Analytics
A research report by the MIT Sloan Management Review, in partnership with the IBM Institute
for Business Value defined three specific analytics capability segments among healthcare
organizations including: aspirational, experienced, and transformed

323

. Each of the three

segments has its own set of challenges and opportunities:


Aspirational: ―These organizations are the farthest from achieving their desired analytical
goals. Often they are focusing on efficiency or automation of existing processes, and
searching for ways to cut costs. Aspirational organizations currently have few of the
necessary building blocks – people, processes or tools – to collect, understand,
incorporate or act on analytic insights 323‖.



Experienced: ―Having gained some analytic experience – often through successes with
efficiencies at the Aspirational phase – these organizations are looking to go beyond cost
management. Experienced organizations are developing better ways to effectively collect
incorporate and act on analytics so they can begin to optimize their organizations 323‖.



Transformed: ―These organizations have substantial experience using analytics across a
broad range of functions. They use analytics as a competitive differentiator and are
already adept at organizing people, processes and tools to optimize and differentiate.
Transformed organizations are less focused on cutting costs than aspirational and
experienced organizations, possibly having already automated their operations through
effective use of insights. They are most focused on driving customer profitability and
making targeted investments in niche analytics as they keep pushing the organizational
envelope ― 323.
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On the analytics sophistication spectrum, the study showed 35 percent of 116 healthcare
organizations in the United States are in the aspirational segment (with the following
characteristics: new or limited users of analytics, focused on analytics at point-of-need, and turn
to analytics for ways to cut costs), 45 percent are in the experienced segment (established users
of analytics, seek to grow revenue with focus on cost efficiencies, and seek to expand ability
share information and insights), and only 16 percent are in the transformed segment (use of
analytics is the cultural norm, highest levels of analytics prowess and experience, seek to target
revenue growth, and feel the most pressure to do more with analytics)

323

. The future demands

that healthcare organizations focus on the biggest and highest value opportunities and within
each opportunity, to start with questions, not data, and embed insights to drive actions and
deliver value, and keeping existing capabilities while adding new ones 67,323.

2.1.12. Physician Performance Measure and Reporting
In 2001, a report by the Institute of Medicine encouraged healthcare organizations and
purchasers to implement policies to increase the likelihood for delivery of ―safe, effective,
patient-centered, timely, efficient, and equitable‖ care

324

. In 2010, the enactment of ACA has

changed the practice of the healthcare industry from volume-based to value-based healthcare
delivery, and with it changed the physician reimbursement model325. The recent changes are
transforming the context in which physicians and other healthcare providers deliver care

104

. ―A

key strategy on the policy agenda is advancing performance measurement at all levels of the
healthcare system, and in particular, at the physician level where there is substantial unexplained
variation in practice that leads to poor quality, inefficient delivery of care, and wasteful spending
on care. Physician performance measurement, including both quality and cost-efficiency, is an
69

important vehicle stimulating improvements in quality and costs of delivering care‖

326

. In order

to move the physician measurement and reporting initiative forward, continued development of
evidence-based quality assessment measures must be developed in a broader and deeper array of
clinical conditions, medical specialties and medical procedures. Efforts are underway nationally,
by CMS, as well as regionally by many private payers to develop reporting and payment systems
that support and reward quality and the efficient delivery of care

326

. Measurement of physician

quality performance has become increasingly important for health plans as the basis for quality
improvement, network design, and financial incentives 327,328.

2.1.13. Need for Data Integration and Analytics to Assess Physician Performance
The shift to reimbursement based on performance is spurring new ways to assess physician
practices and performance. The shift requires use of data analytics capabilities to generate
meaningful insights about physician performance. Analytics capabilities provide a feedback
mechanism to evaluate changes in practice and to provide a deeper understanding of physicians‘
decisions through quantification and assessment of trends. Reporting on compliance to bestpractice guidelines and high level metrics alone is insufficient. An analytics framework is
essential in evaluating changes directly impacted by various initiatives (i.e. best-practice
guidelines, education, incentives, etc.), identifying new areas for improvement, and avoiding
unintended consequences and outcomes.

A key component of analytics capability is data integration, which is the capture, cleansing,
storage, and linkage of data from clinical and financial sources
70

329

. A complete data integration

solution encompasses discovery, cleansing, monitoring, transforming, and delivery of data from
variety of sources

330

. Data integration is the combination of technical and business processes

used to combine data from disparate sources into meaningful and valuable information330. There
are significant barriers to achieving data integration and conducting analytics on quality
improvement and patient outcomes. Some of the barriers are:


The variation that exists in the study of clinical data. There is variation depending on the
complexity of the protocol, the design of an individual study and the method of data
collection. This prevents standardization of approaches to data integration from multiple
disparate source systems.



Difficulty in meaningful integration of clinical data because of the variance of semantics
for different contexts.



Lack of standardization and the unstructured nature of the significant portion of clinical
data which necessitate complex transformations at different phases. This poses a hurdle
for auditability of data for regulatory and compliance purposes.



Interfacing disparate systems requires extensive integration exercises that turn into large
projects and require significant resources.



Diverse systems are used at different phases of clinical data life-cycles because individual
systems are usually put in place to fulfill a specific business need

296,305,331-333

. Individual

systems are combinations of home grown and commercial products from multiple
vendors, which significantly adds to the complexity of the integration process.
A 2013 report by the Health Initiative and the College of Healthcare Information Management
Executives focused on the state of health analytics in the area of improving quality and lowering
cost. The survey group included 102 organizations and was comprised of hospitals (37%),
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integrated delivery networks (33%), academic medical centers (13%), and others (11%). The
study examined attitudes toward data use, trends in business use cases for data and analytics,
technological solutions employed by organizations, and associated challenges and barriers

334

.

―Respondents‘ attitudes toward data and analytics reflect a common understanding of the
potential impact and benefits of using data and analytics to help drive organizational decisionmaking and action. A large majority (82%) indicated that bi-directional sharing of clinical and/or
patient data with local healthcare organizations is important or very important to their
organization. It is likely that increased pressure to meet data sharing requirements under the
federal EHR Incentive Program has contributed to this belief. Additionally, nearly 80 percent of
respondents felt that leveraging big data and predictive analytics is important to their
organization‘s strategic plans and priorities. However, the reality on the ground may not match
the desires of respondents. Eighty-four percent believe that the application of big data and
predictive analytics is a significant challenge for their organization‖334 due to ―uniqueness and
complexity of healthcare data‖

335

. ―Only 45 percent of respondents feel that their organization

has implemented a flexible and scalable plan to adapt to the growing volume, liquidity, and
availability of electronic health data‖334.

The report

334,336

highlighted some of the key analytics applications that were reported by the

participants, which included:


Revenue Cycle Management which focuses on cost reduction. Healthcare institutions are
closely managing and monitoring their revenue cycle to ensure profitability. Analytics
have been utilized to determine patient eligibility, validate coverage, authorize services,
assess payment risk, manage submissions, and track performance.
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Resource Utilization which focuses on ways to concurrently improve patient outcomes
and reduce costs using finite resources. Analytics have been used to track and manage
workforce, patient volumes, services, and supply chain.



Prevention of Fraud and Abuse which accounts for between 3 and 15 percent of annual
healthcare expenditures. ―Fraud refers to a calculated misrepresentation of facts aimed at
convincing payers to process a false claim for financial gain. Similarly, abuse refers to
neglect of accepted business or medical practices resulting in higher reimbursements.
While fraud is a willful act, abuse is unintentional. Common forms of fraud and abuse
include improper coding, billing for services not actually provided, and providing
unnecessary medical services given the patient‘s condition‖334,337. Analyses of billing and
claims data assist in identification of ―fraud and abuse by predicting expected service
utilization and comparing it to actual billing information. Trends and patterns in claims
data can help organizations create a baseline for behaviors indicative of fraud and abuse
and further investigate as necessary‖334.

Population Health Management which is one of the important components of new healthcare
initiatives and the basis for new healthcare delivery models (i.e. ACOs) focused on improving
outcome for the entire population, rather one individual seeking help. It requires ―organizations
to define a population, identify gaps in care, stratify risks, engage patients, manage care, and
measure outcomes‖334,338. Analytics plays a significant role ―given the vast amount of important
health-related data to consider when caring for an entire population. Data analysis can assist
healthcare organizations in recognizing populations consuming the most resources or at greatest
risk for hospital readmissions, enabling them to target high-risk groups to reduce costs and
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improve outcomes. Analytics can also help identify trends in disease prevalence, determine the
comparative effectiveness of treatment options, and derive best practices‖334.
Quality Improvement which focuses on ―broad categories of variations in services, underuse of
services, overuse of services, misuse of services, and disparities in quality‖334,339. Analytics
facilitates quality improvement efforts such as utilization and outcome analyses, patient adverse
outcome reports. Quality improvement has been identified by 88 percent of respondent334 as a
key area of focus.

The key analytics applications reported by the survey highlight the gap that exists in the ability to
perform analytics on different types of data from disparate health information systems. The
analytics functions represented in the survey do not require data from various health information
systems. The reported applications of analytics are mostly focused on extracting data from either
one or two systems. Revenue Cycle Management, Prevention of Fraud and Abuse, and
Population Health Management mostly use claims data. Claims data in the healthcare industry is
known for their cleanliness and completeness. These strengths perfectly counter the limitations
of clinical data. Some of the characteristics of claims data include: use of diagnosis and
procedure codes that are standardized nationwide (i.e. ICD-9 and ICD-10 in October 2014);
incorporation of multiple security levels into coding and claims processes; and automation of
data cleansing to ensure accuracy. In addition, since healthcare institutions‘ workforce has a
stake in successful submission of claims, everyone goes to great lengths to continually improve
accuracy and comprehensiveness of claims before submission. Other robust characteristics of
claims data is in its shareability, partly due to its structured and standardized format, and partly
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because of the powerful incentive behind efficient transmission and exchange of the information.
After all, this is how providers are paid 340.

Data integration and analytics challenges are not unique to healthcare and have been encountered
in other industries. The difference is that the healthcare industry operates in a more
heterogeneous data ecosystem with different levels of regulations, standardization, and clinical
intricacy that add to the complexity of matter. Healthcare institutions are tasked to gain greater
performance and operational efficiencies to unify fragmented clinical processes, quality
performance, people, projects, and siloed systems in order to drive evidence-based decision
making. Meanwhile, healthcare payers are demanding evidence of efficacy of treatments before
authorization of payments. Data and availability of information on the efficacy of various
interventions is at the heart of evidence-based decision making, and quality of patient outcomes.

2.1.14. Performance Management System
Performance measures have been described as ―quantifying the efficiency and effectiveness of
past actions‖

341

. The process involves ―regular collection of data to assess whether the correct

processes are being performed and desired results are being achieved ―342. Performance measures
are a significant part of any organizational strategy, planning, and reporting. They can assist
healthcare institution executives and heads of hospital departments in reviewing trends in various
areas, making decisions on how to improve departments based on a broader scope, and refining
organizational performance. There are many reasons why any healthcare institution must
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measure performance including: quality improvement, transparency, accreditation and
participation in financial incentive programs.

Performance Management System (PMS) encompasses multiple components; measure, metric,
indicator, and key performance indicators. In many organizations, these separate phrases are
used interchangeably, and/or are merged into a single concept. It is important to highlight the
fact that each component represents a different notion.


Measurement is defined as the act or a process of measuring; a figure, extent, or amount
obtained by measuring343. A result of measuring would be a figure expressing the extent
or value that was obtained by measuring against a standard. An example of a
measurement may be ―10 centimeters‖, the centimeter is the standard, and 10 identify
how many multiples or fractions of the standard are being appraised.



Metric is a quantitative measure of the degree to which a system, component, or process
possesses a given attribute344. Metric is a calculated or composite indicator based on two
or more measures. It presents a trend. As an example recording hourly body temperature
provides a trend on whether the temperature is remaining constant, increasing, or
decreasing. Metric is a comparison of two or more measures.



Indicator is an entity that provides insight on process improvement activities concerning
goal attainments. An example is body temperature of 99.1 degrees Fahrenheit as
compared to normal body temperature of 98.6 degree Fahrenheit. Indicator is a device or
variable that can be set to a prescribed state based on the results of a process or the
occurrence of a specified condition344. An indicator generally compares a metric with a
baseline or expected result.
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Key performance indicators are indicators that are very specific. They are measureable
values that demonstrate the effectiveness of a process that is contributing to the
attainment of a single organizational key objective. Performance measures are used in a
type of analytical approach that provides information about key aspects of activities, e.g.
in transfusion medicine, the appropriateness of transfusion. They drive the results of the
key activities in an evidence-based program. Analytical processes must be applied to the
measures. Clinical analytics can be classified into two categories of retrospective
(looking back) and prospective (looking forward) measures. ―Performance measures are
typically considered retrospective analyses; it requires aggregation and analysis of data
and information on a performed task over an extended period of time‖345. Performance
measures are categorized based on whether they analyze an input or am output of a care
process. Types of performance measures include 345:


Resource and Efficiency Measures: track specific resources used, such as red
blood cell, platelet, plasma etc.



Process Measures: track the level of compliance with specific guideline or
standards, for example order of red blood cell transfusion based on a pretransfusion lab value (i.e. hemoglobin level).



Structural Measures: track information about how a care delivery system operates
for example number of transfusions performed by a physician.



Outcome Measures: track the impact of a particular intervention, such as
transfusion on patient‘s health (e.g. review of patient days – ―a unit in the system
of accounting used by healthcare facilities and healthcare planners. Each day
represents a unit of time during which the services of the institution or facility are
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used by a patient

346

‖; meaning 100 patients in a hospital for 1 day would be

represented as 100 patient days.


Patient Experience Measures: are based on surveys conducted from patients to
track perception and satisfaction for the level of care received.

Characteristics of a robust PMS include: strategic support; holistic view of progress through
quantitative and qualitative perspectives; incorporation of the needs and activities of decisionmakers; mechanism for routine and timely reports on progress; detailed attention to accuracy of
data; calculation of measure in reporting the information; and consistency and feasibility in
visual presentation of information back to stakeholders347. To implement an evidence-based
PMS, identification of metrics, indicators, and key performance indicators is required in order to
qualitatively or quantitatively measure the past, and conduct historical analysis to forecast
potential future outcomes

348

. The various measures can portray a snapshot of pre-defined

standards established according to the evidence. Through utilization of the PMS, the success of a
project, program, department, or an organization can be defined and evaluated. Metrics provide a
way for trend analyses. Key performance indicators provide actionable metrics that can be used
to increase the effectiveness and efficiency of operations

348

, directly associating organizational

strategic plans with performance. Key performance indicators differ from other measures. They
are very specific measures that highlight aspects of performance that directly tie strategic
objectives to operational routine (i.e. physicians practice). Therefore, they are integral in
providing insights on the level of performance and progress and in determining whether
improvements are necessary.
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2.2.

Application of New Strategies to Transfusion Medicine Practice

Human error is a nearly constant component of human involvement in any complicated task

349

.

Patient safety is defined as ―freedom from accidental or preventable harm due to events
occurring in the healthcare setting‖350. Healthcare industry and healthcare providers aim to
reduce, if not prevent, medical errors and adverse outcomes. However, studies
performed from various perspective has shown medical errors are a serious problem
involves multiple areas including human factors and systems engineering

354

180,351-353

350

, which

. In clinical and

laboratory medicine, considerable time and expense is invested in institution of policies and
procedures, to include detailed and often redundant patient and specimen identification and test
result verification, with the specific purpose of minimizing human error

349

. However, despite

such intensive measures, ―human errors continue to occur at a seemingly irreducibly small rate in
medical practices, sometimes with catastrophic results‖349. Transfusion medicine, with its
intricacies is unique among clinical laboratory services in that the end result is the delivery of a
biologic product that may be both lifesaving and capable of causing death

349

. The production

and delivery of blood products involves many people in several different areas of the hospital.
Error prevention and patient safety in transfusion medicine have been a serious concern

355

.

There are numerous steps involved in transfusion of a blood product, including physician orders,
patient identification for specimen collection by nursing or phlebotomy staff, blood bank workup, product selection and issue, patient identification for transfusion, and, ultimately, the
administration of the blood products to the patient by nursing or physician staff
can and do occur at any step in transfusion and any point along the way

355

349

. Thus, errors

. Haemovigilance

systems have emerged in the global transfusion community with the ultimate goal of improving
the patient experience and outcome in blood transfusion
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356

. Haemovigilance is required to

―identify and prevent occurrence or recurrence of transfusion related unwanted events, to
increase the safety, efficacy and efficiency of blood transfusion, covering all activities of the
transfusion chain from donor to recipient‖

357

. To incorporate haemovigilance into practice, it is

necessary to incorporate information gained from the investigations and analyses to facilitate
corrective and preventive actions in order to minimize the potential risks associated with safety
and quality in transfusion of blood products. Such information is key to introducing required
changes in the applicable policies, improving standards, systems and processes, assisting in the
formulation of guidelines, and increasing the safety and quality of the entire process from
donation to transfusion 357.

2.2.1. Economics of Transfusion
Transfusion of blood products, which includes whole blood, red blood cells, platelets, plasma
and cryoprecipitate, is a critical part of clinical care. In the United States, an estimated five
million patients receive transfusion of blood products annually, which results in 14.5 million
transfusions per year 159,160,358. In a 2010 statistical report by Agency for Healthcare and Quality
(AHRQ), blood transfusion is among the top ten prominent coded procedures in the United
States hospital discharge records. The cost of transfusion accounts for ten to fifteen billion
dollars annually 132. According to a recent study 21 on the cost analysis of blood transfusion, the
actual cost of red blood cell transfusion is 37 percent higher than previously estimated. The
under-representation in the cost of red blood cell transfusion is a result of an incomplete
accounting of required healthcare resources and associated activity-based costs21. These factors
include but are not limited to, donor recruitment and qualification, blood collection, processing,
laboratory testing, transportation, storage, pre-transfusion preparation, transfusion administration
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and follow-up, and long-term tracking of patient outcome

133-135

. The underestimation in cost of

red blood cell transfusion has the potential to misdirect program-based and strategic decision
making. In addition, it has the potential to negatively affect allocation of monitory resources and
cost of care calculation. A study by Goodman et al

359

states that ―nearly half of transfusion

recipients in the United States are Medicare beneficiaries, and Medicare's prospective payment
system is said to substantially under-reimburse hospitals for the costs associated with
transfusions.‖ The ability of Medicare Prospective Payment System (MPPS) to accurately
reimburse hospitals is dependent on the quality of cost and charge data that are reported to
Medicare by the hospitals

133,359-361

. Lack of consensus on the underlying complexity around

factors associated with blood transfusion has resulted in insufficient reporting of data by the
hospitals

362

. Consequently, the insufficiency in reported data propagates inadequate accounting

for the cost, resulting in under-representation of the accurate cost of blood transfusion, which in
turn results in insufficient reimbursement of hospitals for the provided care.

2.2.2. Current View Points on Transfusion of Blood Products
Transfusion of blood and blood components has been a routine practice for more than half a
century. The rationale behind transfusion of blood products assumes that the replacement of
blood loss should be beneficial for the patient

363

. This assumption has constituted the

underpinning of transfusion medicine for many decades

363

. Although transfusion blood and

blood components has been a lifesaving procedure and a routine practice for more than half a
century, it is not without risks

364

. It has been only over the past 20 years that we have seen a

more concerted effort to answer very basic questions regarding the value of transfusion therapy.
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As commonly transfusions occur in the United States, one may assume physicians practice
transfusion medicine based on strict standard guidelines. However, broad variation exists
regarding what type of blood components to transfuse, how much to transfuse and whether to
administer transfusion at all

152

. There has been a debate in medical literature concerning the

appropriate use of blood components and indications for transfusion of blood and blood products
364

. In a statement by Dr. Jeffrey McCullough, American Red Cross Transfusion Medicine Chair,

author of Transfusion Medicine, ―If red blood cells were a new drug today, it would be very
difficult to get it licensed.‖ In a different statement by the Director of Transfusion Medicine at
the University of Rochester Medical Center ―For 100 years we‘ve assumed blood transfusion are
good for people, but most of these clinical practices grew before we had the research to support
it. The current transfusion triggers were established over sixty years ago at the time when
transfusion medicine was still in its infancy.‖ Over the past ten years scientific studies have
highlighted the overuse of blood transfusion based on outdated transfusion triggers and practice
guidelines

140,141,365

. Over the past twenty years, a growing number of single center and

multicenter randomized controlled clinical trial investigations have been published to ―answer
very basic questions regarding the value of transfusion therapy‖363. The studies are designed in
an effort to optimize transfusion practices, determine appropriate transfusion indications and
develop the necessary knowledge base to assess the impact of transfusion practice on patient
outcomes.

82

2.2.3. Complexities Surrounding Blood Transfusion
Blood transfusion is a medical treatment for replacement of blood lost during surgeries, in
serious injuries, and with critically and chronically ill patients 140. Blood transfusion is performed
with the intention of increasing arterial oxygen content in order to sustain oxygen delivery to the
tissues. Blood transfusion has ―undoubtedly been proven effective in many medical and surgical
conditions, thereby particularly improving the survival of patients with critical impairment of
tissue oxygenation‖

366

. Although blood transfusion is a common and a life-saving procedure,

there are serious risks associated with it 158. Transfusion reaction is defined as any adverse event
or complication that occurs in relation to the transfusion of a blood component

152

. Historically,

infections were considered the main risk but because of the abundant donor testing and thorough
donor screening, the risk of acquired infectious diseases through blood transfusion has been
extremely low

171,367

. The major concern now is the non-infectious complications of blood

transfusion which significantly contribute to adverse patient outcomes, many of which are a
result of human errors and thus may be preventable or reduced 16,179,368. In the field of transfusion
medicine, controversy exists relative to when to transfuse, what blood or blood product to
transfuse, and how much to transfuse.

2.2.4. Infectious Complications
Transfusion-transmitted infections may occur through countless numbers of agents that are
transmitted to the recipient though transfusion of donated blood. These include bacteria, viruses,
and parasites. A study by Maxwell and Wilson showed

369

―Bacterial contamination of blood

components is an infrequent complication of transfusion. However, if it does occur, the potential
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for fulminant sepsis in the recipient is associated with high mortality.‖ This can result from
contamination during venipuncture or if an asymptomatic donor was bacteraemic at the time of
donation. Symptoms can occur during or shortly after transfusion of the contaminated unit 369,370.
Red blood cells are stored at 4oC. At this temperature, contamination of Gram-negative bacteria,
such are Yersinia enterocolitica and Pseudomonas species are more likely as they proliferate
rapidly in this environment. Gram-negative bacteria cause infections such as pneumonia,
bloodstream infections, wound or surgical site infection, and meningitis 371. At room temperature
Gram-positive bacteria such as Staphylococcus epidermidis, Staphylococcus aureus and
Bacillus species proliferate rapidly. These are the most common bacterial contaminants of blood
products. Gram-positive bacteria exist on skin flora and are transmitted to collected blood
through collection needles371. Platelets are stored at 25oC, thus Gram-positive contaminations are
more commonly observed in platelets

369,370

. Another bacterial infection is Anaplasmosis which

is caused by Anaplasma phagocytophilum which is transmitted to humans by tick bites371.

Transfusion related viral infections have been greatly reduced since the mid-1980s, as result of
the implementation of pre-donation questionnaires to identify high risk behaviors and pretransfusion testing of donated blood. Examples of viral diseases that may be transmitted through
transfusion include: Human Immunodeficiency Virus (HIV), Hepatitis A, B, and C, Human T—
Lymphotropic Virus (HTLV I/II), Cytomegalovirus (CMV), West Nile virus, and Dengue Fever
371

. The transmission of these diseases may occur in the ―window period‖, which is defined as

―the time after infection when the donor is infectious, but screening tests are negative‖ 369,372.
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Transmission of parasitic diseases transmitted through blood donations is rare

373

. To determine

the existence of these parasitic infections, donors are asked a series of questions about recent
travel to areas where infections are more common. Examples of parasitic disease include:
Babesiosis, Chagas Disease, Leshmaniasis, and Malaria. Prion diseases that are transmitted
through blood transfusion include Transmissible Spongiform Encephalopathies, ―a family of rare
progressive neurodegenerative disorders that affect both humans and animals‖

371

and variant

Creutzfeldt-Jakob Disease, a rare ―rapidly progressing neurological disease that causes dementia
and death‖371.

Studies

374-376

have shown transfusion reactions are under-diagnosed and under-reported in the

United States. Even though the blood supply in the United States is relatively safe because the
Food and Drug Administration Center (FDA) for Biologics Evaluation and Research regulates
and safeguards the collection of blood and blood components against the infections,
complications of transfusion remain a threat.

2.2.5. Non-Infectious Complications
According to Goodnough and Shander 158, allogenic transfusion may have both a suppressive and
stimulatory effect on the immune system. These effects have been referred to as
―immunomodulation‖. Recently immunomodulatory effects have been a major concern and the
common cause of transfusion related non-infectious complications. Leukocyte mediated
transfusion-related immunomodulation has been correlated an with increased rate of cancer
recurrence and post-operative infections. Transfusion errors have been estimated to occur with a
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ratio of 1:30,000 units transfused

377

. Hemolytic reaction remains a leading cause of fatal

transfusion reaction which occurs as a result of ABO-incompatible blood transfusion. Another
transfusion error is caused by the ―issue of donor blood to patients from whom autologous blood
is available‖

378

. Alloimmunization is more common in patients who receive multiple

transfusions e.g. Sickle Cell Disease patients. The multiple transfusions result in the introduction
of new antigen variants into the body. The new antigens may stimulate the immune system to
produce alloantibodies against minor blood

158

. Alloimmunization to platelets may be caused by

a large number of heterogeneous antigens, thus ―transfusion of patient with preformed
alloantibodies against that antigen (due to sensitization in previous transfusions) may result in
delayed hemolytic reaction which has been estimated in a range of 1:1000 to 1:9000
transfusions‖

158,379

. Transfusion associated graft versus host disease (TA-GVHD) is another

complication. In ‗TA-GVHD, immune-competent HLA-incompatible donor lymphocytes are
transfused to a recipient who is immunologically incapable of eliminating them‖

158,380

. The

donor lymphocytes then generate an immune response against the host cells. Transfusion Related
Acute Lung Injury (TRALI) occurs within six hours of transfusion. It is ―characterized by the
acute onset of respiratory distress, bilateral pulmonary edema, fever, tachycardia, and
hypotension in the presence of normal cardiac function‖

158,381

as a result of increased vascular

permeability. Transfusion Associated Circulatory Overload (TACO) is also characterized by
pulmonary edema and respiratory distress. This is caused by increased central venous pressure
and pulmonary blood volume, resulting in fluid extravasation into alveolar space. TACO is
estimated to occur from 1:3000 to as many as 1:10 transfusions

158,381

. Febrile Non-Haemolytic

Transfusion Reactions (FNHTR) are the ―most common cause of transfusion-associated fever
which occurs in 0.1 to 1 percent of red blood cell transfusions. Other causes of transfusion
86

associated fevers include: allergic reactions, hemolytic reactions, bacterial contamination,
cytokine-medicated, TRALI, and HLA alloimmunization‖158 in febrile patients. Stored blood
undergoes morphologic changes, which results in the cells becoming more rigid and less pliable.
Although scientific evidence remains contradictory in this area, retrospective studies have
reported an increased rate of adverse clinical outcomes and a reduction in survival with
transfusion of older blood units (greater than 14 days) 158,382-388.

2.2.6. Transfusion of Blood Products: Reactions and Fatalities
In a report by the American Association of Blood Banks and the Department of Health and
Human Services in the United States, 14.65 million whole blood and red blood cells, 4.0 million
fresh frozen plasma, and 1.7 million platelet doses are transfused annually

389

. Although

transfusion-related fatalities have been significantly reduced, both transfusion reactions and
fatalities still do occur and laboratories are required to report them directly to regulatory
agencies390. Transfusion-related adverse events, both short- and long-term, are among the
costliest contributors to health care expenditures

391

. Costs associated with the long-term

consequences of the adverse effects of transfusion are among the hardest to quantify

135,392-397

.

―Despite the increasing cost of blood, transfusion practices remain quite liberal 135‖ , varies
widely in a single institution among individual physicians
144

398

and from institution to institution

, and are often inappropriate185 399-401

In the 2011 report by the Nationwide Blood Collection and Utilization Survey

375

,

transfusion-related fatalities were reported to FDA between fiscal year 2005 and 2009
87

267
376

.

Additionally, from October 1, 2010 through September 30, 2011, FDA received a total of 79
fatality reports 159. Of these, 69 were determined to be transfusion recipient fatalities and 10 were
deemed to be post-donation fatalities402,403. The percent breakdown of the 69 transfusion
recipient fatalities include: 43 percent were transfusion related; 41 percent were cases in which
transfusion could not be ruled out as the cause of death, and 16 percent were unrelated to the
transfusion

402

. An FDA report showed, Transfusion Related Acute Lung Injury (TRALI) was

the leading cause of reported transfusion fatalities (43%) in recent years, followed by acute
hemolytic transfusion reactions (23%) 402,403. Both of these reactions typically occur as a result of
human error

397,404,405

. Complications of Transfusion Associated Circulatory Overload (TACO),

microbial infection, and anaphylactic reactions each accounted for a smaller number of the
reported fatalities159,160. Most adverse transfusion outcomes are the result of human error
Reactions due to human errors are often misdiagnosed or under-reported

135

135,350

.

. Statistical studies

indicate in the cases of non-infectious transfusion related reactions, specifically in minor or
delayed onset of reactions, adverse transfusion outcomes are more likely to be underreported
406,407

. The misdiagnosis and under-reporting of adverse events is alarming and has the potential

to increase the number of negative transfusion related outcomes and death on an annual basis.
Many of these events are potentially preventable. The estimated percentage of costs attributable
to inappropriate blood transfusion has been reported to range between 9% and 44%

220,400

.

Frequent transfusions have been linked to poorer patient outcomes, including increased patient
mortality

220,408

, a higher incidence of nosocomial infections

increased length of hospital and ICU stays

408,412,413

409

, multi-organ failure

410,411

, and

. Even though the number of reported

transfusion fatalities in the United States remains small in comparison to the total number of

88

transfusions

135

, the medical and legal cost of transfusion related adverse outcomes further

burdens the fragile healthcare system 135.

2.2.7. Scrutiny of Transfusion Indications
RBC transfusion should be based on the patient‘s clinical condition, hemorrhage treatment need
and need for improvement of oxygen delivery to tissues

414

. In a 2011 study, Sharma and a

colleague defined indications for blood transfusion as acute sickle cell crisis (for stroke
prevention), acute blood loss of greater than 1,500 milliliter or 30 percent of blood volume, and
symptomatic anemia

379

. A restrictive strategy has been defined as transfusion when the

hemoglobin level falls below 7 g/dL. The aim for conservative or restrictive transfusion practice
is to achieve a hemoglobin target level of 8-10 g/dL (low transfusion threshold: 7-10 g/dL)
149,209,415

. Conversely, a liberal strategy has been characterized by transfusion for hemoglobin

levels below 9 g/dL. The liberal transfusion practice aims to achieve a hemoglobin target level of
9-12 g/dL (high transfusion threshold: 9-11 g/dL)

149,183,209

. For more than five decades, a

hemoglobin level of less than or equal to 10 g/dL(100 gram per deciliter) and a hematocrit level
less than or equal to 30 percent was accepted as minimum level, and considered a trigger for
transfusion particularly in surgical settings, regardless of patient's clinical presentation 244,379,414 .
The transfusion trigger, known as ―10/30‖ rule, was first proposed in 1942 and was practiced
until the 1980‘s

416,417

. Physicians have been practicing the ―10/30‖ rule based on faith and

tradition rather than on scientific data

418

. Even though ―transfusion at a hemoglobin level of 10

g/dL is much less common today‖, according to Corwin et al.

218

, only 25 percent of red blood

cell transfusions occur in the range of 7.0 g/dL or less in order to maintain the hemoglobin
89

concentration level between 7.0 and 9.0 g/dL

205

. The red blood cell transfusion itself is an

additional independent predictor for adverse outcomes and therefore, has been referred to as the
―second hit‖ for the recipient

192,419

. The two-hit hypotheses involves two separate components.

The ―first hit‖ is defined as the underlying patient characteristics

420

, which may include ―recent

surgery, hypoxia, infection, trauma, malignancy, massive transfusion, cardiopulmonary disease,
or bypass‖ 421,422. These underlying conditions are believed to ―activate the vascular endothelium
and ultimately result in pulmonary neutrophil priming‖

421,422

. The ―second hit‖ is the

―transfusion of blood products containing lipids, antibodies, or cytokines that stimulate
previously primed neutrophils. The result is endothelial cell damage and non-cardiogenic
pulmonary edema‖

421,422

. Among general complications, blood transfusion leads to higher

mortality, increased rate of ischemic complications, organ dysfunction, infections, delayed
wound healing, non-Hodgkin lymphoma, and increased length of hospital stay

21,126,152,423,424

Numerous transfusions are not required for these adverse outcomes to occur. Studies
428

.

21,126,152,423-

have shown that complications were observed after administration of minimal (i.e. one or

two) units of blood. The ―decision to transfuse is often made without understanding the risk and
benefits of transfusion‖

429

, as a result of the underlying complexities associated with blood

transfusion for a particular patient. This leads to transfusion practices that vary widely.

Over the past two decades, blood transfusion triggers and utilization have been under
considerable scrutiny as studies on the efficacy of blood transfusion show poor patient outcomes
have been correlated with blood transfusion

181,218,265,430

. Recent studies have associated blood

transfusion with a two to four-fold increased risk of postoperative infections when transfused
patients are compared with non-transfused cohorts
90

18,21,181,245,428,431-434

. A dose-response

relationship study by Boucher and Hannon

435

showed ―blood transfusions lead to increased

postoperative infection, higher rates of multisystem organ failure, increased mortality, increased
mechanical ventilator time, and increased length of stay‖. Other studies

382-388

have highlighted

decreased immune function – known as transfusion-related immunomodulation effect – in
patients who have received transfusion although the intensity of the immune response varies
from person to person.

2.2.8. Evidence-Based Indications for Optimization of RBC Transfusion
In 1999, a landmark randomized, controlled clinical trial study of stable adults in multicenter
intensive care units (ICU) by Hébert et al.

205

compared hemoglobin levels of patients with 7

g/dL versus 10 g/dL; and found a ―restrictive strategy of red-cell transfusion and a liberal
strategy produced equivalent results in critically ill patients‖. The study showed restrictive
transfusion practices were as effective as the liberal transfusion strategy and demonstrated that
patients were able to tolerate lower levels of hemoglobin without an increased rate of morbidity
or mortality. In 2001, Wu and colleagues
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in a retrospective cohort study evaluated the effect

of blood transfusion in 78,974 Medicare beneficiaries 65 years old or older hospitalized with
acute myocardial infarction. They determined ―patients with lower hematocrit values on
admission had higher 30-day mortality rates. Blood transfusion was associated with a reduction
in 30-day mortality among patients whose hematocrit on admission fell into the categories
ranging from 5.0 to 24.0 percent (adjusted odds ratio, 0.22; 95 percent confidence interval, 0.11
to 0.45) to 30.1 to 33.0 percent (adjusted odds ratio, 0.69; 95 percent confidence interval, 0.53 to
0.89)‖. In 2004, Corwin et al
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designed a multiple center, observational cohort study of ICU
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patients in the United States to quantify the incidence of anemia and red blood cell transfusion
practice in critically ill patients and to examine the relationship of anemia and red blood cell
transfusions to clinical outcomes. The result showed the ―number of red blood cell transfusions a
patient received during the study was independently associated with longer ICU and hospital
lengths of stay and an increase in mortality. Patients who received transfusions also had more
total complications and were more likely to experience a complication‖
international study by Rao and colleagues

436

412

. In the same year, an

was designed to determine the association

between blood transfusion and mortality among 24,112 patients (in 3 large international
trials) with acute coronary syndromes who developed bleeding, anemia, or both during their
hospital course. The result indicated that ―of the patients included, 2401 (10.0%) underwent at
least one blood transfusion during their hospitalization. Patients who underwent transfusion were
older, had more comorbid illness at presentation and had a significantly higher unadjusted rate of
30-day death (8.00% vs 3.08%; P<.001), myocardial infarction (MI) (25.16% vs 8.16%; P<.001),
and

death/MI

(29.24%

vs

10.02%;

P<.001)

compared

with patients who

did

not

undergo transfusion. In the landmark analysis that included procedures and bleeding
events, transfusion was associated with a trend toward increased mortality. The predicted
probability of 30-day death was higher with transfusion at nadir hematocrit values above 25%.‖
They concluded ―blood transfusion in the setting of acute coronary syndromes is associated with
higher mortality, and this relationship persists after adjustment for other predictive factors and
timing of events‖436. In 2008, Marik and Corwin

181

conducted a systematic review of the

literature using meta-analysis of observational studies (45 studies, 272,596 patients) to determine
the association between red blood cell transfusion, and morbidity and mortality in high-risk
hospitalized patients. Their multivariate analysis of data which corrected for age and illness
92

severity showed, ―in 42 of the 45 studies the risks of RBC transfusion outweighed the benefits.
The risk was neutral in two studies with the benefits outweighing the risks in a subgroup of a
single study (elderly patients with an acute myocardial infarction and a hematocrit <30%).
Seventeen of 18 studies, demonstrated that RBC transfusions were an independent predictor of
death; the pooled odds ratio (12 studies) was 1.7 (95% confidence interval, 1.4-1.9). Twenty-two
studies examined the association between RBC transfusion and nosocomial infection. In all these
studies, blood transfusion was an independent risk factor for infection. The pooled odds ratio
(nine studies) for developing an infectious complication was 1.8 (95% confidence interval, 1.52.2). RBC transfusions similarly increased the risk of developing multi-organ dysfunction
syndrome (three studies) and acute respiratory distress syndrome (six studies). The pooled odds
ratio for developing acute respiratory distress syndrome was 2.5 (95% confidence interval, 1.63.3)‖. Marik and Corwin

181

concluded that ―in adult, intensive care unit, trauma, and surgical

patients, RBC transfusions are associated with increased morbidity and mortality and therefore,
current transfusion practices may require reevaluation‖.

In 2010, Hajjar and colleagues

182

conducted a prospective, randomized, controlled clinical non-

inferiority trial on patients (n = 502) who underwent cardiac surgery with cardiopulmonary
bypass in an ICU at a university hospital cardiac surgery referral center in Brazil in order to
define whether a restrictive perioperative red blood cell transfusion strategy is as safe as a liberal
strategy in patients undergoing elective cardiac surgery. The result, ―hemoglobin concentrations
were maintained at a mean of 10.5 g/dL (95% confidence interval [CI], 10.4-10.6) in the liberalstrategy group and 9.1 g/dL (95% CI, 9.0-9.2) in the restrictive-strategy group (P < .001). A total
of 198 of 253 patients (78%) in the liberal-strategy group and 118 of 249 (47%) in the
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restrictive-strategy group received a blood transfusion (P < .001). Occurrence of the primary end
point was similar between groups (10% liberal vs 11% restrictive; between-group difference, 1%
[95% CI, -6% to 4%]; P = .85). Independent of transfusion strategy, the number of transfused
red blood cell units was an independent risk factor for clinical complications or death at 30 days
(hazard ratio for each additional unit transfused, 1.2 [95% CI, 1.1-1.4]; P = .002). They
concluded that the use of a restrictive perioperative transfusion strategy compared with a more
liberal strategy resulted in non-inferior rates of the combined outcome of 30-day all-cause
mortality and severe morbidity182. In 2013, Villanueva et al 222 studied transfusion strategies for
patients with acute upper gastrointestinal bleeding. They compared the efficacy and safety of a
restrictive transfusion strategy with those of a liberal transfusion strategy in 921 patients with
severe acute upper gastrointestinal bleeding. Out of a ―total of 225 patients assigned to the
restrictive strategy (51%), as compared with 61 assigned to the liberal strategy (14%), did not
receive transfusions (P<0.001). The probability of survival at 6 weeks was higher in the
restrictive-strategy group than in the liberal-strategy group (95% vs. 91%; hazard ratio for death
with restrictive strategy, 0.55; 95% confidence interval [CI], 0.33 to 0.92; P=0.02). Bleeding
occurred in 10% of the patients in the restrictive-strategy group as compared with 16% of the
patients in the liberal-strategy group (P=0.01), and adverse events occurred in 40% as compared
with 48% (P=0.02). The probability of survival was slightly higher with the restrictive strategy
than with the liberal strategy in the subgroup of patients who had bleeding associated with a
peptic ulcer (hazard ratio, 0.70; 95% CI, 0.26 to 1.25) and was significantly higher in the
subgroup of patients with cirrhosis and Child–Pugh class A or B disease (hazard ratio, 0.30; 95%
CI, 0.11 to 0.85), but not in those with cirrhosis and Child–Pugh class C disease (hazard ratio,
1.04; 95% CI, 0.45 to 2.37). Within the first 5 days, the portal-pressure gradient increased
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significantly in patients assigned to the liberal strategy (P=0.03) but not in those assigned to the
restrictive strategy‖. In a 45 day survival comparison with a liberal transfusion strategy, a
restrictive strategy significantly improved outcomes in patients with acute upper gastrointestinal
bleeding.

Evidence and the growing number of studies in the area of transfusion practice have contributed
to a better understanding of the risks associated with transfusion of blood and blood components.
It has ―transformed transfusion medicine through the accelerated development of more
sophisticated donor testing (i.e. ever-improving infectious disease tests), pre-transfusion testing,
recipient identification, and multiple improvements in blood component characteristics and
quality (i.e. leukoreduction, irradiation, pathogen inactivation). These developments have
resulted in improved safety profiles for transfused components and a perception of minimal
risk‖363.

2.2.9. Pillars of Patient Blood Management
Patient Blood Management (PBM) programs have been introduced to ensure that every
transfusion is optimized. The Society for the Advancement of Blood Management

437

defines

PBM as ―timely application of evidence-based medical and surgical concepts designed to
maintain hemoglobin concentration, optimize hemostasis and minimize blood loss in an effort to
improve patient outcome‖. Further it is defined as ―an evidence-based, multidisciplinary
approach to optimizing the care of patients who might need transfusion.‖ It encompasses all
aspects of ―patient evaluation and clinical management surrounding the transfusion decision95

making process, including the application of appropriate indications, as well as minimization of
blood loss and optimization of patient red cell mass‖

438

. Based on the accumulating scientific

evidence on the overuse of blood, liberal transfusion practices, and adverse outcomes of blood
transfusion, the American Society of Anesthesiologists Committee of Blood Management
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and the Joint Commission439 have emphasized the importance of a standardized transfusion
practice142,439. In 2010, World Health Organization (WHO) adopted patient blood management
principles to improve transfusion safety 440; and in 2012 implemented a resolution (WHA63.12)
in favor of patient blood management, with a ―focus on the availability, safety and quality of
blood products, and their safe and rational use‖441. The concept of PBM has been developed to
address known and unknown risks of blood transfusion, preservation of national blood inventory,
and constraints from escalating costs

245

. PBM aims to achieve improved patient outcomes by

avoiding unnecessary exposure to blood products through effective conservation and
management of a patient‘s own blood.

PBM views patients‘ physiological reserves as a natural valuable resource that should be
conserved and appropriately managed. The concept of PBM is still evolving. According to
Shander251 and Gombotz 2, ―an earlier definition of PBM involved the appropriate provision and
use of blood, its components and derivatives, and strategies to reduce or avoid the need for
transfusion, with the ultimate goal of improved patient outcome.‖ The recent concept has been
focused on ―preventative measures that will obviate the need for transfusion‖251. The goal is to
employ a patient-centered pre-operative approach to optimize, conserve, and manage patient‘s
own blood. It aims to identify the patients who are at risk of blood transfusion and provide them
with a managed plan aimed to reduce or eliminate transfusion with an acceptable risk of
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anemia442. Studies have shown low pre-operative hemoglobin levels, excessive surgical blood
loss, and inappropriate transfusion practices are the underlying factors in majority of surgical
patients which result in the therapeutic decision to transfuse2,251. According to Isbister443,
―allogeneic blood transfusion should be considered only when there are no options available.‖
Based on the above findings, Shander251 has defined the three aspects of PBM as ―optimization
of hematopoiesis, minimization of bleeding and blood loss, harnessing and optimizing
physiological tolerance of anemia‖, commonly known as the ―pillars‖ of PBM; more specifically
(i) detection and treatment of pre-operative anemia, (ii) reduction in peri-operative RBC loss,
and (iii) harnessing and optimizing the patient-specific physiological reserve of anemia
(including restrictive hemoglobin transfusion triggers)155,209,245,264,444. In Table 1, Isbister

445

summarized the evidence-based components of the three pillars of PBM in a perioperative
setting.
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Table 3 - Three pillars of patient blood management.

This matrix provides an evidence-based checklist for the decision making process to improve
clinical outcomes. As various approaches to PBM continue to evolve, currently the ―low hanging
fruit‖ has been elective surgeries, where the greatest benefits can be demonstrated in
improvement of patient outcomes through utilization of the above best-practice evidence in
conjunction with customized clinical and personal management of individual patient cases.

Shander and colleagues

251,446

recommended that ―all treatments should be evaluated to

determine their effect on improving patient outcomes as this is the ultimate objective of any
intervention. Despite widespread use, allogeneic blood products have not undergone such
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scrutiny, and the balance between their established risks and questionable benefits is often
obscured by a quest to meet and surpass arbitrary laboratory thresholds. The result is a
transfusion practice that is highly variable, costly, and likely to do more harm than good to the
patients.‖ PBM emphasizes the appropriate use of blood and blood products with the aim of
improving patient outcomes by using a multimodal approach. According to recent evidence,
strategies involved in PBM are often considered a restrictive approach when compared to
common or ―cultural‖ practice. In order to be most effective, PBM requires a multidisciplinary
teamwork approach in the context of an established hospital-wide program 251.

2.2.10. The Joint Commission Recommendation for Effective PBM Programs
The Joint Commission aims to ―continuously improve health care for the public in collaboration
with other stakeholders by evaluating health care organizations and inspiring them to excel in
providing safe and effective care of the highest quality and value‖

447

. The Joint Commission

accredits over 19,000 health care organizations and programs in the United States and more than
400 programs internationally. The Centers for Medicare Services (CMS) recognizes Joint
Commission accreditation as a condition of licensure and the receipt of Medicaid and Medicare
reimbursement. Advisers to HHS Secretary Kathleen Sebelius observed that as a result of the
variability that exists in transfusion practices, the Joint Commission has recognized "there is both
excessive and inappropriate use of blood transfusions in the U.S. Improvements in rational use of
blood have lagged."448.
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In order to reduce the inappropriate use of blood transfusion, in a report by Knowles

449

, ―the

2012 Joint Commission and the American Medical Association have gathered a Physician
Consortium for Performance Improvement National Summit on Overuse which focused on
overuse as a patient safety and quality concern, and advocated PBM programs that include:


A tool kit of clinical educational materials for physicians throughout the learning
continuum, providing information on risks and benefits of transfusion and disseminating
best practices and guidelines supported by evidence;



Education on transfusion avoidance and appropriate alternatives to transfusion;



Identification of subject matter experts to provide guidance;



Advocacy for scheduled periodic assessments of prescriber competency and for
accountability to organizational standards;



Standardization of performance metrics, data collection and vocabulary to allow valid
benchmarking within organizations;



Measurement of individual physician transfusion practice as part of ongoing professional
practice evaluation;



Development of a separate informed consent process for transfusion that communicates
risks and benefits consistent with current evidence;



Identification of research priorities to close evidence gaps in what constitutes optimal
transfusion practice‖.

The metrics of the Joint Commission‘s PBM performance Measures from 2011 include 450:
PBM-01: Transfusion Consent
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Patients with a signed consent who received information about the risks, benefits and alternatives
prior to the initial blood transfusion or the initial transfusion was deemed a medical emergency.
Numerator: Patients with a signed consent who received information about the risks, benefits and
alternatives prior to the initial blood transfusion or the initial transfusion was deemed a medical
emergency.
Denominator: Patients of all ages who received red blood cell, plasma or platelet transfusions.

PBM-02: RBC Transfusion Indication
RBC units transfused with pre-transfusion hemoglobin or hematocrit result and clinical
indication documented.
Numerator: Number of RBC transfusion units with pre-transfusion hemoglobin or hematocrit
and clinical indication documented.
Denominator: Number of red blood cell transfusion units evaluated.

PBM-03: Plasma Transfusion Indication
Plasma units with pre-transfusion laboratory testing and clinical indication documented.
Numerator: Number of plasma transfusion units with pre-transfusion laboratory value AND
clinical indication documented
Denominator: Number of plasma units evaluated
Trauma patients excluded

PBM-04: Platelet Transfusion Indication
Platelet doses transfused with pre-transfusion platelet testing and clinical indication documented.
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Numerator: Number of platelet transfusion units with pre-transfusion platelet testing AND
clinical indication documented.
Denominator: Number of platelet units evaluated
Trauma patients excluded.

PBM-05: Blood Administration Documentation
Transfusions of blood units with documentation for all of the following:
Patient identification, transfusion order and blood ID number confirmed prior to the initiation of
transfusion.
Date and time of transfusion.
Blood pressure, pulse and temperature recorded pre, during and post transfusion.
Numerator: Number of transfusion units (bags) or doses with documentation for all of the
following: patient identification and transfusion order (or Blood ID) confirmed prior to the
initiation of transfusion date and time of transfusion blood pressure, (pulse) and temperature
recorded pre, during and post transfusion.
Denominator: Number of red blood cells, plasma and platelet units or doses evaluated.

PBM-06: Preoperative Anemia Screening
Patients have documentation of preoperative anemia screening 14-45 days before Anesthesia
Start Date.
Numerator: Patients with preoperative anemia screening 14 - 45 days before Anesthesia Start
Date
Denominator: Selected elective surgical patients
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Cardiac patients removed.

PBM-07: Preoperative Blood Type and Antibody Testing
Patients with documentation of preoperative type and screen or type and crossmatch completed
prior to Anesthesia Start Time.
Numerator: Patients with preoperative type and screen or type and crossmatch completed prior to
Surgery Start Time Anesthesia Start Time.
Denominator: Selected elective surgical patients.

The seven blood measures have been added to the measure reserve library.

The Joint

Commission encourages use of the above PBM measures. In addition, the department of Health
and Human Services is organizing further data collection efforts.

2.2.11. Challenges in Establishment of Effective PBM Program
Establishment of an evidence-based approach to blood utilization has the potential to reduce
blood usage which can substantially lower hospitals expenditures and improve patient outcomes.
The same blood products may be re-directed to other patients who are in need of the supply
within or outside the hospital

252

. In order for hospitals or healthcare systems to gain a

competitive advantage from PBM, a robust multidisciplinary, patient-centric, data driven
approach is imperative to optimize the utilization of blood products in patients who may require
transfusion and to simultaneously reduce preventable complications. Establishment of true
metrics to track good practices of blood use and adherence to PBM guidelines are essential
103

elements of the program

245

. The cornerstone of an effective PBM program is identification,

collection, and analysis of relevant data that are captured in disparate hospital information
systems

451

. To effectively monitor the program‘s performance, a performance management

system consisting of measures, metrics, and Key Performance Indicators (KPIs) is required to
quantitatively and qualitatively measure and track the hospital‘s and/or healthcare organization‘s
progress against its goals, and to inform the stakeholders at different levels (operational,
management, and executive level) in the organization of the extent of the progress

439

.

Establishment of such a program faces many different challenges. The practice of transfusion
medicine extends across multiple specialties, covers diverse clinical and laboratory services, and
requires data from many different departments and systems (i.e. admission, billing, laboratory,
pharmacy, transfusion service, etc.) in order to provide a comprehensive view of the hospital and
healthcare organization‘s practice452.

Hospitals are not required to have a PBM program, but they are required to review blood use to
ensure their transfusions meet appropriateness criteria established by medical staff (commonly
by a transfusion committee) based on the hospital‘s blood utilization protocols and guidelines.
However, transfusion committees in hospitals are not as effective as they have been intended to
be

239

. The transfusion committees often conduct cursory chart reviews of the transfusion cases

and frequently fail to recognize the forty to sixty percent of inappropriate transfusions that occur
in almost every hospital

239,453

. The ineffectiveness of chart reviews may be explained by the

following reasons:


Underlying complexities of transfusion medicine 152,158;
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Lack of or limited subject matter expertise; inability to understand the intricacy of
transfusion practice and the latest evidence 217,239;



Lack of proper knowledge and training to identify relevant metrics, and key performance
indicators 239,435,453;



Outdated and inappropriate transfusion criteria and guidelines, such as a single lab value
as a reference point for appropriate use of blood (i.e. hemoglobin level) 435,453;



Ineffectiveness of single chart reviews without holistic view of hospital‘s transfusion
practice at multiple granular levels 453;



Uncompensated physicians‘ review time 453;



Organizational culture 239;



Reviewers‘ bias (when physicians review the work of physicians they know, and with
whom they may have economic, political, social, referral relationships 239,453;

Another significant impediment pertains to the aggregation of many different critical data
elements residing in disparate hospital information systems making data management and
analysis a significant hurdle

452

. Manual data collection and analysis is not feasible and

sustainable. It requires alignment of staff and resources in order to accomplish an arduous
process on an ongoing basis. The process is time consuming, challenging, inefficient, and costly
258

. A further challenge is the regular provision of the meaningful, actionable information needed

to guide transfusion practice and promote a sustainable behavioral change

452

. The meaningful

presentation of information is critical for informed decision-making in order to provide a
baseline for current practice, to support future improvement initiatives, and to permanently
change behavior. Many healthcare organizations lack such a reporting mechanism.
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2.3.

Implementation Challenges of EBP in Current Health Information Ecosystem

After years of underinvestment in information systems, large-scale health infrastructure
initiatives have emerged and with it have brought dramatic change to healthcare. The use of
internet and health information technologies have empowered providers and patients to have a
wealth of information literally at their fingertips

454

. It is believed harnessing the power of

information technology and incorporating it into clinical medicine will improve the delivery and
outcomes of health services. This stems from the belief that changes in knowledge must trigger
changes in health practices, and, as a result, altered practices must improve outcomes. In other
words, ―better information begets better health through the medium of better choice‖ 454.

The national healthcare reform initiatives in the United States have placed evidence-based health
information systems and practice among the top deliverables for this decade.

455

. Historically,

care of the patient was influenced by the experiences and opinions of those involved in providing
treatment

77,456

. Evidence-based practice marks a shift among healthcare professionals from a

traditional emphasis on authoritative opinions to an emphasis on data extracted from prior
research and studies

77,84,457

. However, evidence-based decision making and practice face a

multitude of challenges. Evidence-based practice requires that the healthcare decision maker
discern better from worse information, use that knowledge to trigger a change in clinical
practice, and evaluate the outcome. To make the shift, it is integral for the individual (physicians
and other healthcare providers) to embrace critical thinking values of 458:


Courage: Critically appraise claims regardless of negative reactions;



Curiosity: An interest in deep understanding and learning;
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Intellectual empathy: Accurately understanding and presenting the views of others;



Humility: Awareness of the limits of knowledge including our own; lack of arrogance
(e.g. promoting false claims of effectiveness);



Integrity: Honoring the same standards of evidence to which we hold others;



Persistence: Willingness to struggle with confusion and unsettled questions.

On the organizational level, in order for the decision maker to make the better choice they must
be supported with evidence convenience (all the right information available in the right place at
the right time), discrimination (the relevant and important information filtered by the unique
needs of community, group, and individual), and integration (evidence embedded in work flow
with its use monitored and effective evidence behaviors correlated with health outcomes)

455

. In

order to provide evidence convenience, discrimination, and integration at the point of decision
making, a variety of health information technologies and approaches are necessary to facilitate:
(i) simplicity with uncluttered, straightforward, and consistent presentation of information using
an intuitive interface that requires a minimum effort to use without training; (ii) accessibility
with rapid access wherever healthcare decisions are made; (iii) sensitivity to individual and
group information preferences; and (iv) efficiency in the organization of information resources to
reduce the healthcare professional‘s burden of information management 455.

Information systems are the key to evidence-based practice 459. Information systems can capture,
transform and maintain data at three levels: raw data, processed data, and knowledge

460

. ―If the

raw data is valid, then the processed data, or "information‖, can be considered as equivalent to
evidence. Knowledge is information (evidence) in context‖459. Information and knowledge
management is at the heart of physician and other healthcare providers‘ intellectual and practical
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activities. The applicability of all the available ―best evidence‖ in a particular care management
setting requires other information as well, which may be of a contextual, local, or organizational
nature. ―The integration and exchange of clinical and administrative best practice information
among health professionals outside the restricted scope of the technical and scientific literature
has been shown to be a significant factor in appropriate decision-making‖ 461.

To embed evidence into practice, an iterative approach must be developed to empower the
decision-makers to ―know what to do (best evidence on best practices must be available to
inform decision making), do what is known (recognize problems, formulate questions, select
resources, and apply knowledge appropriately), and understand what is done (health choices and
outcomes must be iteratively validated)‖

455

. There are six major categories of information

systems and technology that contribute to evidence-based practice they include: reference
databases (biomedical literature, clinical trials review, current research, etc.); contextual and
case-specific information (individual patient medical records); contextual information
(environment, anthropology, epidemiology, socioeconomic, etc.); clinical data repositories
(clinical databases from different units or departments); administrative data repositories (claims,
billing, finance, etc.); and clinical decision support systems (web-based interactive health
information).

459

. According to a WHO 2015 report on health evidence networks by Michelsen

and colleagues, 462 the process from data provision to dissemination of information (from data to
information and knowledge) should be integrated. Integration has to take place at each step of the
process. Data have to be collected and integrated in datasets. Datasets have to be consistent (both
operationally and conceptually) and comparable. Different types of data, even across
jurisdictions, have to be collected in a well-coordinated manner to minimize overlaps and allow
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datasets to be combined in order to compare different populations or health service providers, to
monitor developments over time, or to analyze correlations, and to determine the social
determinants of health and the health status of patient or population groups. The approach to the
utilization of clinical and management health information is still a complex, chaotic, and
controversial subject

459

. It is not surprising that many expectations with regard to the

―contribution of health information systems to clinical practice have not been fulfilled‖ 459.

2.4.

Implementation of Evidence-Based Patient Blood Management Program

Patient Blood Management is defined as ―a multidisciplinary, evidence-based approach to
optimizing the care of patients who might need blood transfusion‖463. Recent studies point to a
risk profile associated with the use of blood products

142,164,245,251,364

.

There is increasing

evidence that inappropriate blood transfusions may contribute to increased risk of morbidity and
mortality

142,197,218,464

. There is, therefore, a need to review transfusion practice in order to

identify opportunities for improved patient outcomes and to reduce costs. The key component of
PBM program is a successful employment of a performance measurement system to track blood
product utilization, transfusion appropriateness, providers‘ performance, and patient outcomes.
Effective data integration, data management, and analytics play a critical role in the evaluation of
best-practice evidence, the improvement of performances, and the assessment of quality
outcomes. Aggregation and analysis of data, presentation and interpretation of information
through different measures and indicators allow healthcare professional and healthcare system
identify and recognize the shortcomings of the system, target areas for improvement, and make
corrective adjustments to address the shortfalls.
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However, the diversity of data and disparity of sources in the healthcare information ecosystem
pose a significant challenge for implementation of an evidence-based program. Crossdisciplinary evidence-based programs such as PBMs span multiple specialties (i.e. across
departments), cover diverse clinical and laboratory services, and require data both from multiple
departments in the business side and the clinical side. The types of data sets that are required for
PBMs reside in disparate systems (e.g. admissions, billing, laboratory, pharmacy, transfusion
service, surgical scheduling, etc.) and are not linked. These systems have their own databases,
data architecture, and applications that are different from one another and at times incompatible.
As a result, the limited data exchange between disparate information systems creates barriers to
tapping into all the required information that has been captured relative to physicians and other
healthcare providers practicing transfusion medicine and the patients who receive various blood
products. This makes it very difficult to evaluate physicians‘ transfusion practices, patients‘
quality of outcome, and total costs.

In order to optimize and sustain transfusion medicine best-practice and change providers‘
behavior, there is a need to aggregate clinical, financial, and operational data into a common
platform, develop an evidence-based performance measurement system to track practices against
best-practice guidelines, and evaluate the observed changes using analytics to address the
variability that exists in the practice of transfusion medicine. Such an effort requires an approach,
that (i) brings together targeted data from disparate information systems, (ii) uses methods to
measure performance, track patient‘s outcomes, and evaluate level of adherence to evidencebased best practice guidelines; (iii) provides a meaningful presentation of processed information
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back to stakeholders; (iv) uses targeted education to inform healthcare providers of their
practices; (v) supports program oversight; and (v) employs an analytics framework to evaluate
changes in transfusion medicine practice resulting directly from the program, to fine tune areas
for improvement, to evaluate patient quality of care, and to avoid unintended consequences and
outcomes. In addition, it is important to keep the process collaborative and constructive as the
healthcare institutions and the providers work toward the common goal of eliminating
unnecessary transfusions 465.

Chapter 3:
3.1.

Methods

Rationale

The shift toward evidence-based practice (EBP) empowers healthcare practitioners to move from
a culture of delivering care based on tradition, intuition, and authority, to a system in which
decisions are guided and justified through the best available evidence

466

. The concept of EBP

emerged in the early 1970s as a means to improve clinical practice74,298. Despite the great
advantages of EBP, many healthcare professionals remain cautious about embracing the model.
The complexities of changing to practice based on evidence make it a daunting task

467

with

barriers such as: attitudes toward EBP and research, unmet consumer demand for evidencebased care, logistical and organizational considerations, requirements of institutional and
leadership support, current policies and procedures, access to appropriate evidence

468

, and

technologies needed to support EBP. There are also challenges with implementation of EBP
including dissemination of EBP, audit of EBP approaches, and evaluation of associated
outcomes. The framework developed and implemented in this study was designed to address the
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challenges involved in the integration of evidence into daily medical practice through a
performance management system.

3.2.

Study Basis and Focus

The model presented here was developed based on the review of academic peer reviewed
research literature, industry research reports and white papers on a use of performance
management in healthcare and other industries. Additionally, the model was founded on the
review of case studies based on the experience of professionals in healthcare and other industries
who have successfully developed and implemented performance management systems. Several
international governmental reports on good practices and resources dealing with the development
of key performance measures to monitor healthcare quality were consulted. Furthermore, the
method was designed based on the practical knowledge gained through professional experience
related to this study. The model contained the critical elements that had been identified as
necessary for the successful construction of an evidence-based performance management system.
The factors and processes identified in this method tied strategic objectives of a healthcare
institution to the latest finding in a field of interest. The method provided a mechanism for
healthcare organizations to convert their data into meaningful information and knowledge that
could be applied in practice.

For this study, the discipline of transfusion medicine was chosen with a specific focus on the
patient blood management (PBM) approach. This study aimed to integrate evidence-based
practice (EBP) approaches and relevant data-driven information into the daily practice of
physicians. The paradigm of blood utilization has been shifting toward evidence-based practice
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with a focus on optimal transfusion strategies and utilization of blood products. However,
healthcare institutions struggle to implement a robust and scalable evidence-based PBM program
to promote optimal utilization of blood products and to encourage adherence to latest evidencebased best practice. Optimization of blood product use is complex and challenging but it is an
important task that has direct implications on patient safety, cost containment, and conservation
of a valuable and scarce resource. The Figure 1 below highlights the key objectives, strategies,
and tactics relevant to achieving the goals of a hospital wide evidence-based PBM program.

Figure 1 - Key Objective, Strategies, and Tactics for Implementation of Evidence-Based Patient
Blood Management Program
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3.3.

Implementation Model for Hospital-wide Evidence-based Program

3.3.1. Organizational Engagement
The implementation model which is the focus of this study was put into practice through
collaboration between BloodCenter of Wisconsin and a large local hospital as a pilot project. The
pilot hospital was a not-for-profit, full service, short-term, acute-care facility with 396 total
staffed beds. Under the pilot agreement, BloodCenter of Wisconsin agreed to create a roadmap
for identification, prioritization, implementation, and assessment of patient blood management
initiatives.

Establishment of an evidence-based patient blood management program required close
collaboration between BloodCenter of Wisconsin and the pilot hospital. The first step was the
formation of a cross-organizational management team. Figure 2 below presents a graphical
diagram of the executive sponsors, operation owners, and subject matter expert team leads from
different departments both at the hospital and the BloodCenter of Wisconsin; and the
communication flow between the two organizations.
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Figure 2- Conceptual diagram of communication flow between two organizations.
In order to develop a broad organizational support a Blood Utilization Governance Committee
was established. The committee consisted of hospitals executives, administrative, and clinical
champions including Vice President of Medical Affairs, Vice President of Laboratory,
Laboratory Medical Director, Laboratory Director, Blood Bank Supervisor, physician champion,
and Transfusion Safety Nurse champion. The cross-functional team consisted of a broad range of
proficiencies. A clinical team including physicians and a nurse who specialized in transfusion
medicine, specifically PBM were part of this core group. The overarching goal of the Blood
Utilization Governance Committee was to create a culture of accountability among physicians
who practiced transfusion therapies. It was very important to involve stakeholders at all levels in
the process of devising the performance management system to ensure that the individuals
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impacted understood the measures and metrics and the results in order for the measures to be
effectively used to track and evaluate performance at multiple levels within the hospital. The
chart above indicates the broad range of involvement among the two organizations Table 4.
Table 4 - Roles and responsibilities across organizations.
Hospital Roles and Responsibilities
Roles

Responsibilities


Has a vested interest in the outcome of the
project and is its champion.



Legitimizes the project‘s goals and
objectives, is kept apprised of major
activities, and is the ultimate decision
maker for the project.

Executive Sponsor


Promotes the project within the
organization, making sure that everyone
understands the benefits the project will
provide.



Provides support to the Operations
Manager and Operations Team Lead



Advocates for the business value of the
project and identifies the proper resources

Operations Manager
(funding/people) and ensures they are
available throughout the project
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Serves as a leader in promoting and
implementing Patient Blood Management
and acts as an evangelist for the program
within the organization

Physician Champion(s)



Encourages colleagues to see the benefits
associated with change and to monitor the
progress of the program



Leverages data-driven information in the
performance management system



Responsible for work outside of the IT
deliverables that is needed to support the
implementation of performance
management system (i.e., identifies Subject
Matter Experts and processes that impact
metrics, collaborates with the Transfusion
Safety Officer on User Acceptance Testing,

Operations Team Lead (Owner)

etc.)


Takes the role hospital‘s Subject Matter
Expert on the metrics and leads the efforts
to make the information available
throughout the organization.
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The Operations Team Lead is enabled to

act across facilities.


The Operations Team Lead and the
Hospital IT Project Manager are peers who
work together with the Transfusion Safety
Officer and IS Project Manager to build
and implement the complete solution.



Has the authority to manage the IS project
across facilities. The IT Project Manager
partners with the BloodCenter of
Wisconsin IT Project Manager to lead the
planning and development of all project
deliverables.



Responsible for managing the schedule and
all project management procedures (scope

Information System Project Manager
management, issues management, risk
management, etc.) related to hospital
resources


IT Project Manager and the Operations
Team Lead are peers who work together
with the Transfusion Safety Officer and IS
Project Manager to build and implement
the complete solution.
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Responsible for creating an initial and
ongoing data feed that meets the agreed
upon specification including, but not
limited to, any transformations from the

Analysts/Developer
native format and providing evidence of the
validation of source data.


Responsible for engaging the appropriate
hospital technical resources as needed



Has superior (expert) knowledge of a
discipline, technology, product, business
process or entire business area.

Subject Matter Experts



Collaborates with the Analyst/Developer to
ensure that the information contained in the
data feed accurately captures its intended
content.



Responsible for working with the Hospital
Analyst/Developer and BloodCenter of
Wisconsin Analyst/Developer to deliver

Integration Analyst

data to BloodCenter of Wisconsin.


Responsible for engaging any additional
hospital technical resources as needed
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BloodCenter of Wisconsin Roles and Responsibilities

Program Director

Responsible for all the components
included in the implementation of the
Program at the hospital



Responsible expert for the patient blood
management metrics and partners with the
Operations Team Lead to advocate for
successful implementation of the software
system.

Transfusion Safety Nurse



Advises the Operations Team Lead on
process identification for accurate metric
development, creating user acceptance tests
with the Operations Team Lead‘s
assistance, leads user acceptance testing,
and conducts user training.



Partners with the hospital‘s Physician
Champion to promote and implement
Patient Blood Management within the

Physician Champion
organization.


Leverages data-driven information in the
performance management system to
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monitor utilization data and assess the
impact on patient blood management
strategies
Information Services Project Manager



Authorize and manage the IT project at
BloodCenter of Wisconsin.



Partners with the hospital‘s IT Project
Manager to lead the planning and
development of all project deliverables.



Responsible for management of the
schedule and all project management
procedures (scope management, issues
management, risk management, etc.)
related to BloodCenter of Wisconsin
resources.



Responsible for ensuring that the
requirements are captured and documented
correctly and for understanding the
business requirements and designing a

Analysts/Developer
solution that will meet the business needs.


Responsible for the actual building of the
solution and system testing. If a need arises
for additional internal technical resources,
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the Analyst/Developer will engage them.

Combined Roles and Responsibilities


Responsible for the entire Program and
includes members of the hospital and
BloodCenter of Wisconsin organizations,
including executive and managers, whose
purpose is to provide guidance to the
implementation, ensure that functional
resources are available throughout the

Governance Team
program, remove obstacles impeding
progress, and validate that the program
realizes its intended benefits.


The Governance Team includes, but is not
limited to, the Executive Sponsor,
Operations Manager, and Program
Director.
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3.3.2. Physician Engagement
The Blood Utilization Governance Committee then established sub-committees for assigning
specific responsibilities to various working groups with subject matter expertise including
physician group, laboratory operations, information technology, nursing quality teams.
Blood Utilization Governance Committee formed a sub-committee that included transfusion
medicine expertise from BloodCenter of Wisconsin in the hospitals transfusion committee
known as Transfusion Medicine Steering Committee. The role of the Transfusion Steering
Committee required medical staff to take leadership role in measurement, assessment, and
improvement of clinical processes related to use of blood and blood components, and to analyze
all confirmed transfusion reactions. The committee included: the Laboratory Medical director,
physician champions, the Transfusion Service Supervisor, a quality improvement nurse, in
addition to Transfusion Safety Nurse and a physician champion from BloodCenter of Wisconsin.
In addition, multiple workgroups were formed to serve a variety of purposes. The workgroups
were made up of individuals with the expertise that was recognized as essential for individual
project deliverables. Subject experts from multiple hospital departments (e.g. information
technology, finance, lab, transfusion service, etc.) worked with well-respected physician
champions who were aware of transfusion medicine initiatives and the rationale behind them.
The physician champions were coupled with transfusion medicine experts (physicians and
nurses) from the BloodCenter of Wisconsin to promote various initiatives among the physicians
and nurses within the hospital. The workgroup members were responsible for understanding the
works, planning the activities, completing the assigned work, developing timelines, setting
quality expectations, informing the project management team of any issues, scope changes, risks,
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or quality concerns, and proactively communicating status. Detailed definitions of the roles and
responsibilities of team members were outlined in Table 2.

The BloodCenter of Wisconsin subject matter experts including a transfusion medicine physician
and a nurse, quality improvement laboratory technologists, information systems analysts met
with the hospital expert members from the Blood Utilization Governance Committee and the
Transfusion Medicine Steering Committee in a series of joint strategic meetings to determine the
strategic goals and objectives for the implementation of evidence-based transfusion medicine
program. The team reviewed the hospital‘s goals and objectives, and identified strategies and
tactics to be considered for the implementation of a hospital-wide evidence-based transfusion
medicine program. The overarching goal, the objectives, and the strategies helped determine the
list of tactics needed to achieve particular outcomes. Current state analysis was conducted and
hospitalists were determined to be the first group of physicians to incorporate evidence-based
transfusion medicine program in their daily practice.

The hospital agreed to outsource the implementation of a transfusion medicine PBM program to
BloodCenter of Wisconsin. The high-level tasks involved included:


Development of transfusion medicine best practice guidelines;



Education of physicians and other healthcare providers on latest approaches in
transfusion medicine and particularly PBM;



Identification of data elements to track transfusion practices of physicians;



Construction of a performance management system to track compliance with evidence
and appropriateness of transfusion orders;
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Distribution of reports to physicians, other healthcare providers, and administrative staff;



Construction of an analytics layer to evaluate changes in practice.

The hospital provided BloodCenter of Wisconsin with the resources required to aggregate, report
and analyze the identified relevant data. The hospital reviewed the reports in monthly
Transfusion Medicine Steering Committee meetings and took the necessary actions to help
encourage adherence to best practice evidence. Quarterly meeting was held with the Blood
Utilization Governance Committee to provide updates with regard to the advancement of the
program and to inform of changes in practice since the implementation of the program.

3.3.3. Promotion of Evidence-Based Medical Practice
One aspect of the strategic vision was the promotion of evidence-based practice in the area of
transfusion medicine at all levels of the healthcare system, particularly at the physician level.
Literature has reported that substantial, unexplained variations in practice at the physician level
have led to poor quality patient outcomes, inefficient care delivery, and unnecessary or wasteful
expenditures126,140,152,155,158,183,193,209,237,433. The area of focus of this study was the reduction in
transfusion of blood products, as blood transfusion was one of the most common, resourceintensive clinical interventions in the hospital1,21,133-135. The strategic objective was to implement
a model that fostered a shift from authority-based medicine to evidence-based conservative
transfusion strategies in order to reduce the unexplained differences in practice.

The process began with a series of continuing medical education sessions in which the
hospitalists were exposed to increasingly refined information on blood transfusion practice. The
presentations began with general evidence-based transfusion medicine practice, got more
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specific with patient blood management strategies, and concluded with very specific training in
the transfusion of individual blood components.

3.3.4. Transforming Data into Meaningful Information
Performance management is the strategic use of performance standards, measures, progress
reports, and ongoing quality improvement efforts to ensure an achievement of desired results 469.
It requires the active use of data to measure and improve performance across all areas of activity.
In the case of transfusion medicine, the ultimate purpose of these efforts is to enhance physician
knowledge on the latest evidence, improve transfusion practices, improve patient outcomes and
reduce costs. While the concepts of quality improvement, accountability, and performance are
not new, they are increasingly embraced by healthcare organizations to evaluate decisions,
measure activities and processes, in order improve quality of care, patient outcomes, and reduce
cost.

Critical elements were identified for the successful construction of an evidence-based
performance management system. The framework provided a means for construction of a
performance management system that tied evidence-based recommendations to metrics and
indicators that informed physicians, departments, and healthcare institutions on the level of
adherence to the recommendations and guidelines and provided the necessary information to
evaluate outcomes of compliance both from patient care and cost containment measures. It
included the following performance management components:
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Performance Standards that focused on establishment of organizational standards, goals,
and targets;



Performance Measures that focused on development, application, and use of performance
measures to assess achievement of standards;



Progress Reporting that focused on documentation and reporting of progress in meeting
the standards;



Quality Improvement that focused on establishment of program or processes to achieve
quality improvement based on performance standards, measurements, and reports342.

The conceptual framework below Figure 3 represented the overarching model for development,
implementation, and evaluation of a performance management system as a cornerstone for
implementation of an evidence-based PBM program within a healthcare institution.

The

activities were identified through an extensive review and analysis of literature and applied
knowledge

341,347,439,470-474

. The conceptual framework highlighted a series of activities which

must be undertaken throughout the development process of performance measures to ensure
successful deployment of an evidence-based transfusion medicine program. The activities follow
a logical order; the order of the activities ensured the comprehensiveness of the approach. Figure
3 has been periodically referenced throughout the study as a roadmap that highlighted the
intricacy involved in the development and progression of the steps that were involved in the
process. Figure 3 represents a conceptual model for development, documentation,
implementation, and evaluation of a Performance Management System. The modified figure was
partially adapted from Health Information and Quality Authority 472.
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Figure 3 - Represents a conceptual model for development, documentation, implementation, and
evaluation of a Performance Management System.
Evidence-based Performance Standards
Evidence-based performance standards play a foundational role in efforts to improve the quality
of patient care in the United States

475

. Evidence-based performance standards were deployed in

public and private reporting and payment systems purportedly to shape provider behavior toward
doing what works and away from rendering inappropriate, even dangerous, care. They were
based on scientific findings and therefore, represented an objective standard for provider
behavior. Evidence-based performance standards follow the logic of evidence-based medicine as
a whole. Clinical science can determine ―what works,‖ and providers can and should replicate
these findings in the care of individual patients‖ 475.

The first component of a performance management system was the development of evidencebased standards. The evidence-based performance standards used for this study were based on
the blood utilization guidelines entitled BloodCenter of Wisconsin 2011 Adult Blood Utilization
Review Guidelines published by the BloodCenter of Wisconsin (Appendix A). The guidelines
were developed by the physicians and staff of BloodCenter of Wisconsin Medical Science
Institute. The evidence-based guidelines were compiled after review of the cited references and
best available evidence. The review and the final approval were completed by the Medical
Advisory Committee at the BloodCenter of Wisconsin. The evidence-based guidelines were used
as a reference for best practices and minimum performance levels in order to encourage
consistency and uniformity across various service lines. To provide easy access to references and
the literature used in the blood transfusion guidelines, a commercial reference management
software package, EndNote by Thompson Reuters (Philadelphia, PA), was used. An EndNote
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web-based shared reference library was created to provide quick and easy access to detailed
reference components used in creation of BloodCenter of Wisconsin 2011 Adult Blood
Utilization Review Guidelines. The web-based shared reference library enabled healthcare
providers to appraise and assess the validity of the guidelines or find further information on a
specific topic if needed.

The use of the adult blood utilization review guidelines developed by BloodCenter of Wisconsin
transfusion medicine experts as the performance standard served to address multiple barriers to
the creation and use of evidence-based guidelines in clinical practice by the hospital. The use of
these guidelines minimized barriers such as adequate time and ability of clinicians to review,
interpret, and synthesize the available evidence, to translate knowledge into clinical practice, and
to perform deductive reasoning to determine if study findings could be uniformly applied to the
majority of patients in routine practice.

This study focuses on optimization of red blood cell transfusion according to the latest available
evidence. Adult blood utilization review guidelines (Appendix B) stated that red cell transfusion
may be appropriate for improving oxygen carrying capacity. Documentation of the indication(s)
for transfusion and special circumstances for transfusion that take place outside these guidelines
is recommended. Indications for transfusion of Red Blood Cell were as follows:


Red Blood Cell Indications:
I.

Acute Blood Loss: maintain circulating blood volume and hemoglobin
concentration ≥7 g/dL in otherwise healthy patients; >8g/dL in elderly patients
and those with known cardiac or respiratory disease.
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II.



15-30% loss of blood volume: RBC transfusion likely not required;



30-40% loss of blood volume: RBC transfusion probably required;



>40% loss of blood volume: RBC transfusion almost certainly required.

Stable hospitalized patients including those in the critical care unit: hemoglobin
≤7g/dL. Patients with co-morbid conditions such as coronary artery disease,
pulmonary disease, or evidence of acute MI have less tolerance for anemia.

III.

Peri-operative transfusions:


Hemoglobin concentration <7 g/dL: RBC transfusion usually required;



Hemoglobin concentration 7-10 g/dL: RBC transfusion may be
appropriate if any of the following are present: organ ischemia, increased
potential for or ongoing blood loss, volume status and risk factors for
complications of inadequate oxygenation;



Hemoglobin

concentration

>10g/dL:

RBC

transfusion

usually

unnecessary.
IV.

Symptomatic anemia in a normovolemic patient (generally symptoms from
anemia donot occur when Hgb ≥10g/dL).

V.

Outpatients with bone marrow failure may be prophylactically transfused to
maintain Hgb >7g/dl.



Outcome Indicators:
I.

Improvement in clinical status of patient (relief of symptoms of decreased oxygen
carrying capacity);

II.

Improvement in Hgb/Hct (one unit of red cells should raise the Hgb on average
1g/dL or Hct 3% in an adult). One hour post-transfusion Hgb is equivalent to one
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drawn within 24 hours of transfusion if there is no ongoing blood loss in a
normovolemic patient.


Comments:
o Transfusion of a single unit may be sufficient; transfusion of additional units
should be based on clinical assessment of patient. Avoid transfusions based solely
on Hgb or Hct value.
o Transfusions should be performed only after appropriate alternative therapies
have been considered (e.g. iron, vitamin B12, folate and erythropoietin).
o Certain patient populations (e.g. patient with hemoglobinopathies) may tolerate
lower hemoglobin thresholds and transfusions in such patients should not be
based solely on hemoglobin values.

Initial Baseline Analysis
A current state analysis was conducted to understand the hospital‘s transfusion practices. High
level data was collected to evaluate the total number of units of blood product the hospital
purchased and the cost per unit, and high level analysis was conducted of the number of
transfusions. Lean methods476 were used to evaluate the work processes, including value stream
maps, product and operator process flow analyses, and error potential analysis. Orders for testing
or for blood products were analyzed and timed from the point of entry into the transfusion
services department until the test results were released or the product was issued. Processes were
evaluated for the percentage of value-added and non-value added time. Non-value added
activities were eliminated. Processes were assessed using lean concepts to optimize inputs such
as labor components, to reallocate intellectual capital in order to enhance service levels and to
support more effective blood management and utilization.
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Measures to Track Performance
An integrated health care system or a hospital may have several distinct levels of organization,
and therefore, several distinct levels of performance measurement. The same levels will not be
present in all systems, but there are some that will be common across organizations. For this
study, the performance management system was designed at the system level (i.e. macro level to
incorporate the healthcare organization and the hospitals) to be meaningful to the healthcare
providers whose behavior was reflected in the measures. It was also designed to integrate
performance measures at the operational level (i.e. micro level to incorporate individual
physicians, other healthcare providers, clinical specialties, inpatient or outpatient units) with
measures that could be rolled up to hospital or healthcare organization level, in order to
incorporate a consistent set of messages about priorities, goals, and level of performance.
Although this study focused on implementation of evidence-based transfusion practice for one
hospital within a larger healthcare system, the performance management system was designed to
scale up if the healthcare system decided to implement the program system-wide.

Design of Performance Measure Levels
The most macro level is the healthcare system itself which is composed of a number of different
distinct operating units. Macro-level measures reflected performance across all hospitals and
facilities or performance for major operating units. The macro level measures provided a whole
system view allowing for assessment of transfusion of blood products across multiple hospitals
using nationally accepted benchmark metrics, or for evaluation of strategic objectives and the
effectiveness of individual hospitals on the strategic initiatives, etc. The next macro unit of
measurement was the hospital. Measures designed for this level included quality and efficiency
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measures such as rates of readmission, transfusion of blood products to inpatients and outpatients
depending on their condition. The performance management system was designed so Dthat if a
hospital had a specific role within a healthcare system (e.g. mental health vs. acute medical or
surgical vs. long-term rehabilitation facility), the performance measures could be identified and
parameters could be changed with a focus on the unique strategic goals and mission for the
specific hospital.

Although the performance management system was designed with flexibility to allow building of
unique measures to address specific goals of each hospitals, the same groups of performance
measures (i.e. utilization, quality, inventory management, appropriateness) allowed comparison
across an integrated healthcare system. The macro-level performance measures were the stable
measures used to report to management and executive levels. Some concepts and measures must
be kept constant over time, so that trends can be analyzed and results of various performance
enhancement initiatives assessed477. Reporting frequency was set at a quarterly basis with the
capability to compare the current quarter with the prior quarter and with same quarter in the
previous year.

More granular level measures were built at the micro level, consisting of the measures used by
departments, clinical service lines, physician groups, and individual clinicians. The micro level
measures allowed analysis of groupings of physicians based on their primary role within the
hospital (i.e. hospitalists, internists, cardiologists, intensivists). At this level, measures were
designed to include analysis based on clinical quality of care and utilization (i.e. rate of
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transfusion of different blood products, comparison of number of units issued per transfusion
order, etc.).

Below the micro, clinical service line level, were measures for the analysis of individual
physicians. The level above the physician level, i.e. department or clinical service line measures,
allowed for rate analysis. This type of analysis was too small at the physician level to allow for
calculation of meaningful rates. Physician profiling was at a low level in the organization
because of sample size issues and questions related to adjustments of clinical measures for case
mix differences among physicians. Therefore, to assess physician practice at this level,
utilization measures, clinical lab values, and outlier measures were used to assess the
appropriateness of the practice. If a physician was flagged as an outlier in the outlier measures,
then a process for individual chart review was put into place for further analysis of the patient
condition and evaluation of the appropriateness of physician‘s practice.

The micro-level measures were more dynamic. The performance management system was
designed to allow setting of targets and thresholds to track performance and to facilitate retiring
of measures that were no longer useful or adding measures that reflected new priorities. These
measures tended to be more specific and smaller for targeted work units and specific groups of
stakeholders. The micro measures tended to answer questions such as ―How well is my group
doing? Where do we need to focus our efforts in order to do better?‖ The frequency of reporting
at micro-level depended on the availability of data and the information needed for stakeholders
to take action. The goals of the micro-level measures were to create awareness and
accountability and to encourage change at the smallest levels.
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Figure 4 depicts the association between organization‘s strategic goals and development of a
performance management system. It highlights the need for a robust and clear strategic goals and
objectives to be formulated prior to development of a performance management system. A well
designed performance management system can directly connect to specific components of
strategic objectives and measure progress towards the overarching goal. Thus, the metrics were
designed to tightly relate to the strategic goals and objectives, link with activities to outcomes, in
order to influence decision making, be consistent with national benchmark metrics, and be
meaningful to macro and micro level stakeholders. In addition the performance management
system was designed with an emphasis on a closed feedback loop as a valuable mechanism for
quantification of change and a means to inform on target areas for improvement, refinement, and
to avoid unintended consequences by responding to change and outcomes rather than reacting to
them.
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Figure 4 - Illustrates association between an organization‘s strategic plan and the performance
management system. It highlights the continuous feedback loop as a mechanism to respond
outcomes rather than react.

Data Elements and Appropriate Source Systems to Build Various Indicators
The performance management system was constructed to provide information that was
significant in attaining organizational goals and priorities by representing the activities
associated with each priority and measuring and reporting the outcome of those activities. Four
major categories were defined for development of measures, metrics and indicators including:
inventory management metrics, utilization measures, quality metrics, transfusion appropriateness
indicators and key performance indicators, and benchmark metrics. Key performance indicators
were the most specific of performance measures and were an important component of a
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measuring performance at the micro-level (i.e. clinical specialty and individual physician).
Meaningful key performance indicators had the potential to influence decision-making at the
time of care by allowing physicians to consider factors deemed to be important when making
decisions and by explicitly identifying desired outcomes. Development of the key performance
indicators used in this study involved five key steps including; review of the strategic goals and
objectives; alignment of evidence with activities and linking activities to outcomes; close
involvement of key stakeholders; development of clear definition around each key performance
indicators; and evaluation.

Key performance indicators were designed to tie to the hospital and clinical service line strategic
objectives and required involvement of key stakeholders both on the business administrative and
the clinical side of a hospital. Key stakeholders reviewed strategic goals and objectives and
identified strategies and tactics for the implementation of a hospital wide evidence-based
transfusion medicine program. Goals and objectives helped determine the list of strategies and
tactics needed to achieve particular outcomes. Tactics and desired outcomes were considered for
different levels within the organization (i.e. physicians‘ level, departmental level, and facility
level), with key performance indicators used to measure and track individual performance. Key
performance indicators were designed around the results of these identified activities to ensure
that the hospital could track its success in reaching established goals and objectives. A target was
determined for each key performance indicators; each target could neither be too easy nor too
difficult to achieve. Where possible, key performance indicator targets were aligned with
available benchmarks. Results from the key performance indicators were required to be
measurable, attainable, accurate, and timely. Each key performance indicator was worded
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carefully to ensure that the results being monitored were sufficiently quantifiable and specific
enough to allow meaningful discussion of performance and evaluation of achievement.

The methodological framework described in this section ensured construction of an effective
performance management system. The focus had been to design a series of logical steps that took
into account the interconnectedness of the sequence of events involved in a set of processes
necessary to achieve an objective. This was in contrast to employment of a variety of measures
for separate entities to evaluate discreet and fragmented events. This section describes the
fundamental building blocks in the construction of performance indicators that are repeatable
measures designed to produce particular outcomes. The use of key performance indicators
provided a mechanism to quantify progress towards key organizational objectives. This approach
enabled corrective action to be taken if a particular process or decision failed to meet its
designated outcome.

Performance Measure Documentation
Reporting outcomes with a performance management system must go beyond simply reporting
inputs used during the reporting period e.g., utilization of red blood cells, output of the activity,
or number of patients transfused. Instead, reporting outcomes must provide information on how
these inputs and outputs have helped the hospital fulfill its high-level strategy, i.e. reducing
patient days. The Performance Measure Documentation Form (Table 5) was constructed to
highlight key elements for documentation of each performance measure. In all tables, including
Table 5, each element has been accompanied by a definition and examples to clearly identify the
type of information that must be understood, recorded, and communicated across teams and
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functional areas. Performance measure specification ensures that the results reach the intended
audience in the most coherent manner and format for interpretation and utilization.

Table 5 - Performance Measure Documentation Form.
Performance Measure Documentation Form
Performance



Measure Type
Title

Check one: ⧠ Metric ⧠ Indicator ⧠ Key Performance
Indicator



Indicate the exact title



Indicate a unique identification for every performance measure



Use alphanumeric format:
1. Choose a prefix depending on the type of the measure
APR for Appropriateness of transfusion

Unique ID
UTZ for Utilization
INV for Inventory
2. Flow by using a three digit number starting at 001


Example: APP001, UTZ001 etc.

Version



Indicate version (e.g. 1.0)

Date



Indicate today‘s date



Indicate the individual(s) responsible for formulating the
measure

Author(s)
Name:
________________________________________________
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Department:
______________Position:_______________________
Email:
__________________________Phone:_________________


Describe performance measure including targeted population,

Definition
and the audience whom the measure is intended to inform.

Rational



Give rational for measurement (include references).



Include reference in a sharable reference library (i.e. End-Note
Web).


Objective

Indicate the objective behind development of the performance
measure (i.e. reduction in utilization of a certain test or product
by 10%).

Measure Category



Indicate category to which the measure belongs.

Level of Health



Indicate the level of health information (e.g. Facility, Service

Information

Line, Physicians, Encounter, and etc.).


Indicate how the performance measure is being calculated.
Include information on numerator and denominators, and
provide information on inclusion and exclusion criteria.

Calculation



Indicate if there a standardized method of calculation available
for this performance measure: ⧠ Yes ⧠ No
If Yes, indicate if this performance measure is in compliance?
⧠ Yes ⧠ No – Provide explanation
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__________________________



Establish a target for acceptable level of performance; include
primary, secondary, tertiary, etc. if necessary. More

Target

specifically, the target can be initially establish based on the
result of the current state (as a baseline), and improve
incrementally.


Threshold

Establish threshold to indicate minimum level of performance.
Threshold can be established according to best-practice
guidelines.

Graphical



Indicate best type of visual presentation for the information.



Indicate target audience whom this measure is intending to

Presentation

Intended Audience
inform.
Name:

Date:

Department:

Approved by
_________________
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Position:

Email:

Phone:

Development of Minimum Data Set
Identification of a minimum data set was required for
construction of performance measures. Data set was defined as ―a
set of data that was collected for a specific purpose‖ and a
minimum data set was defined as core data elements that were
essential

in

construction

and

operationalization

of

the

performance measures, 471,472,478.
Once performance measures were defined based on the
performance standard, the next step was to identify what data
elements were required to calculate the performance measure.
This task was achieved by reviewing the documentation for every
performance measure in Table 3. The Performance Measure
Documentation Form identified the category of an indicator (e.g.
utilization measures) and the types of calculation required to
build the indicator. This information enabled the identification of
the data elements that were required to build the performance
measure and the source systems for extracting the required data.
Once the data elements were defined, the data elements were
incorporated into a data dictionary (Figure 5). The data dictionary
was created as a repository of information which included data
elements with their definitions and various attributes to support

Figure 5 - Data
Dictionary. Contains a
list of data elements,
definitions, and
attributes which supports
the consistent collection
of data and information
about the data.

consistent identification and aggregation of each data elements. Figure 5 indicates the attributes
that were captured as part of the data dictionary to ensure each data element and its associated
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values were clearly defined. Based on the information in the data dictionary, data feeds which
contained the series of data elements to be extracted from a specific source system (e.g.
laboratory information system, finance system, etc.) were defined. (This approach varies from
one hospital to another depending on how the back end infrastructure is set up.) Once detailed
information was captured, a Data Specification Documentation form was developed and used
(Table 6) to document detailed information about the specific set of data elements associated
with a particular performance measure. The Data Specification Documentation contained
additional file format information including: the format in which data had to be collected, the
frequency of collection for a particular performance measure and the contact information for the
subject matter expert for the specific system.

Table 6 - Data element and data feed specifications documentation form
Data Element and Data Feed Specification Documentation
Unique ID



Use the UID from the Performance Measure Documentation Form



Indicate core data elements with reference to specific sections of

Data Set(s)
the Data Dictionary for complete descriptions


Indicate the source system(s), where a data element and/or data set

Data Source(s)
is located and extracted from


Indicate the exact name of the file for individual data sets to be

Data File Name
transfer


Include a brief explanation of file content



Indicate whether manual or IT supported feed

Description
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Indicate the format of the file(s) e.g. .dat, .txt, .csv, .xls, .xml. and

File Format
etc.


Indicate the required frequency of data collection

Data Collection

⧠ One-Time ⧠ Daily ⧠ Weekly ⧠ Biweekly ⧠ Monthly ⧠

Frequency

Quarterly ⧠Annually ⧠ Other – Provide
details:____________________


Include the individual(s) responsible for collection and extraction
Name: ________________________________________________

Contact Information

Department:
______________Position:_______________________
Email: __________________________Phone:_________________

Reporting on Performance Measures to Stakeholders
The next step was to define reporting specifications and the level of health information needed
for reporting purposes. Once performance measures were defined as part of the process, a plan
was outlined on how and when to disseminate the results of measurements to the intended
audience. Table 7 specifies details and definitions on reporting criteria for each performance
measure. Reports were designed to provide information to multiple audiences rather to an
individual.

The reporting period and the frequency of publication of the results ensured

information was made available to the audience in a timely manner.
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A listing of all reports on which a specific performance measure was used to report ensured
relevancy of information and provided certainty that the information needs of all stakeholders
were being met without any duplications or replication. Literature

479

suggests that when

reporting off the same data to various audiences, relevant information should be provided that
speaks to each of the various audiences (e.g. physicians versus quality improvement personnel).
In this instance, physicians better understood information with more clinical detail as compared
to quality improvement personnel who needed the same information at a more summarized level.
The purpose of each report was to inform each of the audiences from diverse backgrounds on the
available and relevant information so improvement can be made. Reporting dashboards were an
example of a method that can be effective in presenting information in a way that facilitates
informed decision making to various audiences. With dashboards, the outcome of performance
measures could be presented graphically through a series of charts, gauges or tables. The
graphical presentation of information facilitated comparison of actual performance against
desired results.

Table 7 - Reporting specification documentation form.
Reporting Specification Form
Unique ID



Use the UID from the Performance Measure Documentation Form.

Fiscal Year



Indicate organization‘s fiscal year.



Indicate

Reporting Period

the

period

in

which

data

applies

⧠ Real-time (Information reported as data generated)
⧠ Daily

⧠ Weekly ⧠ Biweekly
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⧠ Monthly ⧠ Quarterly

⧠Annually
(Information is reported within the indicated time period)
⧠ Monthly in arrears ⧠ Quarterly in arrears
(Information is reported in the following time period)
⧠ Other – Provide details:________________________________


Indicate the required frequency for reporting.
⧠ Daily ⧠ Weekly ⧠ Biweekly ⧠ Monthly ⧠ Quarterly ⧠

Reporting Frequency
Annually
⧠ Other – Provide details:________________________________


Indicate the frequency of data processing based on the reporting
frequency chosen above.
⧠ Daily ⧠ Weekly ⧠ Biweekly ⧠ Monthly ⧠ Quarterly ⧠
Annually
⧠ Other – Provide details:________________________________

Frequency of data


If applicable, indicate the frequency of analysis based on the

processing & analysis
reporting frequency chosen above.
For instance it may be practical to aggregate data on daily basis, but
for comparison purposes it may be appropriate for the data to be
analyzed on weekly, monthly, annually, bi-annually.
⧠ Daily ⧠ Weekly ⧠ Biweekly ⧠ Monthly ⧠ Quarterly ⧠
Annually
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⧠ Other – Provide details:________________________________


Indicate in detail the method, in which performance measure is

Method of Analysis
computed.


Indicate the type of measure (i.e. rate-based, count based, and
etc.).472,479
⧠ Proportion Measures
This type of measure allows comparison among organizations or
trends over period of time. This measure requires both a numerator
and denominator. The measure identifies target population, the time
period, which the event may take place (e.g. proportion of
cardiovascular surgery patients who were transfused). This type of
measure often is expressed as a percentage and the numerator is

Type of measure

contained in the denominator.
⧠ Ratio Measures
This type of measure the numerator is not contain in denominator
(i.e. ratio of cardiovascular patients transfused and not transfused)
⧠ Count Measures
This type of measure includes number of events without
denominators (i.e. Number of single RBC units transfused in the
past month)
⧠Outlier Measure
This type of measure highlights events that are inherently
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undesirable and usually warrant detailed analysis to determine why
the event occurred. It indicates poor performance (i.e. Patient
transfused with Hgb level above 10 g/dL)

Aggregation Level

Indicate the level within the system to which information must be
reported (i.e. physician level, service line level, department level,
organizational level, etc.).



Indicate whether risk adjustment strategy is required. 472,480
⧠ Required – Provide details:___________________________
⧠

Not

Applicable

⧠

Other

–

Provide

details:__________________
Risk-Adjusted
A risk adjustment strategy reduces the possibility of external factors
influencing the measure and ensures that the measure is a true
reflection of the process being measured. Certain characteristics
may influence outcome (i.e. age, disease condition, etc. )
List of reports



List the various reports, where this measure will be used to report

performance measure
on performance.
is included in
Comparative



Analysis

institution or nationally for benchmarking purposes.


Monitoring

Indicate whether the measure is being measured in other healthcare

Indicate how often measure will be monitored and by whom.
⧠ Daily ⧠ Weekly ⧠ Biweekly ⧠ Monthly ⧠ Quarterly ⧠
Annually
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⧠

Other

–

Provide

details:

______________________________________


Include the individual(s) responsible for collection and extraction
Name: ___Department: ____Position:______ Email: ______
Phone:______________

Evaluation Criteria
Once specifications were completed and the indicators were comprehensively defined, the next
step was to evaluate the attributes of performance management system components (metrics and
indicators). Table 6 outlines a list of characteristics and related questions for assessment of the
different components. The criteria were partially adapted from Health Information authority,
472,479

World Health Organization

481

, and the Joint Commission480.

Each component of PMS

had to be approved based on the judgment and consensus of subject matter experts, and, if
possible, potential users481,482.

Measures that had been selected using scientific evidence

possessed high content validity relating to important aspects of the quality of care provided.
Measures selected through consensus and guidelines had to have high face validity to ensure that
performance measurements made logical and clinical sense based on extensive past observations.
Reliability could be influenced by training, the measure‘s definition and the precision of the data
collection methods

483

. Based on the theory of reliability, reliability could not be exact, thus had

to be estimated 484. Inter-rater reliability testing compared variations among different evaluators
performing the same measurement, in order to identify inconsistencies among the evaluators

472

.

Internal consistency was used to assess the consistency across results within a test. It examined
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the relationship between sub-indicators of the same overall measurement, and if reliable, there
were correlation of the results. Test retest reliability compared the difference in results when the
same evaluator performed the measurement at different times. The preferred method for
choosing measures was through the systematic evaluation of the scientific evidence in support of
a specific measure. This was achieved through rating the strength of the scientific evidence itself.
For instance, an alphabetical grading scale was used to evaluate the strength of the evidence. The
rating scale was determined as A through C. Measures supported by meta-analysis of
randomized controlled trials, controlled studies without randomization, epidemiological studies
received scores of A, B, and C respectively485. In healthcare, there may be limited scientific
evidence in support of a certain measures, therefore it became necessary to benefit from expert
opinions486.

Data collection feasibility was one of the critical elements of evaluation criteria. The burden of
collecting the types of data elements required to construct the measure was an important
consideration. However, it did not outweigh the value of information that could potentially be
obtained. The driving force behind data collection programs has to be focused on continuous
improvement of processes and domain knowledge, with the goal of applying that knowledge to
devising improved performance management strategies. Data collection and analysis were
considered as the foundation on which sound performance management system strategies could
be devised and implemented. Data collection must take on a culture that begins at the onset of a
key improvement initiative and is maintained throughout its life as long as it is economical. In
other words, the value of information gained from the data must outweigh the cost of collection
and analysis of the data.487. Cost benefit analyses was done to determine the cost effectiveness
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of data collection. This included the type of approaches that were used to collect data and the
limitations of the systems used for collection. Reporting arrangements was outlined, including
reporting arrangements for existing data collection and frequency of data collection and analyses.

Table 8 - Performance measure evaluation criteria.
Performance Measure Evaluation Criteria
Title



.

Unique ID



Use the UID from the Performance Measure Documentation Form

Version



Indicate version (e.g. 1.0).

Date



Indicate today‘s date.



Does the measure what it is supposed to measure?
⧠ Yes

⧠ No

⧠ Not Applicable

⧠ Other – Provide details:_________________________________

Validity

A valid (metric, indicator, or key performance indicator) measures
what it is supposed to measure and captures an important aspect of
quality that can be influenced by the healthcare facility or system.
Ideally performance measures selected should have links to
processes and outcomes through scientific evidence.


Reliability

Does the measure provide a consistent output?
⧠ Yes

⧠ No

⧠ Not Applicable

⧠ Other – Provide details:_________________________________
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The metric, indicator, or key performance indicator should provide
a consistent measure in the same population and settings
irrespective of who performs the measurement. Reliability is
similar to reproducibility to the extent that if the measure is
repeated the same result should be obtained. Any variations in the
result of the metric, indicator, or key performance indicator should
reflect actual changes in the process or outcome.


Is the measure supported by scientific evidence or the consensus of
experts?
Score:________ ⧠ Yes

⧠ No

⧠ Not Applicable

⧠ Other – Provide details:_________________________________

Evidence-Based
Explicitness

Metric, indicator, or key performance indicator should be based on
scientific evidence, the consensus of expert opinions among health
professionals or on clinical guidelines.


Is the metric, indicator, or key performance indicator acceptable?
⧠ Yes

⧠ No

⧠ Not Applicable

⧠ Other – Provide details:_________________________________
Acceptability

The data collected should be acceptable to key stake holders (i.e.
Physicians, Transfusion Service, etc.) those being assessed and to
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those carrying out the assessment.


Is it possible to collect the required data? Is it worth the resources?
⧠ Yes

⧠ No

⧠ Not Applicable

⧠ Other – Provide details:_________________________________

Required data elements must be available and accessible
The feasibility analysis should determine what data sources are
currently available, resources required to collect required data, and
Data Collection

if they are relevant to the needs of the current project. This will

Effort and Feasibility

include determining if there are existing metric, indicators, key
performance indicator, or benchmarking processes based on these
data sources.

There should be a feasibility analysis carried out to determine what
types of data are currently being collected in what format, and
whether those can be leveraged, also the resources required to
collect any additional required data.


Are small changes reflected in the results?
⧠ Yes

Sensitivity

⧠ No

⧠ Not Applicable

⧠ Other – Provide details:_________________________________
Changes in the component of care being measured should be
captured by the measurement process and reflected in the results.
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Does the measure actually capture changes that occur in the service
for which the measure is intended?
⧠ Yes

⧠ No

⧠ Not Applicable

⧠ Other – Provide details:_________________________________
Specificity
Changes in the component of care being measured should be
captured by the measurement process and reflected in the results.
The measure should be capable of detecting changes in the quality
of care and these changes must be reflected in the resulting values.


Can the rational and the result of the measure be easily understood
by the intended audience?
⧠ Yes

⧠ No

⧠ Not Applicable

Results

⧠ Other – Provide details:_________________________________

Interpretability

Presentation of the results and information must be demonstrated in
a meaningful manner to ensure intended audience can understand
and interpret the results and information in a same manner and with
no variation for decision making purposes.


Does a decision(s) can be made from the measure?
⧠ Yes

⧠ No

⧠ Not Applicable

⧠ Other – Provide details:_________________________________
Relevance
The results of the measurement should be of use in planning and the
subsequent delivery of healthcare and contribute to performance
improvement
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Is there a set of measures that calculate different aspects of the
service?
⧠ Yes

⧠ No

⧠ Not Applicable

⧠ Other – Provide details:_________________________________

Balance

The final suite of indicators should measure different aspects of the
service in order to provide a comprehensive picture of performance,
including user perspective488.


Have national and international measures been considered?
⧠ Yes

⧠ No

⧠ Not Applicable

⧠ Other – Provide details:_________________________________
Tested
Consideration must be given to measures that have been tried and
tested in the national and international arena rather than developing
new indicators for the same purpose.


Will an unwarranted focus on the measure lead to potential adverse
effects on other aspects of quality and safety?
⧠ Yes

⧠ No

⧠ Not Applicable

⧠ Other – Provide details:_________________________________

Safe

The indicator should not lead to an undue focus on the aspect of
care being measured that may in turn lead to a compromise in the
quality and safety of other aspects of the service.


Has other previously developed measures been reviewed to ensure

Duplicated
measure is not duplicated or overlapped?
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⧠ Yes

⧠ No

⧠ Not Applicable

⧠ Other – Provide details:_________________________________
Prior to developing the measure, considerations must be made to
ensure none of the measures are duplicated or the results overlap
with one another. Individual measure should be distinct in the
measure itself and the result of the measure to prevent any
confusion or misinterpretation of results.

Has consideration been given to other projects or initiatives?
⧠ Yes

⧠ No

⧠ Not Applicable

⧠ Other – Provide details:_________________________________
Prior to developing the indicator consideration should be given to
other projects or initiatives to ensure that there will not be a
duplication of data collection.


Will the information be available within an acceptable time period
to inform decision-makers?
⧠ Yes

⧠ No

⧠ Not Applicable

⧠ Other – Provide details:_________________________________
Timeliness
The data should be available within a time period to empower
decision-makers to utilize the result to inform their decision-making
process. (i.e. If the data is required for operational purposes, then it
will be required within a shorter timeframe than data used for long
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term strategic purposes).


Does the measure provide capability to supplement or enhance the
current accreditation process and support healthcare organization
quality improvement efforts?
⧠ Yes

⧠ No

⧠ Not Applicable

Accreditation
⧠ Other – Provide details:_________________________________
Usefulness

Consensus, evidence, or guideline must provide information on the
usefulness of the measure for the purpose of benchmarking or
identification of best-practice.

Final Consensus

The measure:
⧠ Pass

⧠ Fail- See notes below ⧠ Re-evaluation Required:

⧠ Other – Provide details:_______________________ Notes:

3.3.5. Identification of Information Silos
Using the method described system feasibility, analysis, and design for the transfusion medicine
PBM data systems were conducted by reviewing the reporting requirements of the PBM program
in relation to the available data sources. After deciphering the content of the hospital‘s current
information systems, five major source systems were identified as holding the required data
elements. The sources systems are listed in Table 9; the source systems identified and crossexamined for development of transfusion medicine performance management system.
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Table 9 - List of required source systems for generation of data feeds.
Source Systems

Content

Finance Information System

Patient days and patient admission information

Health Information System

Patient encounter, discharge information
Patient Transfusion and crossmatch information.

Transfusion Service Information
Blood products inventory and wastage
System
information
Lab Information System

Patient lab results information
Information on all current and historical

Medical Credentialing System
healthcare providers

Minimum datasets were identified from each of the above systems. The datasets were
sufficiently refined to enable cross-examination at levels required to ensure a contextual view of
information. A single database was created at the BloodCenter of Wisconsin to collect and link
the hospital‘s diverse source systems from existing databases in order to provide reports and
perform analytics related to transfusion medicine practices.

Extract Contextual Dataset
An analytic and reporting solution was needed in order to code and construct performance
measures for the study. It was necessary to aggregate relevant data and information from the
hospital‘s diverse source systems in order to build reports and perform the analytical (e.g.
statistical and quantitative) manipulations required to support informed decision making.
InSight™ is a reporting and analytics solution from Mediware based in Lenexa, KS which had
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been licensed by BloodCenter of Wisconsin. InSight™ is a performance management solution
designed to optimize operational performance through presentation of trends. InSight™
performance management solution encompasses a back-end called DataLoader, which provides
limited, non-enterprise-level Extract – Transform –Load or ―ETL‖ capabilities. This function
most readily integrates with Microsoft and SQL databases. The front end is called InSight, which
provides a web interface to the end users as a portal to view pre-defined reports and dashboards.
In addition, the solution offers array of capabilities, few include:


Customization and dynamic viewing of reports,



Sequential drill down capabilities on performance measures to view the information from
top-level to the most granular detail levels,



Graphical display of information,



Interactive reporting capabilities,



Customizable graphs and changeable time periods,



Integrated email and export functionality to Excel.

A license agreement was drafted with Mediware (Lenexa, KS) to allow both internal (i.e.
BloodCenter of Wisconsin Transfusion Medicine team) and external users (i.e. hospital‘s end
users) to access the portal for reporting and viewing purposes. The data sets were transferred
from the hospital to BloodCenter of Wisconsin using a secure file transfer protocol (sFTP) and
were stored in a central repository (Figure 6 and 7).
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Figure 6 - Conceptual representation of data acquisition, aggregation, processing, and reporting.

Data Sources
There was an abundance of data surrounding transfusion medicine. These data often resided in
several different ‗transactional‘ systems. In general, transactional systems are designed for the
various aspects of running day to day operations. These systems are considered the originators of
data for analytics purposes. Although, it may be possible to run reports directly out of the
transactional systems, there are cautionary reasons to avoid direct manipulation of data in a
transactional system including the possibility of slowing down or compromising the source
system. In addition, in the case of transfusion medicine which spans across multiple departments,
the majority of reports required data from more than one transactional system. Therefore, for this
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study data had to be moved into a different data repository, a SQL database that was located at
BloodCenter of Wisconsin, for data processing, analysis, and reporting. The hospital was
responsible for providing the required data on a routine basis to BloodCenter of Wisconsin for
processing using a secure file transfer mechanism. In order to comprehensively complete this
phase, a high-level questionnaire was drafted that was used as a discussion guide to learn about
the various health information systems and other transactional systems within the hospitals. The
questionnaire was aimed at identifying various source systems for aggregation of relevant data,
confirming the availability of certain data elements in specific source systems and accessing
support from the hospital Information Technology Department when necessary for aggregation
and transfer of data. Ultimately, to successfully implement the analytics program, a crossorganizational project team was engaged. The key milestones of an implementation and the
roles of individuals required for the success of an implementation were outlined and reviewed
(Appendix B).

Data Transport
In order to transfer the data from the hospital to BloodCenter of Wisconsin, a Secure File
Transfer Protocol (sFTP) was established for accessing and managing the data file transfers. A
lightweight enterprise service bus, MuleSoft (San Francisco, CA) was employed as integration
software to pick up the data files from the sFTP server and deliver them to an internal repository
at BloodCenter of Wisconsin (Figure 7).
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Figure 7 - Overview of connection architecture.

Data Intake
Once data was securely received from the hospital‘s diverse and disparate source systems, data
was loaded and transferred into a data repository. This process is typically referred to as ―ETL‖
and is the process of taking selected transactional data (both structured and unstructured) into a
type of a data store (i.e. data warehouse, data mart, operational data store, analytic databases,
etc.) in an organized form. More specifically, extract was the process of reading data from a
database. Transform was the process of converting the extracted data from its previous form into
the form it needs to be in so that it could be placed into another database. Transformation
occurred by using rules or lookup tables or by combining the data with other data. Load was the
process of writing the data into the target database. Data Loader offered basic ETL capabilities to
perform this step.
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Data Linkage
There were no direct links between patients‘ administrative and clinical system records. Even
among clinical records there was no links among datasets from the lab information system and
the transfusion service information system dataset. There was the same lack of a linkage of
various events and procedures for healthcare provider among the various health information
systems. Only actual blood transfusion sessions (excluding wastage) and laboratory results were
linked with the administrative records which indicated blood information and laboratory results
with the dates and times that fell between admission and discharge data and time. To protect
patient privacy of information across the diverse source systems, a single unique identifier was
created. The identifier employed a combination of patient encounter identification and facility
designation. The patient medical record number, a single unique patient identifier, was only used
for validation of the linkage on the back end system and was not reported.

Database Design
Once data was successfully loaded into Data Loader, they were stored in a relational SQL server
database, which was considered the operational data store. A unified metadata layer was defined;
and data from the various source systems were mapped to enable contextual information.
Various views (virtual tables) were created to join subset of data from different tables (populated
from disparate information systems) with coded logics built-in for contextual view of data, and
to limit exposure to the underlying source data. The logics were coded in the views to link data
on patient, provider, blood products and clinical details that were required to for individual
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measures in the performance management system. Finally, the data was configured through the
design of various data models to match the constructed measures.
Security Measures
Health information is very sensitive and has formal definitions around the security of patient
data. Data feeds were partially de-identified to reduce the risk of exposure of patient health
information. Patient identifier data elements that were used to validate patient records across
different source systems were minimized. In addition, access to the data repository, Data Loader,
and InSight™ web application were restricted through authorization and authentication. Audit
services were put in place to track access to different the types of data and measures. Session
timeout was placed for InSight web application to prevent users to remain logged in for a long
period of time.

End-User Analytical Capabilities
The Insight application provided the end users with a portal to view pre-defined reports and a
dash board. It enabled more advanced users to export data into Microsoft Excel for further
analysis. Most of the capabilities have been mentioned above.

Develop a Performance Management System
Once the identified data feeds were received through the mechanism described above, the next
step was to construct the performance measures (Figure 8). Figure 8 represents a simplified
overview of the performance measures build process from raw data to the metrics and indicators.
The construction of the performance measures followed the instruction provided by Mediware
(Lenexa, KS). Briefly, Data Loader allowed administrators to setup data flows that import legacy
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data into the database and perform calculations on it so that its data can be utilized by InSight
web application. InSight web application allowed users to view the information using the
performance

measures

perform

further

needed

for

analysis

reporting

management

and
if
and

purposes.

―Measures‖ were used to answer
questions as to the performance
of

monitored

services.

―Indicators‖ were used to give

Figure 8 - Represents the conceptual view of the processes
involved in building of a performance measure.

the users the information so that
they could manage performance proactively. ―Data flows‖ indicated all the steps required to
transform raw data from a text file, Excel file, or a database table, or a view into one or more
measure(s). A data flow consisted of three components of ―job‖, ―template‖, and ―table‖. The
table stored the data. The template helped transform the data in the text file, Excel file or
database table/view into a table. One or more job(s) were required to perform operations on the
data, including the file processing step to transform the data into the table.

To design data flows, raw data was received from the hospital. The acceptable data sources were
delimited text files, fixed width text files, Microsoft Excel files, Microsoft SQL server database
or Microsoft Access both using a Microsoft Data Link (UDL) file. The table consisted of three
different table structures: time series, reference tables, and hierarchies tables. Time series table
held a set of information over time that measured a process. This information was typically
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intended to be displayed in the InSight web application for the end users. Reference tables
contained data whose purpose was to be mapped into time series tables. They could contain any
combination of text and numerical data. Reference tables allowed the combination of data from
different systems for use in a single table. The tables received and held the data. Hierarchies
tables enabled drill down capabilities to provide granularity in viewing the information. It
enabled the user to progressively delve into increasing level of detail.

Once the tables were set up, the next step was to develop the jobs for the import processes into
the time series tables for display of the information on the InSight web application. Prior to
publishing the information on the web application, it was important to note that both Data Loader
and the InSight web application used tables to store table structures and their corresponding data.
In this context, a table encompassed both a Data Loader table and a data table. A Data Loader
table was a collection of data that represents the structure of a data table in the database. It
specified the format of the table, table fields and field types contained, etc. The Data Loader
table contained the meta-data for a data table. Data table was a SQL table that contained the data
itself for a table. Data tables used jobs for the import of data. The template related the data fields
in the source repository to data fields in a target database table. It allowed the user to link
between fields, add expressions to set the value of database fields and add variables that could be
used in other expressions.

All database tables were initially populated with data as specified in a template. Templates were
used by the process file job step which took the data from the source system and used it to add
data into a target database table. The template was the second of three arguments used by the
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process file job step. A job was a set of steps that processed the data and loaded it into a table for
delivery and viewing in the InSight web application. The job(s) were first run to populate the
reference tables and then run the second time to import data into the time series table. As
indicated, jobs could have one or more steps. A job always contained the ‗get parameters‘ job
step as the first step. The ‗get parameter‘ step was not editable in the Data Loader user interface.
In addition, the jobs had parameters; supplying parameter values to the job gave Data Loader the
information to supply parameter values to all the steps defined for the job.

Every different step required different parameters, which had to be set individually. Common
job parameters included input files, input template, and production table. The input file
parameters were typically used when the job contained a process file job step to import data from
a source system into a database table. The process file step defined which type of file would be
obtained from the source data (i.e. file that contained a flat data file or a file that told that step
where to get the data from was referred to as data link file or UDL).The input file parameter was
typically used when the job contained the process file step to import source data into a database
table. This parameter referred the process file step to which template should be used to map the
source data to the database target table. The production table parameter told the job from which
database table the data should be used. Once data flow was processed and deployed successfully,
the performance measure would be ready for viewing by the end user on the InSight web
application.
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3.3.6. Awareness and Education
Healthcare Performance Management Dashboard
Performance dashboards were a component of the performance management system that enabled
communication of strategic goals and empowered the stakeholders to measure, monitor, and
manage key initiatives and processes required to meet objectives and accomplish tasks.
Dashboards provided tailored reports that informed specific individuals or groups of
administrators and healthcare professionals. For example, a clinical dashboard had to provide
the capability to:
i.

Monitor defined processes and activities using measures and to show trends that identify
potential problems;

ii.

Facilitate analysis of the root cause of problems by exploring relevant and timely
information from multiple perspectives and at various levels of granularity;

iii.

Inform management of individuals‘ performance and processes to improve decisions,
optimize performance, and guide the program towards the intended objective.

The next step was the integration and display of the information in a timely and meaningful
manner to the intended audiences (physicians, administrators, managers, department heads, etc).
InSight web application provided physicians, other healthcare providers, and administrators with
access to the aggregated information in a form of a report which promoted informed decision
making and allowed tracking trends of individual healthcare provider or service line groups. User
access to the dashboards was defined for the end users using a uniform resource locator (URL).

For this study, the dashboard was utilized to monitor blood product utilization, transfusion
appropriateness based on pre-transfusion lab values, quality of blood products transfused, and to
169

inform hospital management and administrator of the transfusion medicine practice. The
dashboard was customized to take into account specific department‘s information needs. It was
designed to provide custom reports to individual groups of stakeholders such as physicians,
nurses, transfusion service lab technicians, departments, executives and the medical director of
transfusion safety committee. The customization enabled a specific set of information to be
presented to the intended audience. This ensured security of information and provided a means to
avoid information overload which remains a barrier to healthcare providers using specialized
resources. Therefore, designing the level of granularity, type of information, and method of
presentation were key factors in designing dashboards that presented measures in a meaningful
way while avoiding fatigue and desensitization. The dashboard followed a build instruction
provided by the software vendor.

Effective Interventions to Encourage Best Practices
A multi-pronged intervention strategy was adopted to encourage continuous adherence to
transfusion medicine best-practice guidelines. The strategy was based in part on an extensive
review of literature on the most effective education strategies that affect physician behavior,
performance, and healthcare outcomes. The search included a bibliographic search of published
research and a citation review of relevant articles. In addition, past approaches of the transfusion
safety nurse were evaluated to determine any correlation between educational and reporting
interventions (i.e. dissemination and review of reports with department heads, individual
physicians, educational newsletters, formal presentations, posters, blogs, etc.), and change in the
associated transfusion practice trend. Periodic conversations with the medical director of the
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transfusion committee also were used to determine best approaches and incentives to help
change inappropriate transfusion practices. The intervention strategy included:
i.

Distribution of evidence-based practice guidelines as a performance standards;

ii.

Use of newsletters and posters on transfusion best practices;

iii.

Creation of continuing medical education courses on evidence-based transfusion
practices;

iv.

Distribution of paper transfusion summary reports to individual physicians and
department heads;

v.

Review of outlier (i.e. physicians not practicing in accordance with evidence-based
guidelines) reports by the Transfusion Committee Medical Director followed, when
necessary, with a formal letter citing cases and recommendations.

vi.

Creation of an environment focused on information, not punishment. (Reports would
eventually be tied to Physician Performance Evaluation reviews.)

vii.

Evaluation of the effect of blinded and un-blinded reports for comparing individual
physicians with their peers.

3.3.7. Develop Feedback Mechanism
In order to assess the changes in physician practice an analytics framework was developed and
used to address the following fundamental questions:


What types of improvements (quality, performance, safety) were desired?



What processes had to change or be created to result in improvement?



What change (if any) had occurred?
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Figure 9 represents the position of the analytics framework in the context of information value
chain. The goal of the analytics is to continuously improve efficiency and effectiveness of every
decision and action. Figure 10 details the steps involved in the analytics framework used for this
study. It begins with the emphasis on data quality, addresses cross functional inefficiencies due
to heterogeneity of various information systems and data silos, emphasizes contextual
development of data models, and enables use of different applications of analytics from
diagnostics and, to predictive and perspective, it incorporates statistical framework to understand
sources of uncertainty between observation and what actually occurred. The analytics model
below took into account system of tools, technologies, techniques, and people to consistently and
reliably generate data-driven information with the focus to drive clinical insight needed to take
appropriate actions and achieve measurable and desired outcomes.
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Figure 9 - Details the steps involved in building and using the analytics framework.
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Figure 10 - Details the steps involved in building and using the analytics framework.

Moreover, the information value chain served as continuous feedback mechanism loop to
evaluate changes directly impacted by the promotion of restrictive transfusion approach, to
identify new areas for improvement, and avoid unintended consequences and outcomes.

3.3.8. Evaluation of Change in Physicians Practice
Evaluation of physician performance and feedback across multiple organizational levels were
key components in the success of the project. Evaluation was based on the performance of
hospitalists relative to the consensus RBC utilization recommendations which included:
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A restrictive transfusion strategy with a transfusion threshold of hemoglobin level of 7
g/dL, or 8 g/dL for patients with cardiac conditions.



Order of single-unit RBC transfusions with a restrictive pre-transfusion Hgb trigger.



Post-transfusion reassessment for determination of patients need for subsequent
transfusion.

Pursuant to transfusion medicine best practices education programs, the transfusion medicine
PBM performance management system tracked various aspects of healthcare providers‘
transfusion practices. Hospital data was actively used to develop reports and an analytical
framework was used to retrospectively evaluate changes in the transfusion practices of the
hospitalists. The hospitalists and department heads were provided with reports on individual
physicians‘ which included transfusion metrics on RBC ordering on a quarterly basis. For the
purpose of the global review, the report to the department chair was unblinded with identified
physicians and their transfusion information; the report to individual hospitalists was blinded to
allow comparison of each. Corrective feedback on the reports was provided as needed through
multiple avenues including: further education, peer to peer education, formal letters from the
Transfusion Steering Committee Chair, and reflection on performance evaluations.

Data analysis was conducted over a 24 month period in order to evaluate pre and post
intervention periods. The time period for data collection and analysis was from October 1, 2012
to September 30, 2014. The 24 month period was chosen to take into account 12 months of preintervention and 12 months of post-intervention and to allow for the seasonality that was
observed in the number of patient admissions to the hospital in different months. The patient type
included in this study was hospitalized individuals with an inpatient designation.
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Cost Analysis of Red Blood Cell Utilization
A value stream map based on lean management methods for analysis of current and future state
was employed.

Diagnostics, therapeutic, technical, laboratory, logistics, administrative,

education, and quality activities associated with RBC transfusion ordered for patients were
observed and documented by the transfusion safety officer prior to implementation of the
framework. To determine activity-based cost of RBC transfusion, processes and activities
associated with RBC transfusion were divided into six major categories including:


Maintenance of blood products by blood bank including activities such as: inventory
monitoring, blood components ordering, unit checking, blood grouping, returns
processing, antigen screening, etc.



Pre-transfusion activities including: physician evaluation of patient, obtaining pretransfusion samples, sample processing, Hgb and CBC testing, and etc.



RBC unit preparation by transfusion service including: receiving and processing
transfusion order, label creation, delivery to patient, patient type and screen,
reconfirmation of patient blood type, unit selection, unit labeling, etc.



Transfusion nursing staff including: ordering transfusion, verification of entered order,
consent form preparation and completion, assembly of supply, receipt and verification of
blood unit, verification of match, re-identification of patient, monitoring patient vitals
every 15 minutes, monitoring patient for duration of transfusion, documentation, posttransfusion assessment, transfusion reaction support, etc.



Post transfusion activities including: Hgb and CBC testing, transport of samples to the
lab, receipt and log of samples, post transfusion testing and assessment, etc.
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Other activities include: rework factor, overhead, product and supply wastage, inventory
carry cost, and etc.

A cost model adapted from a landmark study that focused on an in-depth examination of the
complex array of activities surrounding the decision to transfuse on transfusion activity-based
cost 21 was used to determine the cost of RBC transfusion.

3.4.

Statistical Analysis

After receiving approval from the hospital under Business Associate Agreement, 24 months of
data from October 2012 to September 2014 was collected for inpatient encounters (32, 870) at
the institution. Neonate patients less than 1 year of age (3,652) were eliminated due to higher
Oxygen binding affinity of fetal hgb. There were 11,553 inpatients whose attending physicians
were hospitalists (35 physicians with hospitalist designation as primary specialty). ETL
processes, mapping and linkage of data were performed prior to storage of data in a central SQL
server repository using a performance management analytics portal (InSight, Mediware Inc.,
Lenexa, KS). The central repository contained data from the hospital‘s diverse and disparate
information source systems (including: finance, transfusion service, laboratory, medical staff
services, and EHR systems). Data was extracted from the central repository using SQL queries,
and was processed and analyzed using software programs including Excel statistical package
(Microsoft Inc., Richmond VA), and MATLAB (MathWorks Inc., Natick, MA). Categorical
variables were reported as frequencies and percentages; continuous variables were reported as
means with standard deviations. Comparisons of categorical and continuous variables were done
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using Pearson Chi-Square test and two sample t-test, respectively. All significance tests were
two-tailed, with α level of 0.05 to denote statistical significance.
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Chapter 4: Results
The study results are based on 32,870 patient encounters with inpatient status from October 1,
2012, to September 30, 2104. During this time period, 9.12% of discharged inpatients received
RBC transfusions using a total of 8,905 RBC units (not including wasted units). Patient
information was linked across disparate source systems using a composite unique key which
consisted of the hospital facility code and an encounter identification number. Approximately
99.15% of discharged inpatients were linked to their transfusion events and clinical details.

October 1, 2012 to September 30, 2013 represents pre-implementation of an evidence-based
restrictive transfusion medicine framework. October 1, 2013 to September 30, 2014 represents
post-implementation of the evidence-based restrictive transfusion medicine framework period.
The post-implementation period included the following hospital-wide interventions:


Recommended a restrictive transfusion strategy with a transfusion threshold of
hemoglobin level of 7 g/dL, or 8 g/dL for patients with cardiac conditions.



Recommended orders of single-unit RBC transfusions for non-bleeding stable medical
patients with a restrictive pre-transfusion Hgb trigger.



Recommended post-transfusion reassessment for determination of patients need for
subsequent transfusion.



Offered continuing medical education courses on the latest evidence-based approaches to
transfusion medicine.



Distributed educational and materials in the form of newsletters, posters, and flyers.



Constructed and implemented performance management system to track and measure the
evidence-based recommendations.
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Implemented transfusion medicine reporting and utilized data analytics software to
analyze the trend and report on transfusion practices.



Distributed transfusion reports targeted to individual hospitalists and department heads
for all relevant service lines.



Implemented an analytics framework to evaluate changes directly impacted by the
promotion of restrictive transfusion strategies, to identify new areas for improvement,
and to avoid unintended consequences and outcomes.

4.1.

Performance Management System

A performance management system (PMS) was constructed to achieve the following objectives
in transfusion medicine including: identification of areas for best practices, facilitation of actions
to improve health services, improvement of patient care and outcomes, and assurance that
operational activities are linked to the overall organizational strategies.

Specifications documents were used (Tables 3-7) to construct the different metrics and indicators
as part of PMS which: helped define targets and thresholds across key aspects of service delivery
including management of resources (e.g. blood products); enabled a comprehensive picture of
the service lines (e.g. hospitalists) progress towards achieving goals recommended by the
evidence-based best practice guidelines; provided a mechanism for early indication of emerging
issues that may require corrective actions; and indicated where there was a potential to improve
the cost effeteness of services.
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4.1.1. Performance Monitoring
The hospital, as part of a larger healthcare system, was composed of a number of separate and
distinct levels of operating units. To accommodate the different levels of operating units, the
performance measures were designed and constructed to accomplish a granular level of reporting
(e.g. system, hospital, clinical service line, and individual physician) pertaining to these different
units. There were dimensions that were different across service lines, but there were also
dimensions that were common. The PMS system was designed and constructed to scale as
additional hospitals were added in the future (Figure 11). Figure 11 represents a conceptual
representation of the PMS for the hospital. It represents a combination of performance measure
including: measures (e.g. Hgb, INR, Fibrinogen lab values), metrics (i.e. blood products
utilization metrics), scorecards (i.e. tracking physicians‘ ordering of blood product transfusions),
and key performance indicators (i.e. measure progress towards achieving objectives). Scorecards
play a key role within a PMS. They enable translation of strategic goals into tangible objectives
and measures. It allows measuring, monitoring, and assigning key performance indicators to
track and optimize performance towards organizational goals.
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Figure 11 - Conceptual representation of the performance management system for the hospital.
The construct PMS was used to implement evidence-based transfusion medicine strategies in the
hospital.

4.2.

Hospital Activity Profile

4.2.1. All Inpatient Demographics and Hospital Activity Profile
The hospital‘s activity profile and patient demographic during the study time period are
represented in Table 10 using descriptive statistics.
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Table 10 - Hospital activity profile and patient demographic.

4.2.2. Transfused Inpatient Demographic and Hospital Activity Profile
Table 11 represents the demographic of inpatients who received at least one unit of RBC
transfusion using descriptive statistics. The rate of inpatients that were transfused with RBC unit
was significantly decreased during post intervention period X2 (1, N = 32870) = 18.66, p < 0.01.
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Table 11 - Hospital wide transfused patient demographic.

4.3.

Current State Assessment of RBC Usage

The percentage of RBC units in individual clinical service lines compared to total hospital wide
RBC units was calculated as a baseline analysis for the pre-intervention period (Oct. 2012 to
Sep. 2013) 2013 (Figure 12).

During the pre-intervention period 4910 RBC unit were

transfused. Hospital Medicine represented 34.09 % (1,674 Units) of RBC usage, followed by
Cardiothoracic Surgery 12.53 % (615 Units), General Surgery 9.84% (483 Units), Hematology
and Oncology 9.41 (462 Units), and Pulmonary Medicine 8.76% (430 Units). The five clinical
specialties accounted for 74.62 % of the hospitals total RBC use. In this study the specialty is
defined as the physician in charge of ordering the RBC transfusion.
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Figure 12 - Hospital wide usage of RBC units by clinical specialties.

Following AABB guidelines for PBM

489

as a starting point, annual, and later quarterly, data on

the overall RBC usage adjusted per 1000 patients was collated. The collated data provided a
mechanism for benchmarking the hospital against itself and in the future against similar hospitals
with a similar patient mix. Blood component usage data was collated by clinical service line (e.g.
internal medicine, hospitalists, hematology/oncology, cardiothoracic surgery, orthopedic
surgery) and even more specifically by physician group and individual healthcare provider which
allowed focusing the efforts on identifying clinical service lines that utilized the most blood
products and thus targeting the areas where education and change would have the greatest
impact.

(Figure 13) shows RBC transfusion per 1000 patient days by clinical service line.
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Clinical specialties with the highest yield of RBC transfusion per 1000 patient days included:
Hospital Medicine with 21.73, followed by Cardiothoracic Surgery with 7.98, General Surgery
with 6.27, Hematology and Oncology 6.00, and Pulmonary Medicine with 5.58 RBC units
transfused per 1000 patient days.

Figure 13 – Hospital-wide inpatient RBC transfusions per 1000 patient days.
4.4.

The Impact of the Model on Hospitalists Transfusion Practice

Figure 14 is adapted from Dzik, W. Transfusion 2003; 43 (9):1190-1199. The figure represents
the spectrum of activities and processes involved in transfusion of blood component(s). The
overarching aim of this study was to implement restrictive transfusion strategies among
hospitalists, using evidence-based guidelines, data analytics, reporting, meaningful presentation
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of information, and focused education to drive appropriate decision making and interventions
prior to formulating the decision to transfuse and prior to issuing of blood component(s). The
arrow on Figure 14 represents the point on the transfusion spectrum where this study aims to
influence the hospitalist‘s decision of whether to transfuse or not and how much.

Figure 14. Represents the spectrum of activities and processes involved in transfusion of blood
or blood components (adapted from Dzik, W. Transfusion 2003;43 (9):1190-1199). The arrow
shows the stage in the process at which the framework was employed to influence physicians‘
transfusion decisions.

Figure 14 - Represents the spectrum of activities and processes involved in transfusion of blood
or blood components.
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4.4.1. Changes in RBC Transfusions 1000 Patient Days
Figure 15 and 16 represents changes in inpatient RBC transfusions per 1000 patient days by
hospitalists, comparing pre and post intervention periods. The dotted line identifies the
separation between the Pre-Intervention and Post-Intervention time periods. Comparison of
quarterly percent difference of Hospitalists‘ RBC transfusion activity per 1000 patient days
showed a significant decline of 26.23% (p < 0.01), when comparing the Post-Intervention with
that of Pre-Intervention periods. The average inpatient RBC transfusion per 1000 patient day
during pre-intervention (Oct. 2012 to Sep. 2013) was 21.67±2.29 compared to 15.69±1.91 during
post-intervention time period (Oct. 2013 – Sep. 2014).

Figure 15 - Trend in Inpatient RBC transfusions per 1000 patient days among hospitalists.
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Figure 16 represents quarterly changes in inpatient RBC transfusions per 1000 patient days by
hospitalists and interventions that took place during pre and post intervention periods.

The

diamond end dotted line indicates circulation of newsletters (Appendix C) on the latest evidence
on restrictive RBC transfusion approaches and a newsletter on one vs. two unit RBC ordering
practice highlighting the following factors:


Recommended a restrictive transfusion strategy with a transfusion threshold of
hemoglobin level of 7 g/dL, or 8 g/dL for patients with cardiac conditions.



Recommended orders of single-unit RBC transfusions for non-bleeding stable medical
patients with a restrictive pre-transfusion Hgb trigger.



Recommended post-transfusion reassessment for determination of patients need for
subsequent transfusion

The solid line indicates continuing medical education on pillars of PBM (Appendix C). The
green and blue arrows represent distribution of physician performance measure unblinded reports
(created using InSight data analytics and reporting software) to the department heads for
different clinical service lines and reports to individual hospitalists using a blinded comparison
approach to their peers. The (Figure 16) represents quarterly changes in inpatient RBC
transfusions per 1000 patient days by hospitalists and interventions that took place during pre
and post intervention periods and timing of continuing medical education and reporting.
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Figure 16 - Trend in Inpatient RBC transfusions per 1000 patient days among hospitalists and
representation of the interventions.
4.4.2. Change in Transfusion Medicine Practice
Performance of individual physicians and the capability to assess that performance are
increasingly the key drivers for improving the quality and efficiency with which health care is
delivered. Expanding the capabilities to measure, report, and improve physician performance is
among key initiatives that could be employed by wide variety of stakeholders (physician group,
quality improvement team, etc.) in the hospital. This study reported performance information to
individual physicians that followed objectives outlined in evidence-based transfusion guidelines
(performance standard) and PBM newsletters highlighting three key areas including:


Transfusion threshold of hemoglobin level of 7 g/dL, or 8 g/dL for patients with cardiac
conditions;
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Orders of single-unit RBC transfusions for non-bleeding stable medical patients with a
restrictive pre-transfusion Hgb trigger;



Post-transfusion reassessment for determination of patients need for subsequent
transfusion.

The underlying goal was to make physicians aware of their performance based on the evidencebased guidelines and to encourage improvement in specific aspects indicated above. Since the
implementation of the evidence-based transfusion medicine framework, change was observed
among hospitalists‘ transfusion practices.

4.4.3. Change in RBC Unit Orders
Figure 17 Comparison of pre – intervention (Oct 2012 – Sep 2013) orders (n = 1093) and post –
intervention (Oct 2013 – Sep2014) orders (n = 800) showed a significant change in overall RBC
ordering practice X2 (2, N = 1893) = 49.07, p < 0.01; analysis of one vs. two unit RBC orders
also showed a significant change in X2 (1, N = 1847) = 43.90, p < 0.01. The percent of one-unit
orders to total orders increased by 31.7%, and the percent of two-unit orders to total orders
decreased by 30.9%. The green and blue arrows represent distribution of physician performance
measure unblinded reports (created using InSight data analytics and reporting software) to the
hospitalists‘ department head and reports to individual hospitalists using a blinded comparison
approach to their peers.
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Figure 17 - Trend in hospitalists RBC unit ordering practice.

4.4.4. Change in Pre-Transfusion Hemoglobin Threshold
Figure 18, 19 represents analysis performed on one-unit and two-unit orders to determine
whether there was a change in the transfusion threshold of hemoglobin level based on the
performance standard. One-unit orders with pre-order Hgb values  7 and > 7 g/dL showed a
significant shift towards a lower pre-transfusion Hgb trigger when the pre- and post-intervention
periods were compared using a Chi-Square test X2 (1, N = 849) = 4.60, p = 0.032. Analysis of the
mean pre-transfusion Hgb for one-unit orders during the pre-intervention period was 8.0 g/dL
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(SD =0.71); the pre-transfusion Hgb trigger lowered to 7.7 g/dL (SD = 0.69) during the postintervention period. Two-unit orders with pre-order Hgb values  7 and > 7 g/dL showed no
significant change towards a lower pre-transfusion Hgb trigger when the pre and post periods
were compared using a Chi-Square analysis X2 (1, N = 701) = 3.52, p = 0.06. Analysis of the
mean pre-transfusion Hgb for two-unit orders during the pre-intervention period was 7.5 g/dL
(SD =0.80); the pre-transfusion Hgb trigger lowered to 7.4 g/dL (SD = 0.90) during the postintervention period with no statistical significance. Although results are statistically not
significant the trend is moving towards lower pre order Hgb trigger (Hgb values  7 g/dL
(21.38% to 27.73%) and > 7 g/dL (78.62% to 72.27%) when compared pre to post intervention
periods.

Figure 18 and 19 represent the observed changes in pre-transfusion Hgb (g/dL)

threshold.
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Figure 18 - Comparison of pre-order Hgb (g/dL) trigger for one-unit RBC transfusion orders
among hospitalists.
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Figure 19 - Comparison of pre-order Hgb (g/dL) trigger for two-unit RBC transfusion orders
among hospitalists.

4.4.5. Change in Post-Transfusion Assessment
Post-transfusion assessment of the effect of the RBC transfusion, specifically the increment in
hemoglobin and hematocrit, is important. Blood specimen were collected as ordered by the
hospitalists, however, timing of the phlebotomy may vary depending on the clinical condition of
patient. Post-transfusion reassessment was quantified by examining the post-transfusion Hgb
testing. Figure 20 for one-unit orders with pre-order Hgb value =< 7; Chi- Square analysis of the
post-transfusion reassessment rate showed a significant change during post-intervention period
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(X2 (1, N = 90) = 12.52, p < 0.01). The odds ratio analysis showed the odds of post-transfusion
Hgb reassessment were 5.41 times greater during post-intervention period. The same analysis
was conducted for one-unit orders with pre-order Hgb value > 7. The post-transfusion
reassessment rate showed no change X2 (1, N = 759) = 0.04, p = 0.831, however the
reassessment rate after transfusion of one unit with pre-transfusion Hgb >7 g/dL remained steady
during pre and post intervention periods with 84.91 and 85.52 percent respectively. The same
analysis was performed for two-unit orders. For two-unit orders with pre-order Hgb value =< 7;
Chi- Square analysis of the post-transfusion reassessment rate showed no significant statistical
change X2 (1, N = 165) = 0.17, p = 0.674. The rate of post transfusion reassessment after
transfusion of two unit RBC orders remained steady during pre and post intervention periods
with 93.94 and 94.45 percent respectively. The same analysis was conducted for two-unit orders
with pre-order Hgb value > 7; the post-transfusion reassessment rate did not show a change X2
(1, N = 530) = 2.49, p = 0.11. The rate of post-transfusion reassessment after transfusion of one
unit RBC order with pre-transfusion Hgb >7 g/dL also remained steady during pre and post
intervention periods with 98.90 and 96.99 percent respectively. The analysis showed no
significant difference for post-transfusion reassessment Hgb testing because the rate of testing
was already close to the maximum.
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Figure 20 - Post-transfusion Hgb (g/dL) reassessment of one-unit and two-unit orders.

4.5.

Economic Impact of the Change in Practice

4.5.1. RBC Transfusion Cost Breakdown
The cost model included product acquisition cost, and direct and indirect overhead costs. Direct
overhead costs included elements such as blood bank staff (manager, laboratory, technician,
etc.), related overhead costs for the blood bank, laboratory, nursing staff, and pathologist.
Indirect overhead costs included three major process steps such as patient testing, pre-transfusion
processes, and administering and monitoring transfusions. The national average blood product
acquisition cost of $210.74 ± 37.9 was used based on the latest hospital-based blood banks and
transfusion services 2011 survey 133. This cost did not include wasted RBC units and additional
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services such as irradiating, washing, or warming of RBC units. Product acquisition cost
contributed 33.19 % of the total cost of transfusion. The evaluation of direct overhead cost
contributed a small percentage (8.91 %) of the overall blood-related costs; the indirect cost
contributed the highest proportion of total transfusion cost of 57.90 %. Using the cost model, the
total cost per RBC unit transfusion was determined to be $ 634.97 ± 36.76 (Mean, SD). Using
the cost model, an estimated 33.19 % (210.74 ± 37.9) of the total cost of transfusion was
associated with the product acquisition cost and the remaining 66.81 % (424.23) was attributed
to direct and indirect overhead cost (Figure 21.).

Figure 21 - Total cost breakdown per RBC unit transfusion.
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4.5.2. Cost Analysis RBC Orders among Hospitalist and Non-Hospitalists
Based on the above cost estimates, the total cost of inpatient RBC transfusions among
hospitalists and non-hospitalists during pre and post intervention periods was compared using the
RBC unit acquisition cost and RBC transfusion activity-based cost An independent sample t-test
was conducted to compare unit cost of RBC transfusions among hospitalists (1675 to 1085
issued units) and non-hospitalists (3184 to 3005 issued units) during pre and post intervention
periods. The cost analysis of RBC orders by hospitalists during the post-intervention time period
showed a significant 27.49 percent decrease in cost per unit of RBC transfusion per 1000 Patient
Days when compared the post-intervention period (M = $3,296.95, SD = 397.39), with the preintervention period (M = $4,547.08, SD = 485.46), p < 0.01. The same analysis was performed
for non-hospitalists. The comparison of the post intervention period (M = $9,151.80, SD =
1,542.01) with the pre-intervention period (M = $8,673.77, SD = 1,211.53), p = 0.42 showed no
statistical change in cost of RBC utilization among non-hospitalists.
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Figure 22 - Comparison of total cost per 1000 patient days of RBC transfusion (cost per unit and
activity-based cost) during pre- and post-intervention periods among hospitalist.
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Figure 23 - Comparison of total cost per 1000 patient days of RBC transfusion (cost per unit and
activity-based cost) during pre- and post-intervention periods among non-hospitalist.

4.5.3. Trend Cost Analysis of Hospitalists Practice
The cost analysis breakdown of inpatient RBC orders among hospitalists showed a significant
overall decrease of 27 percent (p < 0.01) in cost of RBC transfusion per 1000 patient days as a
result of the decline in the number of orders. Figure 24 represents the trend in quarter-year
decline in the cost of RBC orders per 1000 patient days including one, two, and three or more
unit RBC orders.
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Figure 24 - Quarterly trend in hospitalist utilization and total cost of RBC transfusion per 1000
patient days.
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Chapter 5: Discussion

Rising healthcare costs and declining quality of care have heightened the need to identify and
implement new strategies to address shortcomings in the United States healthcare system. This
study focuses on promoting evidence-based medical practice and leveraging healthcare data to
improve quality of care, outcomes, and control costs. The study demonstrates the effectiveness of
a framework that bridges the gaps that exist between data, knowledge, and practice in a
healthcare setting through the use of evidence-based guidelines, enhanced contextualized datadriven reports, analytics and education focused on current evidence.

This study focuses on transfusion medicine. Transfusion is one of the top ten coded hospital
procedures in the United States. Unfortunately, the costs of transfusion are underestimated and
the benefits overestimated. The particular aim of the study was to reduce practice inconsistencies
in red blood cell transfusion among hospitalists in a large urban hospital using focused
education, evidence-based guidelines, and reporting based on physician-specific data to drive
appropriate decision-making prior to the decision to transfuse or prior to issuing the blood
component, and data analytics to serve as a feedback mechanism to evaluate changes in behavior
and practice. The study‘s integrated framework proved to be effective in encouraging evidencebased best practices and lowering costs.

This study sought to achieve an institutional shift to evidence-based transfusion medicine
practice using a framework that took into account the administrative, cultural, clinical, and
technical issues that make the implementation of an evidence-based program and utilization of
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healthcare data so challenging. What follows is a discussion of the components of the framework
that proved to be effective in addressing the issues associated with the study‘s deployment of
healthcare data in the shift to evidence-based medicine.

5.1.

Administrative Issues

5.1.1. Strategic Focus
There were challenges related to the introduction of the strategic and organizational changes that
were needed to promote new programs and that would encourage the uptake and use of new
knowledge. This required clear top down direction, administrative support and action,
collaboration, re-working of resources and priorities, resource dedication to goals that were
specific to evidence-based practice, and commitment to dedicating the skills and technologies
needed to measure changes, track and evaluate programs77,279,282,490-494. High level support and
involvement were needed to meet the ambitious goal of encouraging hospitalists to move from a
culture of delivering care based on tradition, intuition, and authority, to a system in which
decisions were guided and justified through education, awareness of the best available evidence,
and measure of performance based on physicians‘ specific practice data.

5.1.2. Resource Commitment
Administrative buy-in and support at the highest levels of the organization was essential for the
successful implementation of this hospital-wide, cross-departmental, evidence-based patient
blood management program with its heavy reliance on a performance management system, data
analytics, and reporting. While the healthcare organization may have already recognized the
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importance of the use of data, it was critical that they make the resource commitment to address
issues related to the development of the components of the performance management system
including: data location (diverse and disparate information ecosystem); data definitions (
inconsistencies in data definitions subjected based on the source system); data structure
(inconsistency in data capture structured vs non-structured); data complexity (presence of
numerous identical parts in amalgam of individual systems) , and staff allocation (with
appropriate skills and time) .

5.1.3. Coordination
It was important that structures be put into place that insured ongoing communication and
coordination between the hospital and BloodCenter of Wisconsin and as well as among all the
involved individuals and departments within the hospital. The Blood Utilization Governance
Committee was established as a way to develop and sustain broad organizational support. The
overarching goal of this committee was to create a culture of accountability among physicians
who practiced transfusion therapy. The committee consisted of hospital executives,
administrative, and clinical champions including the Vice President of Medical Affairs, the Vice
President of Laboratory, the Laboratory Medical Director, the Blood Bank Supervisor, a
hospitalist physician champion, and transfusion safety nurse champion. The Blood Utilization
Governance Committee established sub-committees that assigned specific responsibilities to
various working groups.
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5.1.4. Ongoing Feedback
Developing an analytics framework to provide a continuous feedback mechanism contributed to
the overall success of the program and provided the tools to inform the executives and
administration on progress. The framework served to provide a feedback mechanism relative to
the strategic objectives, aggregate data obtained from the performance management system, and
the effectiveness of the education that healthcare providers received. The analytics framework,
through quantification and long-term reassessment of trends, facilitated a deeper understanding
of the clinical changes that the hospitalists made in their transfusion practice as a result of
informed decision-making. In addition, it enabled evaluation of changes directly impacted by the
program, identified new areas for improvement, and helped avoid unintended consequences and
outcomes. A set of high-level indicators were used to provide feedback to the Blood Utilization
Governance Committee for determination and any needed adjustment to goals, objectives,
priorities and strategies. The operational indicators included: hospital-wide trends of blood
product inventory and rate of wastage; total number of blood products transfused by product
type, patient type, and by nursing unit; and measures of blood product ordered by various clinical
specialties. In addition to reporting the operational indicators, a set of nationally accepted
benchmark indicators were constructed and used to inform the Blood Utilization Governance
Committee with regard to the hospital‘s current trends on patient transfusions and blood product
utilization. These benchmark indicators included: measure of inpatient and outpatient
transfusions per 1000 patient days based on patient census, and measures of admitted patients
who received transfusions by a specific blood product.
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5.2.

Cultural Issues

5.2.1. Behavioral Change
An informative rather than punitive approach was employed with regard to implementation of
the evidence-based PBM program in order for the message to be well-received among physicians
and other healthcare providers. Strategies included physician education promoting conservative
RBC transfusion strategies through continuing medical education courses, newsletters, and
posters and quarterly reports to department chairs and to individual hospitalists highlighting RBC
ordering practices of the physicians and other healthcare providers. The department reports on
physicians‘ transfusion practice was unblinded for the review of the department chair. The
individual physician report was blinded using a system-generated identifier for each physician to
allow comparison of individual physicians to their peers. Individual physicians responded
differently making varying levels of intervention (e.g. education, peer-to-peer discussions,
performance reports, letters from the department head and performance review consequences) a
valuable framework component.

5.2.2. Tradition, Intuition and Authority
Studies have shown each unit of allogeneic RBC increases the rate of nosocomial infection by
fifty percent; transfusion of patients with two units of RBC can highly increase the rate of
hospital acquired infections 409,495-498 . Thus the common practice to ―automatically place twounit RBC orders makes no sense from a resource consumption or patient safety standpoint 498‖. It
has been more than a decade since the publication of the landmark study ―Transfusion
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148

Requirements in Critical Care (TRICC) trial‖

and many others studies

supporting the restriction of RBC transfusions for patients

185

140,142,149,155,182-184

. Since then, there have been some

reports indicating improvements in transfusion practices, mostly with regard to reduced
hemoglobin thresholds at which patients are transfused

186-188

. Nonetheless, the overall use of

allogeneic RBC transfusions in clinical practice remains relatively high and still varies widely
among many centers and practitioners

185,189-191

. One underlying issue is that many physicians

were trained before transfusion research and evidence were available regarding transfusions.
Historically, some physicians have been taught liberal transfusion practice and to follow the
maxim ―if you are going to transfuse, why not give two‖
research studies have examined RBC

15,194,195

148,149,155,162,182,183,196,197

Nonetheless, many clinicians are slow to change

15

. Now, however, numerous
and platelet use

27,198-202

.

, and some are even skeptical without seeing

hard evidence, such as individualized data-driven reports, information on latest research
evidence in practice, reports on their individual practice and the practice of their peers. The
framework developed for this study was designed to promote a move beyond tradition, intuition
and authority-based practice to practice informed by education focused on current evidence,
evidence-based guidelines, and enhanced contextualized data-driven reports.

5.2.3. Transfusion Medicine Expertise
The practice of transfusion medicine extends across multiple specialties and covers diverse
clinical and laboratory services. It requires specialized subject matter expertise and an
understanding of the intricacies, underlying complexities and latest transfusion medicine bestpractice evidence. In transfusion medicine, as in other areas of medical practice, there is a gap
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between the latest knowledge and current physician practice. As commonly as transfusions occur
in the United States, one may assume that physicians practice transfusion medicine based on
strict standard guidelines. However, the efficacy of blood transfusion is poorly understood
among practicing physicians 139-143. Partnering with BloodCenter of Wisconsin to provide access
to best-practice expertise and the latest research findings was essential in off-setting any lack of
transfusion medicine expertise among the hospitalists. The committee used the performance
standard, BloodCenter of Wisconsin 2011 Adult Blood Utilization Review Guidelines, to establish
key objectives and relied on BCW expertise throughout the process.

5.4.

Clinical Issues

5.4.1. Relevant Clinical Information and Evidence
Challenges in a shift from authority-based medicine to evidence-based medicine include the lack
of relevant clinical information, inadequate time and the inability of physicians to review and
interpret available evidence and translate new knowledge into clinical practice 4. Offering
continuing medical education courses, training, and distributing educational materials on
conservative transfusion therapy strategies (including lower pre-transfusion Hgb trigger and
transfusion of a single RBC unit followed by patient reassessment for determination of additional
interventions) and appropriate and inappropriate use of blood products (including adverse effects
of blood products, misuse and overuse of blood components that increases the risk of morbidity
in patients, cost and financial resources associated with unwarranted blood transfusions) were
important parts of the strategy to change or enhance clinical practice. In addition to the courses,
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training sessions and educational materials, physicians were provided access to EndNote to allow
them to delve further into relevant information.

5.4.2. Performance Management System
Use of a performance management system improved transfusion medicine practice through the
synthesis and utilization of scientific evidence and the more rigorous use of data analytics to
provide meaningful information and to guide daily activities of physicians by creating a culture
of accountability.

In addition it provided a feedback mechanism for assessment and

reassessment of change and the evaluation of the impact of strategic decisions. Developing and
using a performance management system served to identify, select objectives and set goals,
increase awareness on the latest evidence to promote conservative strategies on transfusion
therapies and to create a culture of accountability by tracking physicians‘ transfusion criteria in
accordance with the latest evidence. The performance management system aimed to optimize
transfusion decision-making, reduce inappropriate transfusions, improve patient outcomes,
reduce cost, and preserve a scarce resource through consolidation of measures to monitor and
manage physicians‘ performance according to set of indicators and key performance indicators.

5.4.3. Dynamism in Medicine
Another aspect that adds to the complexity of evidence-based practice is its dynamic nature. As
research advances, medical knowledge is enriched; thus clinical practice and healthcare
technology evolve and new best-practices arise with new definitions of terms, new criteria, and
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different approaches. As a result, evidence-based best-practices continue to be redefined in an
unpredictable manner and with it clinical approaches, regulatory, and reporting requirements
change. It was for this reason that highly specialized subject matter expertise, flexible and
scalable performance management systems, and a feedback mechanisms were built into the
framework.

5.5.

Technical Issues

5.5.1. Data Silos
A central database and the performance management system architecture were fundamental to
the patient blood management program. The linkage of transfusion-related data across the
hospital‘s disparate source systems was an essential first step to monitor compliance with
transfusion best-practice guidelines across various clinical service lines. A patient blood
management database was established at BloodCenter of Wisconsin to centralize data from the
disparate source systems from within the hospital and as a means to evaluate the hospital‘s
transfusion practices both as a baseline before intervention (the implementation of transfusion
medicine best practice program) and as an ongoing monitoring system. There were three critical
components to the success of this implementation model including: 1) the ability to collect and
use recent and precise data that could be processed into meaningful information to show where,
how, by whom, and how much blood product was used within the hospital wards; 2) the ability
to use the information gained from data in a continuous feedback mechanism to inform the
strategic decision makers as a means to assist in the strategic level decision making process; and
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3) the ability to use the clinical practice data to benchmark clinical performance and blood
product utilization.

5.5.2. Data Determination
The method used to identify relevant and contextual data elements across the source systems
included the involvement of the of Blood Utilization Governance Committee in reviewing the
organizational and departmental (i.e. clinical service lines) strategic goals and priorities;
determining of target audiences aligning of patient blood management evidence-based guidelines
to the strategic goals; identifying activities to track progress toward the established goals; linking
the activities to a specific measure or group of measures; setting target and threshold for
expected outcomes; and developing meaningful reports from the measures to inform on the
outcome and progress. The approach facilitated construction of the performance management
system through identification of relevant datasets and the correct source system for extraction of
the data. For each department and the source system, characteristics of data and the quality of
source system was determined. Based on the frequency of data capture, automated or semiautomated data feeds were scheduled to actively (depending on the specific processes and
timeliness of data capture on a daily, weekly, or monthly intervals) transfer the data into the
central repository for processing.

5.5.3. Data Linkage
The linkage of transfusion-related data across the hospital‘s disparate source systems was a
fundamental first step in monitoring compliance with transfusion best-practice guidelines across
clinical service lines. Using the study method, 99.15 percent of discharged inpatients were linked
212

to their transfusion events and clinical detail; 97.77 percent of physicians and other healthcare
providers (including physician‘s assistants and nurse practitioners) were linked to their primary
clinical specialty within the hospital. Thus 99.98 percent of inpatients who received at least one
unit of blood products were linked to their transfusion event and clinical details, in addition to
the issuing physician information. Once the linkage of patients to their clinical detail and
providers was completed, the performance measures were used to track and trend healthcare
providers‘ practice and blood product utilization across the hospital.

5.5.4. Data Transfer
The data feeds were transferred to the central repository via a secure file transfer (e.g. sFTP)
connection. A unified metadata layer was defined; and data from the various source systems
were mapped to enable contextual information. Data was stored in SQL database, where
numerous views (virtual tables) were created to join the subset of data from various tables
(populated from disparate information systems) with coded logics built-in for contextual view of
data, and to limit exposure to the underlying data. The logics were coded in the views to link data
on patient, provider, blood products and clinical details that were required to for individual
measures in the performance management system. InSight (Lenexa, KS), an analytics and
reporting software, was used for construction of the measure as part of the performance
management system with dashboard and reporting capabilities for dynamic views of information.
The reports from the performance measures were presented back to the hospital via a secure
web-based portal which depicted blood product use, and physician ordering practice at multiple
levels including by system, facility, cost center, clinical service line, and healthcare provider.
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5.5.5. Information Reporting
Data analysis was regularly communicated throughout multiple levels of the healthcare
organization including at healthcare system level, hospital level, clinical service line level, and
physician level based on guidelines established by the Blood Utilization Governance Committee.
Dashboards were tailored to meet the information requirements of administrative and clinical
personnel.

5.6

Study Outcome

The Blood Utilization Governance Committee made the determination to target RBC utilization
as the most frequently issued blood component (69.75% RBC, 22.73% FFP, 6.81% PL, and
0.72% CRYO), and hospitalists as the highest users of RBC units. The indicator measuring the
percentage of RBC units in individual clinical service lines compared to total hospital wide RBC
units was calculated as a baseline analysis for the pre-intervention period (Oct. 2012 to Sep.
2013). It showed hospitalists (34.09%) were the highest users of RBC units, followed by
cardiothoracic surgery (12.563%), and general surgery (9.84%). The first five clinical specialties
(e.g. Hospital Medicine, Cardiothoracic Surgery, General Surgery, Hematology/ Oncology and
Pulmonary Medicine), accounted for 74.62 % of the hospitals total RBC use. Benchmark
indicators showed an annual rate of RBC transfusions per 1000 patient days to be 62.95 and
21.67 across all clinical service lines and hospitalists respectively during pre-intervention period.
The study focused on reducing the inconsistencies in practice of transfusion medicine,
particularly in the transfusion of allogeneic RBC among Hospitalists in the hospital.
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Retrospective analysis of hospitalists practice during pre (Oct. 2012 – Sep. 2013) and post (Oct.
2013 – Sep. 2014) intervention periods showed a 27.62 percent decline in inpatient RBC
transfusion per 1000 patient days. Analysis of hospitalists ordering practice showed a significant
change in number of one and two unit RBC orders. The rate of two-unit RBC orders significantly
decreased by 30.88 percent (p < 0.01), while the rate of one-unit RBC orders significantly
increased by 31.67 percent (p < 0.01).

More in-depth analysis was performed on one-unit and two-unit orders to determine whether
there was a change in transfusion threshold of Hgb level based on the performance standard.
Comparison of the mean Hgb threshold for one-unit orders during pre and post intervention
periods (8.0 ± 0.71 to 7.7 ± 0.69, p < 0.01 ) showed a significant shift towards lower pretransfusion Hgb threshold. Although, the trend showed a positive shift toward lower Hgb
threshold, hospitalists‘ decisions on transfusion triggers

will require more interventions to

further lower transfusion triggers (Hgb concentration of 7 g/dL or less for non-bleeding stable
patients or 8 g/dL for patients with cardiac conditions). The same analysis was performed for
two-unit orders and no statistically significant change was observed. Post-transfusion assessment
of the effect of the RBC transfusion for assessment of incremental change in hemoglobin and
hematocrit level was quantified by the rate of post-transfusion Hgb testing. For one-unit orders in
patients with pre-order Hgb value =< 7, the post transfusion assessment rate showed a significant
increase of 35.06 percent (p < 0.001). The same analysis was performed for two-unit orders and
no statistical significant change was observed. However, during the pre and post-intervention
period the rate of post transfusion assessment after transfusion of two unit RBC order had
remained steady with the average of 94.19 % ± 0.36 in across the two time periods.
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The post-intervention period showed a 35.24 percent (p < 0.001) reduction in the total number of
RBC units issued by hospitalists. The reduction in the number of RBC unit transfusions had a
significant financial impact, which had led to an annual saving of $124,337 based on the priceper-unit (national average) of RBC acquisition alone during post intervention period. However,
estimating cost of transfusion based on the price-per-unit acquisition cost has been criticized by
the Cost of Blood Consensus Conference. Traditional cost models lack the complex pretransfusion preparation and post transfusion steps, thus attributable cost per unit has been greatly
underestimated135. A recently developed cost model by the Cost of Blood Consensus Conference
included activity-based costing, which comprehensively accounted for the cost of transfusion
through analysis of technical, administrative, and clinical processes. Using the activity based cost
model, the technical, administrative, and clinical processes that occurred sequentially and in
parallel were mapped.

Each process step that involved diverse personnel, capital, and

consumable resources was multiplied by the usage frequencies. National average price per unit
acquisition cost of RBC unit and the activity based cost analysis of a single unit RBC transfusion
at the hospital were estimated to be $ 210.74 ± 37.9 and $424.23 respectively. Total cost of a
single unit RBC transfusion per patient was determined to be around $634.97. Analysis of the
reduction in hospitalist RBC transfusions using total cost RBC transfusion (price per unit
acquisition cost and activity based cost) showed and annual saving of $374,632 during post
intervention period.

The effectiveness of the various educational and reporting interventions used during the study
time period to influence prescribing behavior were evaluated. Although the report to the
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department chair provided visibility to hospitalists‘ practices and allowed for an avenue of
conversation, individual peer-comparison-blinded reports had the greatest impact in changing the
practice of the hospitalists. Trends began to significantly shift when the individual hospitalists
were able to view their practice information and compare themselves to their peers.

The study model empowered the hospital, through the Blood Utilization Governance Committee
and the Transfusion Medicine Steering Committee to encourage hospitalists to move from a
culture of delivering care based on tradition, intuition, and authority, to a system in which
decisions were guided and justified by education, awareness of the best available evidence and
specific data relative to performance-based measures. The model provided an effective way for
hospitalists to avoid over-transfusion of their patients through the order of one RBC unit at a
time in stable non-bleeding patients, and re-assessment of the patient prior to ordering additional
RBC units. If a single unit increased the patients Hgb into 7 to 8 g/dL range, the needed
symptomatic patient relief was achieved.

Thus, the hospitalists were able to avoid over-

transfusion, which would only increase the future risk of adverse outcomes to their patients. This
approach facilitated a sense of accountability among hospitalists by holding them accountable for
their decisions on a daily basis. The totality of all hospitalists being accountable for their
decisions served to create accountability at individual, department, and organization level. . The
success of the pilot program that was executed for this study has led to the expansion of the
program to all of the healthcare system‘s other hospitals. .
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A way to address unexplained differences in clinical practice requires evidence-based guidelines,
identification and collection of contextual data from diverse and disparate source systems,
development and use of a performance management system, analysis of healthcare providers‘
transfusion practice data, and meaningful presentation of information firmly coupled with topicfocused education to drive appropriate decision-making and interventions. In addition, the model
requires a closed feedback mechanism to quantify and evaluate the changes in practice.
Reporting on compliance to evidence-based guidelines and performance measures are
foundational; the addition of an analytics framework as a feedback mechanism is essential to
further evaluate changes related to implementation and adherence to an evidence-based program.
The study demonstrated that focus on tight integration of the above elements can bridge the gap
that exists between knowledge and practice, and thereby can alter behavior.

5.7.

Study Limitations

5.7.1. Organizational Agreements
Legal agreement between the two organizations imposes a rigid boundary around the scope of
the project, and resources. Additionally, limited opportunities for interactions with key
stakeholders and practitioners confines opportunities and makes it difficult to test new ideas or
hypotheses.
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5.7.2. Software System
Historically, business intelligence and reporting consisted of pre-defined reports and data
visualizations that centered on classic tables, pie charts, and bar charts. BI tools have evolved to
contain advanced analytics and visualizations, which encourage business users to have a more
active role in data analysis. InSight™ is a metrics-based dashboarding software system that
adheres to the out-dated business intelligence model. InSight™ has limitations that preclude it
from fulfilling the evolving needs of end-users.


ETL / Data Warehouse Capabilities
InSight™ provides limited, non enterprise-level ETL capabilities and no true data
warehouse functions. It most readily integrates with Microsoft databases and flat files,
but does not easily integrate with other types of databases (i.e. Oracle) or any other data
sources. The ETL processes are fragile and prone to failure which requires manual
intervention on a regular basis.



Scalability & Multi-Tenancy
InSight™ is not a scalable solution and does not support multi-tenancy. The study needs
a single view of the data that spans multiple healthcare systems in order to inform
performance within each hospital, create benchmarks for partner organizations, and to
provide an internal view of program success. Due to its architecture, requires its own
development and production databases, and application environment for every healthcare
system.
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Rigid Metric Hierarchy
The metric implementation is rigid; the drill down paths are confining and do not allow
users to apply multiple filters to the data set (i.e., select a service line AND a type of
blood product.) The lack of flexibility requires multiple measures to be created for each
hierarchy drill path.



Visual Analysis
InSight™ contains very limited visual analysis capabilities. Users are unable to create the
simplest visual representations such as clustered or stacked bar charts; this requires
transfer of data to Excel for further graphical capabilits.



Report Creation
The lack of presentation capabilities necessitates users to export most data into Excel to
prepare the information for analysis or for presentation back to the healthcare systems.
The Insight™ does not create pixel perfect reports for electronic distribution or print.



Dashboard
Dashboards are inflexible, and the configuration required to create and maintain them
does not provide a sustainable model. The Flash player tool becomes overwhelmed with a
large data set and it can take several minutes (3-4) to add a single row to a view.



Ease of Use
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The product is not positioned as a business user solution because complex SQL is needed
to create views for reporting purposes.



Data Discovery & Ad hoc Analytics
The product does not support data discovery capability or ad hoc analytics to enable
system users to slice and dice data.



Collaboration
InSight™ only supports file export, print, and email capabilities. There is no ability to
notate or collaborate within the tool.



System Integration
InSight™ does not provide the ability to embed its metrics into other websites.
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